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Abstract 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a human oncovirus associated with 
multiple malignancies, including Kaposi’s sarcoma (KS). Like all herpesviruses, KSHV can 
establish either a latent or a lytic infection in host cells. During latency the virus remains in 
a dormant state, with limited gene expression. After reactivation, KSHV enters the lytic life 
cycle, characterised by production of infectious virions and subsequent dissemination of 
the virus from its latent reservoir. Importantly, lytic replication is critical for KS 
tumourigenesis.  
KSHV replicates in the nucleus of the host cell and requires cellular mRNA export factors to 
efficiently export viral mRNAs from the nucleus, allowing their translation in the 
cytoplasm. But while mammalian mRNA export is linked to splicing, the majority of the 
KSHV genome encodes intronless mRNAs, prompting the virus to circumvent this step. 
KSHV therefore expresses ORF57, a multifunctional protein essential for lytic replication. 
ORF57 recruits members of the cellular human transcription/export (hTREX) complex to 
form an export competent viral ribonucleoprotein particle (vRNP), facilitating efficient 
nuclear export of intronless KSHV mRNAs.  
This study presents a novel mechanism for the specific disruption of the vRNP and 
subsequent inhibition of virus lytic replication. Results suggest an ATP-cycle dependent 
remodelling of hTREX, which affects the ability of ORF57 to interact and form an export 
competent vRNP. Specifically, inhibiting ATP hydrolysis by the hTREX component and 
ATPase UAP56 prevents ORF57 from recruiting the hTREX complex, while key components 
of the endogenous complex remain able to interact.  
Following this finding, UAP56 was targeted by small molecule inhibitors, using a structure-
based drug design approach, to prevent ATP hydrolysis and thereby inhibiting vRNP 
formation. Strikingly, a hit compound identified was shown to disrupt formation of the 
vRNP, lytic protein expression and infectious virion production, while allowing endogenous 
hTREX formation within a therapeutic window, where no cytotoxicity was observed.  
Bearing in mind the conserved mechanism for herpesvirus intronless mRNA export, this 
study finally presents a series of compounds that are able to prevent both KSHV and HSV-1 
lytic replication. 
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1 Introduction 
1.1 Herpesviridae 
1.1.1 Classification of Herpesviruses 
Herpesviruses are a class of viruses with distinct architecture and morphology. The order 
of Herpesvirales, all members of which are related to each other by a very distant common 
ancestor, comprises of three families: Herpesviridae, including all mammalian, avian and 
reptilian herpesviruses, Alloherpesviridae, infecting fish and amphibians, and 
Malacoherpesviridae, which cause disease in invertebrates (Davison et al., 2009). 
Estimates put the point of evolutionary divergence of the Herpesvirales families between 
180–200 million and up to 400 million years ago (Davison, 2007). Only three conserved 
genes have been identified across the Herpesvirales, whereas more than 40 genes are 
conserved across all Herpesviridae (McGeoch et al., 2008).  
In 1979, the largest of all Herpesvirus families, the Herpesviridae was further divided into 
three subfamilies: Alpha-, Beta- and Gammaherpesvirinae (Figure 1.1) (Matthews, 1979). 
While the original classification occurred based on biological properties, such as host 
range, site of infection, cytotoxicity and length in reproductive cycle (Roizmann et al., 
1992), more recent developments in genome sequencing now allows classification based 
on genome comparison (Davison, 2010).  
 
1.1.1.1 Alphaherpesvirinae 
Herpesviruses belonging to the Alphaherpesvirinae subfamily establish latent infection in 
neuronal cells, primarily sensory ganglia, with lytic replication often occurring in epidermal 
cells. They distinguish themselves from other subfamilies through a short reproductive 
cycle and the ability to progress rapidly in cell culture. Alphaherpesvirinae also have a 
variable and broad host range.  
Prominent members of the Alphaherpesvirinae subfamily include the human pathogens 
herpes simplex virus type I and II (HSV-1/2) and varicella zoster virus (VZV), also known as 
human herpesvirus (HHV) type 1, 2 and 3, respectively. Important herpesviruses in animal 
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virology also belonging to the Alphaherpesvirinae include; porcine herpesvirus 1 (Suid 
herpesvirus 1, SuHV-1), which causes pseudorabies in pigs, gallid herpesvirus 2 (GaHV-2), 
responsible for Marek’s disease in chicken, as well as bovine herpesvirus 1 (BoHV-1), which 
is known to cause several worldwide diseases in cattle.  
 
Figure 1.1: Phylogenetic tree for Herpesviridae. The phylogenetic tree shows the evolutionary 
relationship of Herpesviridae based on amino acid sequence alignments. Adapted from (Strauss and 
Strauss, 2007).  
 
1.1.1.2 Betaherpesvirinae 
Betaherpesviruses latently infect lymphoreticular cells, secretory glands and kidneys 
(Strauss and Strauss, 2007). They have a long reproductive cycle, are restricted in their 
host range and spread very slowly in tissue culture, compared with other members of the 
Herpesviridae family. Cells infected with betaherpesviruses are often found enlarged, 
forming cytomegaly. 
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Betaherpesvirinae include the human pathogens human cytomegalovirus (HCMV, HHV-5), 
as well as HHV-6 and HHV-7, both belonging to the Roseolovirus genera.  
 
1.1.1.3 Gammaherpesvirinae 
Latent infection of Gammaherpesvirinae occurs in lymphoblastoid cells, with most viruses 
specific for either T- or B-lymphocytes. Some members of this subfamily are also able to 
lytically replicate in epithelial cells and fibroblasts. Gammaherpesvirinae have a narrow 
host range and can only infect members of the family or order to which their natural host 
belongs. 
To date, two human gammaherpesviruses are known: Epstein-Barr virus (EBV, HHV-4) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV, HHV-8), belonging to the 
Lymphocrytovirus and Rhadinovirus genera, respectively.  
 
1.1.2 Virion architecture 
Herpesviruses have a unique architecture and morphology (Figure 1.2), which was 
previously used to be the distinguishing criteria in their taxonomy. The large, linear, 
double stranded (ds) DNA genome is packaged into an icosahedral capsid in the form of a 
torus (Furlong et al., 1972). The capsid is assembled out of 162 capsomers, to form an 
icosahedron with T = 16 symmetry, with a final size of around 100 nm in diameter. One 
pentameric capsomere in the capsid is replaced by the so-called portal complex, which 
allows packaging and release of the genetic material (Cardone et al., 2007; White et al., 
2003). The viral capsid is surrounded by the tegument, an amorphous protein coat, 
consisting of about 20 different viral and cellular proteins, that can vary in thickness. The 
roles of the tegument are diverse, from host cell shut-off, evasion of host immune 
response, to capsid transport and envelopment (Kelly et al., 2009; Mettenleiter, 2004). The 
tegument layer is enclosed by a viral envelope. This envelope consists of a lipid bilayer and 
contains several viral glycoproteins necessary for host cell binding and membrane fusion 
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(Mettenleiter et al., 2009). The final size of a virus particle varies from 100–300 nm, due to 
the difference in tegument thickness.  
 
Figure 1.2: Herpesvirus structure. Schematic representation of structural components of a herpesvirus 
particle. Figure taken from Viral structures and antibodies, abcam®. 
 
1.1.3 Genomic structure 
The genome of herpesviruses consist of a single, linear double-stranded DNA, ranging from 
125 to 291 kbp in length. The genomic ends contain unpaired nucleotides, which are 
neither covalently closed nor covalently linked to a protein. The majority of the 
herpesvirus genome consists of unique sequences, but most viruses also have some 
repeated sequence elements. These repeated sequences can be 103–104 bp in size and 
their unique distribution pattern can be used to classify Herpesviridae genomes into six 
distinct types (Figure 1.3). Interestingly, classification of genome type does not correlate 
with evolutionary relatedness, and all genome types occur throughout the Alpha-, Beta- 
and Gammaherpesvirinae. Genomes of type A have two identical, large terminal repeat 
(TR) sequences at either end of the genome. Amongst others, HHV-6 belongs to group A. 
Herpesviruses of type B, such as KSHV, have genomes with multiple direct repeats at both 
termini. Type C genomes, as is found in EBV, have similar multiple repeat regions at the 
end of the genome, but in addition contain several internal repeat (IR) sequences 
scattered throughout the unique genome region. Genome type D is distinguished by two 
inverted repeat sequences, one internally and one occurring at a terminus. This creates 
6 
 
the characteristic unique short (US) and the unique long (UL) sequence in between these 
repeats. An example of genome type D is VZV. Members of genome group E, such as HSV-1 
and 2, also contain US and UL sequences; however, here both are flanked by separate 
inverted repeat domains. In contrast, genomes of type F, exemplified by MCMV-1, do not 
contain any extended DNA repeat sequences (Roizman et al., 1981).  
During evolution, many herpesviruses have acquired pirated genes from their host cells. 
These cellular homologues help regulate host defence mechanisms and apoptosis, as well 
as function in immune evasion. 
 
Figure 1.3: Herpesvirus genome structures. Schematic representation of the six Herpesviridae genome 
types. Unique regions are shown by lines and repeat domains are represented as boxes. Arrows indicate 
the orientation of the repeat elements. TR, terminal repeat; IR, internal repeat; UL, unique long region; 
US, unique short region. Adapted from (McGeoch et al., 2008). 
 
1.1.4 Life cycle 
The herpesvirus life cycle begins when an infectious virus particle binds to the cell surface. 
This contact is established through glycoproteins embedded in the virus envelope. The 
genes for three glycoproteins are conserved across all herpesviruses and accordingly, 
these three glycoproteins are essential for entry of all Herpesvirales: gB, gH and gL.  The 
viral envelope proteins bind to cellular receptors during entry. Some of these receptors 
function as binding receptors, which increase the concentration of viruses on the cell 
surface, others are entry receptors, which activate fusion of the viral envelope with the 
cell membrane (Spear and Longnecker, 2003) (Figure 1.4a). Common cellular receptors are 
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proteoglycans, such as the glycosaminglycan heparan sulphate that is responsible for KSHV 
and HSV-1 binding. However, some herpesviruses require endocytosis to enter cells, with 
membrane fusion occurring after acidification of the endosomal compartment (Figure 
1.4b). The type of entry mechanism is dependent on herpesvirus and cell type. After 
fusion, the capsid and tegument proteins are released into the cytoplasm of the cell. From 
here, the uncoated capsid traffics via the microtubule network to the nucleus, where the 
viral DNA enters through the nuclear pore complex (Shukla and Spear, 2001; Mabit et al., 
2002; Naranatt et al., 2005). Once inside the nucleus the viral DNA circularises 
immediately (Mabit et al., 2002). The virus can then enter one of two distinct life cycles: 
latency or lytic replication.  
 
Figure 1.4: Herpesvirus entry mechanisms. a) Membrane fusion: (1) Virus particles approach the cell 
surface. (2) The virus attaches via cell surface receptors, which induces (3) fusion of the viral and cell 
membrane. (4) The virus capsid and tegument layer are released into the cytoplasm. b) Endocytosis: (1) 
The virus attaches via cell surface receptors, which induces (2) invagination of the virus into endosomes. 
(3) Acidification of the endosome leads to (4) membrane fusion and release of the capsid and tegument 
into the cytoplasm. Taken from (Tortora et al., 2012). 
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1.1.4.1 Latency 
During latency the virus remains in a dormant state with no infectious progeny virions 
being produced (Werner et al., 1978; Kaschka-Dierich et al., 1982). The viral genome is 
maintained as a non-integrated episome in the nucleus of the infected cell (Collins and 
Medveczky, 2002; Griffiths and Whitehouse, 2007). Usually latency is established in a 
specific cell type dependent on the virus. Only a small number of genes are expressed 
during latency, producing the so called latency-associated transcripts (LATs). Most of these 
LATs code for proteins involved in persistence of the viral genome, prevention of apoptosis 
and immune evasion (Croen, 1991; Friborg et al., 1999).  
 
1.1.4.2 Lytic replication 
Reactivation of latent virus leads to lytic replication, the second distinct life cycle all 
herpesviruses can enter. During lytic replication, an expression cascade regulates the 
strong increase in viral gene expression: three main temporal phases control the de novo 
protein synthesis (Figure 1.5). All viral genes are transcribed in the nucleus by the host cell 
RNA polymerase II, whereas translation occurs in the cytoplasm of the host cell after the 
viral mRNA has been exported. The first viral proteins to be expressed are called 
immediate early (IE). These are required for the efficient expression of delayed early (DE) 
genes. DE genes encode proteins that are essential for viral DNA synthesis by the viral DNA 
polymerase or function in immunomodulation of the host cell. The circular DNA is 
replicated in a rolling circle manner, producing concatamers which are subsequently 
cleaved into monomers within the terminal repeat region. In turn, expression of DE genes 
and DNA synthesis regulates the expression of late (L) genes. Late genes include those 
coding for structural proteins involved in capsid formation and virion production. The 
capsid is assembled in the nucleus of the host cell and packages the newly replicated DNA. 
The capsid matures by budding from the nuclear double membrane, resulting in primary 
envelopment and de-envelopment of the capsid (Skepper et al., 2001). The tegument layer 
is then added in the cytoplasm through a series of intricate protein-protein interactions 
(Mettenleiter, 2002). Finally, re-envelopment and thereby production of mature progeny 
virions takes place in the cytoplasm. For a long time it was believed that this occurred 
9 
 
through budding into trans-Golgi vesicles, however, a more recent report has also 
implicated a role for endocytic tubules (Hollinshead et al., 2012). Following secondary 
envelopment, the infectious virions are released by exocytosis, resulting in lysis of the host 
cell.   
 
Figure 1.5: Herpesvirus lytic replication. a) After infection of the host cell the capsid is transported to 
nuclear pores, where viral DNA enters the nucleus and circularises immediately. b) Reactivation of the 
virus causes expression of immediate-early (IE) genes. c) IE gene products promote an expression 
cascade where delayed-early (E) genes are expressed d) Delayed-early genes are required for viral DNA 
replication, which in term stimulates late (L) genes expression. e) Structural proteins, encoded by late 
genes, assemble viral capsids, f) which encapsulate the newly synthesised viral DNA. g) The 
nucleocapsids travel through the nuclear membrane and acquire their envelope when budding from the 
golgi, before exiting the cell. Taken from (Knipe and Cliffe, 2008). 
 
1.2 The Gammaherpesvirinae 
The Gammaherpesvirinae subfamily contains four genera: Lymphocrytovirus (gamma-1), 
Rhadinovirus (gamma-2), Macavirus and Percavirus (Davison et al., 2009). Gamma-
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herpesviruses latently infect either B- or T-lymphocytes, however, they undergo lytic 
replication in epithelial cells or fibroblasts. The genomes of Gammaherpesvirinae show a 
high degree of conservation. They contain a conserved central region, arranged in four 
gene blocks and interspersed with unique open reading frames (ORFs), which is flanked by 
a variable number of terminal repeat (TR) sequences. Due to high similarity in orientation 
and arrangement of core genes in their central sequence, genomes of gamma-
herpesviruses are described as co-linear (Albrecht and Fleckenstein, 1990; Nicholas et al., 
1992; Russo et al., 1996).  
While Alphaherpesvirinae establish latency in non-dividing cells, Gamma-herpesviruses 
undergo latent infection in replicating cells. To ensure propagation of the viral genome 
during cell division, several copies of the genome are tethered to host mitotic 
chromosomes (Cotter and Robertson, 1999). Furthermore, Gammaherpesvirinae express a 
number of proteins that function to enhance survival of the host cell, by supression of 
apoptosis, subversion of the host immune system and enhancement of cell cycle 
progression (Friborg et al., 1999; Li et al., 1997; Sarid et al., 1999). Subsequently, through 
manipulation of host cell mechanisms, many gamma-herpesviruses have the ability to 
induce neoplasia in their hosts and transform cells in culture (Damania, 2004). Both EBV 
and KSHV are human gamma-herpesviruses capable of causing cancers and other 
proliferative disorders.  
 
1.2.1 Epstein Barr virus (EBV) 
Over 50 years ago, EBV was identified as the first human oncogenic virus, after the virus 
was isolated from lymphoblasts cultured from a Burkitt’s lymphoma (Epstein et al., 1964). 
In the following years, EBV has been implicated in a series of malignancies summarised in 
Table 1.1.  
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Table 1.1: EBV associated diseases.  
Associated Malignancy Name 
B-cell lymphoma Burkitt’s lymphoma 
Hodgkin’s lymphoma 
Post-transplant lymphoma (PTL) 
T-cell lymphoma Extranodal natural killer/T-cell lymphoma 
Carcinoma Nasopharyngeal carcinoma 
Gastric carcinoma 
 
EBV infection occurs usually asymptomatically in early childhood and leads to lifelong 
persistence of the virus. In contrast, primary infection taking place during adolescence 
often results in infectious mononucleosis, characterised by flu-like symptoms and severe 
fatigue. Here, proliferation of B-cells infected with lytic replicating EBV causes a 
hyperproliferation of T-cells, including EBV-specific CD8+ cytotoxic T-cells (Callan et al., 
1996). While this system-wide response leads to the pathology of infectious 
mononucleosis, it is a self-limiting process ending with most EBV infected cells cleared 
after a few weeks. However, some B-cells with latent EBV can avoid immune surveillance 
and thus, the virus is able to establish a lifelong reservoir. In addition to B-lymphocytes, 
EBV can also establish an initial infection and replicate in oral epithelial cells, allowing 
transmission of the virus via contaminated saliva (Kurth et al., 2000; Webster-Cyriaque et 
al., 2006; Tugizov et al., 2003). As a result, over 90% of the global adult population is 
seropositive for EBV. Development of malignant diseases following EBV infection is 
extremely rare and invariably associated with immune suppression; such as through co-
infection with human immunodeficiency virus (HIV) or malaria, or after tissue and organ 
transplants (iatrogenic immune suppression) (Pagano, 2008; Taylor and Blackbourn, 2011).  
In contrast to many other herpesviruses, EBV does not attach to the host cell via the 
proteoglycan heparan sulphate, but utilises the cellular receptor CR2 (also known as 
CD21), expressed on mature B-lymphocytes by binding of the viral gp350 (Fingeroth et al., 
1984). Furthermore, a second glycoprotein, gp42, binds to human leukocyte antigen (HLA) 
class II molecules, functioning as a co-receptor (Borza and Hutt-Fletcher, 2002). Infection 
of endothelial cells occurs in a much less efficient manner; however, this distinct pathway 
is to date poorly understood.  
12 
 
1.2.1.1 EBV life cycle 
After initial EBV infection, a brief phase of lytic replication occurs, leading to a pool of 
infectious virions. These can establish a reservoir of latently infected cells, which does not 
require re-infection through rounds of lytic replication to be maintained. Four distinct EBV 
latency expression programmes have been described, which are essential for host 
colonisation and persistence, termed latency 0, I, II and III.  After initial infection of naive 
B-cells, latency III, the broadest of all latency expression programmes, drives proliferation 
and differentiation in these cells. While many of these infected B-lymphocytes are 
removed by the primary T-cell response, some are transformed into a proliferating 
lymphoblastoid cell line (a process called B-cell activation). To avoid host immune 
responses in healthy individuals, a down regulation of gene expression is induced, giving 
way to an expression programme known as latency II. A further reduction of expressed 
proteins and RNAs, leads to latency I. Though this process is highly complicated and not 
well understood, it is believed that this reduction in EBV transcription takes places during 
transit through a germinal centre reaction, resulting in EBV-positive memory B-cells (Young 
and Rickinson, 2004). These resting memory B-cells enter circulation and form the latent 
reservoir in immunocompetent individuals (Babcock et al., 1998). This state, also known as 
latency 0, is characterised by almost complete suppression of viral antigen expression 
(Young and Rickinson, 2004).    
While all EBV-induced malignancies are driven by viral latency, the contrasting expression 
programmes are linked to different diseases (summarised in Table 1.2). Latency I, the most 
restrictive expression programme associated with a malignancy, is observed in all cases of 
endemic Burkitt’s lymphoma. These tumours are often found in children co-infected with 
malaria and therefore have a high incidence rate in regions of Africa and New Guinea, in 
which malaria is holoendemic. Transcription of the EBV genome in latency I is limited to 
EBNA1 (an EBV-encoded nuclear antigen essential for episomal maintenance) and the 
Epstein-Barr virus-encoded small RNAs (EBERs), a group of non-coding RNAs (ncRNAs). 
Latency II, which is found in Hodgkin’s lymphoma and EBV-associated carcinomas, such as 
nasopharyngeal carcinoma and gastric carcinoma, is characterised by expression of EBNA1, 
the latent membrane proteins (LMP) 1, 2A and 2B, as well as the EBERs and certain virally 
encoded microRNAs (miRNAs), often referred to as BARTs. LMP1 has anti-apoptotic 
function, whereas LMP2A and 2B promote cell survival and motility (Huen et al., 1995; 
13 
 
Caldwell et al., 1998). Latency III is characterised by the expression of all EBV-encoded 
nuclear antigens (EBNA1, 2, 3A, 3B, 3C and leader protein), the LMPs, as well as the EBERs 
and BARTs (Pagano, 2008; Klein et al., 2007; Speck and Ganem, 2010). As only EBNA1 is 
able to evade the CD8+ immune response, whereas some other EBNAs are 
immunodominant, a healthy immune system is able to suppress development of 
lymphoproliferative diseases through latency III. Hence this expression programme is only 
associated with malignancies in severely immunocompromised patients and found in B-
cells of post-transplant lymphomas (PTLs) that develop in the absence of effective T-cell 
surveillance.  
Table 1.2: Overview of EBV latency programmes, their associated malignancies and gene expression 
profiles. ncRNAs = non-coding RNAs, miRNAs = microRNAs.  
 Latency 0 Latency I Latency II Latency III 
Associated 
malignancy 
- Burkitt’s 
lymphoma 
Hodgkin’s lymphoma 
& Carcinomas 
Post-transplant 
lymphomas 
EBNA-1 - + + + 
EBNA-2, 3A, 
3B, 3C, LP 
- - - + 
LMP-1, 2A, 
2B 
- - + + 
EBERs 
(ncRNAs) 
+ + + + 
BARTs 
(miRNAs) 
- - + + 
 
 
1.2.2 Kaposi’s sarcoma-associated herpesvirus (KSHV) 
In 1994, herpesvirus-like DNA fragments were first isolated from KS tumours and 
subsequently identified as a novel human herpesvirus. Thus, KSHV is the eighth and most 
recently identified human herpesvirus, and one of the currently known seven human 
oncoviruses.  
The viral genome is 138 Kb in length and encodes 87 open reading frames (ORFs), 12 pre-
miRNAs expressing 25 mature miRNAs, (Grundhoff et al., 2006; Cai et al., 2005; Pfeffer et 
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al., 2005), as well as long non-coding RNAs (lncRNAs) (Sun et al., 1996). Furthermore, the 
existence of another 50 upstream and small ORFs (uORFs and sORFs, respectively) has 
recently been proposed (Arias et al., 2014). Figure 1.6 displays a genome map of KSHV 
ORFs. 
 
Figure 1.6: KSHV genome map. Viral latent genes are shown in teal, early, delayed-early and late lytic 
genes are shown in shades from orange to red. KSHV encoded miRNA are shown as gray arrowheads. 
Adapted from (Coscoy, 2007) after data in (Paulose-Murphy et al., 2001) and (Arias et al., 2014). 
 
Unlike EBV, KSHV infection is not ubiquitous across the world’s population (Figure 1.7). 
The prevalence is highest in sub-Saharan Africa, with seropositivity rates of over 50%, but 
is less common in Mediterranean countries (20–30%) and most of Europe, Asia and the US 
(less than 10%) (Uldrick and Whitby, 2011). Infectious KSHV virions are shed from oral 
epithelial cells and hence make transmission via saliva the most common route of 
infection (Ambroziak et al., 1995; Webster-Cyriaque et al., 2006; Blackbourn et al., 1998; 
Pauk et al., 2000). This is especially important, as this route is thought to be responsible 
for the high prevalence of childhood infections in certain regions of Africa (Bagni and 
Whitby, 2009). It has furthermore been reported that transmission can also occur via 
blood (Whitby et al., 1995; Hladik et al., 2006) and sexual contact (Martin et al., 1998). 
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However these findings are still subject of discussion (Engels et al., 2007; Martin and 
Osmond, 2000). 
 
Figure 1.7: KSHV prevalence worldwide. A high seroprevalence is visibile in sub-Saharan Africa. In 
contrast, Asia, the US and most part of Europe have low infection rates. No data is available for 
countries shown in white. Taken from (Mesri et al., 2010). 
 
1.2.2.1 KSHV associated diseases 
KSHV was first identified as the aetiological agent of HIV-associated Kaposi’s sarcoma (KS) 
(Chang et al., 1994) and has since been shown to cause all forms of KS. In recent years, 
KSHV involvement has also been shown in primary effusion lymphoma (PEL) (Cesarman et 
al., 1995) and multicentric Castleman disease (MCD) (Soulier et al., 1995).  
 
1.2.2.1.1 Kaposi’s sarcoma (KS) 
KS was first described by the Hungarian dermatologist Moritz Kaposi in 1872 (Kaposi, 
1872). Due to the geographically constrained distribution of KS incidents (Oettle, 1962) 
and the association with immune suppression (Penn, 1978), it was suggested well before 
the first KS epidemic occurred that the tumours might be caused by an infectious agent. 
With the onset of the AIDS epidemic in 1989, KS morbidity increased drastically: Studies 
showed more than 15% of people in the US infected with AIDS also reported with KS (Beral 
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et al., 1990). This epidemic-like morbidity and the high mortality of KS led to intense 
research into the etiology of KS, which ultimately resulted in the identification of 
herpesvirus DNA fragments in KS biopsies and subsequently the discovery of KSHV (Chang 
et al., 1994). 
Even though the introduction of effective anti-retroviral therapies led to a decrease in the 
occurrence of KS, tumours have been reported in individuals with well controlled HIV 
(Grulich et al., 2001; Maurer et al., 2007). Furthermore, as KS has become one of the most 
common cancers in sub-Saharan Africa (termed endemic KS) (Parkin et al., 2008), many 
people in resource poor countries are still greatly affected by KSHV (Figure 1.8).  
 
Figure 1.8: Kaposi’s sarcoma incidence rate worldwide. Concurrent with the high seroprevalence and 
HIV-epidemic a high KS incidence rate is visible in parts of Africa. No data is available for countries 
shown in white. Taken from (Mesri et al., 2010). 
 
In addition to AIDS-associated KS, patients receiving organ transplants or chemotherapy 
are also at a higher risk of developing so called iatrogenic KS, due to immune suppression. 
While healthy individuals are less likely to be affected by the onset of KS, the so called 
classic KS commonly affects elderly men from the Mediterranean. However, opposed to 
the aggressive forms of cancer found in AIDS-associated or iatrogenic KS, which spreads 
rapidly to internal organs and lymph nodes (Ganem, 2010), classic KS tumours are usually 
benign. 
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KS presents itself as a spindle cell tumour of endothelial origin, which is highly 
vascularised. These microvascular channels fill with blood and give KS skin lesions their 
characteristic dark appearance. Through its association with the infectious agent KSHV, KS 
tumours progress and regress based on the host immune system and as such withdrawal 
of immunosuppressive medication (in iatrogenic KS) or treatment with HAART (in AIDS-
associated KS) can lead to a remission of the skin lesions.  
Several KSHV genes expressed in tumour cells exhibit direct pro-oncogenic activities by 
inhibiting the tumour suppressor genes p53 and Rb, and inducing NF-κB (Cai et al., 2010; 
Mesri et al., 2010). Viral proteins, especially the products of “pirated” host cell genes, 
subvert cell signalling pathways and lead to the expression and secretion of pro-
inflammatory, angiogenic and proliferative cytokines (Ballon et al., 2011; Bottero et al., 
2011). This effect is aggravated by KS tumour cells expressing receptors for these cytokines 
on the cell surface and thereby creating an autocrine signalling system (Hengge et al., 
2002). 
In contrast to EBV, where all malignancies are associated with viral latency, both latent 
and lytic replication cycles are indispensible for KS occurrence (Ye et al., 2011). For 
example, only lytic replication allows dissemination of infectious virions from the B-cell 
reservoir into the blood stream allowing infection of other cells types, including 
endothelial cells. Furthermore, while the majority of tumour cells are latently infected, 
sporadic rounds of lytic replication are essential for maintenance of the viral episome in 
endothelial cells (Staskus et al., 1997). Finally, in addition to the pro-oncogenic activities of 
latent gene products, lytic proteins also contain tumourigenic properties (Figure 1.9).  
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Figure 1.9: Proposed mechanism of KSHV-induced sarcoma. a) The early lytic genes vGPCR, K1, vIL-6 
and K15 (shown in red) manipulate host cell signalling pathways, leading to the expression and secretion 
of inflammatory, angiogenic, proliferative cytokines (including, vascular endothelial growth factor 
(VEGF), platelet-derived growth factor-β (PDGFB), angiopoietin 2 (ANGPT2), IL-6 and IL-8). b) Secreted 
factors from lytic cells in turn act on receptors in latently infected cells through a paracrine mechanism. 
Together with direct pro-oncogenic activities of KSHV latent genes, such as vFLIP, vCyclin and latency-
associated nuclear antigen (LANA), as well as the KSHV-encoded microRNAs, this enhances the 
tumourigenic potential of KSHV infection. Taken from (Mesri et al., 2010). 
 
19 
 
1.2.2.1.2 Primary effusion lymphoma (PEL) 
PEL, originally called body cavity based lymphoma, is a rare non-Hodgkin’s lymphoma 
mostly affecting patients with end stage AIDS. During PEL, transformed, proliferating B-
cells enter serosal cavities of the body, such as the pleura, pericardium, and peritoneum, 
where they establish lymphomatic growth. To date, no effective treatment against PEL is 
known and as such, survival rates are very poor, with a median of 6 months after diagnosis 
(Chen et al., 2007; Boulanger et al., 2005). All tumour cells contain several copies of the 
KSHV genome, are fully immortalised and grow readily in culture (Ganem, 2007). PEL-
derived cell lines are commonly used in the laboratory, as they present a useful tool to 
study KSHV in vitro (Pagano, 2008). 
 
1.2.2.1.3 Multicentric Castleman disease (MCD) 
MCD is a rare disease, characterised by extreme hyperproliferation of lymphoid tissue 
which frequently spread to multiple organs as the disease progresses. Most cases of MCD 
are associated with AIDS, however, MCD is also known to occur in HIV-negative 
individuals. In AIDS patients, co-infection of HIV and KSHV is found in 100% of cases, 
whereas in non-HIV infected individuals only 40% of MCD cases are associated with KSHV 
infection (Soulier et al., 1995). While the involvement of KSHV in the development of MCD 
is still poorly understood, a link might involve the “pirated” KSHV-gene coding for the IL-6 
homologue, vIL-6. It is proposed that lymphoproliferation in MCD occurs via an IL-6 
mediated pathway and high levels of IL-6 are often found in tumour cells (Oksenhendler et 
al., 2000). It is therefore speculated that vIL-6 contributes to the development of MCD.  
 
1.2.2.2 KSHV life cycles 
Initial infection with KSHV occurs via attachment of the virus to the host cell plasma 
membrane. Adhesion is facilitated by the viral glycoproteins K8.1, gB, gH and gL, that bind 
to cell surface receptors. Specifically, K8.1 and gB interact with the proteoglycan heparan 
sulphate (Birkmann et al., 2001), while gB also interacts with the integrin α3β1 (Akula et 
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al., 2002). Furthermore, the glycoproteins gB, gH and gL are also important for mediating 
membrane fusion. Additional interactions with co-receptors and integrins on the cell 
surface are believed to take place prior to fusion of the viral envelope with the plasma 
membrane, allowing infection of different cell types (Garrigues et al., 2008; Kaleeba and 
Berger, 2006; Rappocciolo et al., 2006; Pagano, 2008).   
After KSHV has entered a host cell and inserted its genome into the host cell nucleus, 
primary infection is cleared through a cytotoxic T-cell response. However, virus which has 
established the latent state in B-cells is able to escape this host response, allowing 
persistence in infected individuals (Wang et al., 2001).  
 
1.2.2.2.1 Latency 
The KSHV genome circularises rapidly after entering a cell and is maintained as a non-
integrated episome in the nucleus of the infected host cell (Collins and Medveczky, 2002; 
Griffiths and Whitehouse, 2007). Only seven KSHV genes are expressed during latency, 
which are referred to as latency-associated transcripts (LATs). Three of these genes are 
transcribed from the same locus as a polycistronic mRNA undergoing alternative splicing, 
as well as translation initiation to produce LANA (ORF73), v-cyclinD (ORF72) and vFLIP 
(K13) (Jeong et al., 2004; Dittmer et al., 1998). 
The viral latency-associated nuclear antigen (LANA) is responsible for attaching the circular 
viral episomes to the host chromosome during mitosis, allowing even distribution and 
maintenance of the KSHV episome upon B-cell division (Figure 1.10) (Ballestas et al., 1999). 
Furthermore, LANA facilitates KSHV genome replication during latency, by binding to the 
ori-P and recruiting it to the nuclear matrix, where the cellular DNA replication machinery 
assembles in a cell cycle-dependent manner (Ohsaki et al., 2009). LANA has also been 
reported to influence expression of cellular and viral genes through transcriptional 
regulation mechanisms (Ballestas et al., 1999; Renne et al., 2001). Furthermore, an 
interaction with p53 and subsequent inhibition of the tumour suppressor protein has also 
been described (Friborg et al., 1999), suggesting LANA-mediated modulation of cell cycle 
control and cell growth mechanisms. KSHV v-cyclinD is the viral homologue of cyclinD and 
as such able to perform similar cellular functions. While it is able to deregulate the cell 
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cycle through interaction with cdk6 and phosphorylation of the retinoblastoma protein 
(Rb) (Godden-Kent et al., 1997), it is less responsive to cdk inhibitors p21, p27 and p16. 
Recently, v-cyclinD has also been shown to functionally cooperate with vFLIP: this viral 
homologue of the FLICE-inhibitory protein (FLIP) is known to inhibit apoptosis through 
activation of NF-κB (Liu et al., 2002; Matta et al., 2003). Specifically, although vFLIP-
dependent activation leads to p21 and p27 overexpression and subsequent G1 cell cycle 
arrest, v-cyclinD prevents this senescence through degradation of p27 (Zhi et al., 2014). 
Therefore, through its ability to resist p21/p27 inhibition and degrade p27, v-cyclinD can 
contribute to permanent vFLIP-dependent NF-κB activation.  
 
Figure 1.10: Schematic of KSHV genome segregation during mitosis. The viral protein LANA facilitates 
viral latent DNA replication by recruiting the ori-P to the nuclear matrix, where the cellular DNA 
replication machinery is assembled. LANA then functions to attach the viral episome to host 
chromosomes during mitosis to ensure even distribution of viral genome during cell division. Adapted 
from (Ohsaki and Ueda, 2012).  
 
The four other proteins expressed during latency include the Kaposin transcripts (A, B and 
C from the K12 locus), which are also expressed during lytic replication. Kaposin A has 
been shown to stabilise cellular cytokine transcripts and has transforming potential 
(Muralidhar et al., 1998), whereas Kaposin B has been implicated in activation of the 
proto-oncogene STAT3, causing chronic inflammation characteristically found in KS 
(McCormick and Ganem, 2005; King, 2013). Similarly, the latent and lytic protein LAMP is 
also associated with generating an inflammatory environment (Pietrek et al., 2010). 
Another latent protein, vIRF2, is able to act like its cellular homologues and thereby 
deregulate mechanisms controlled by interferon regulatory factors (IRFs) (Burysek et al., 
1999). Finally, the last latently expressed protein is B-cell specific: LANA2 (or vIRF3) is 
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known to interact with p53 and thereby regulates antiviral mechanisms as well as 
apoptosis (Rivas et al., 2001). 
KSHV latently infected cells also express viral miRNAs. While they are believed essential for 
maintenance of latency (Cai et al., 2005), their function is still not fully elucidated.   
 
1.2.2.2.2 Lytic replication 
External stimuli, such as a suppressed immune system, inflammation or stress stimuli can 
cause reactivation of the virus from the latent state, allowing entry into the lytic life cycle. 
The precise mechanisms of this process are yet to be completely understood. However, 
the role of the regulator of transcription activation (RTA, expressed from ORF50), which 
functions as the viral latent/lytic switch protein, has been established. Expression of RTA 
alone is sufficient to induce KSHV lytic replication (Lukac et al., 1998; Lukac et al., 1999). 
Following reactivation and expression of RTA, the temporal cascade of gene expression is 
activated, culminating in assembly, egress and finally budding of infectious KSHV virions 
from B-cells (as described before under 1.1.4.2).   
Hypoxia is known to cause KSHV reactivation via a RTA response. During this process, 
transcription factors, called hypoxia-inducible factors (HIFs), bind to the RTA promoter and 
induce RTA expression, subsequently inducing KSHV lytic replication (Davis et al., 2001; 
Haque et al., 2003). Hypoxia also activates the X-box binding protein 1 (XBP-1), which can 
in turn transactivate the RTA promoter (Dalton-Griffin et al., 2009). Moreover, XBP-1 is 
induced upon B-cell differentiation, which is also believed to initiate reactivation of the 
virus (Wilson et al., 2007). A further cell stimuli involved in the induction of KSHV lytic 
replication is signalling of the inflammatory cytokine interferon-gamma (IFN-γ) 
(Blackbourn et al., 2000). KSHV reactivation can also be initiated by co-infection with other 
herpesviruses, such as HSV-1 and CMV (Qin et al., 2008; Vieira et al., 2001). The HIV-1 
transactivator Tat is also able to induce expression of RTA and thereby KSHV lytic 
replication (Zeng et al., 2007). Furthermore, activation of toll-like receptor signalling, 
which occurs during innate immune response to some viral infections, has been implicated 
in KSHV reactivation (Gregory et al., 2009). 
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The expression of the ORF50 gene leads to the presence of RTA, the first protein following 
KSHV reactivation (Sun et al., 1998; Sun et al., 1999). RTA functions as a viral transactivator 
that can initiate gene expression through three distinct mechanisms: direct, indirect and 
via its E3 ubiquitin ligase activity (Figure 1.11).   
RTA is a transcription factor that is able to directly bind multiple promoters using a 
consensus RTA response element (RRE) (Goodwin and Whitehouse, 2001). The C-terminal 
domain of the protein contains the transcriptional activation domain, similar to that of 
many cellular transcription factors (Lukac et al., 1999), whereas the N-terminus facilitates 
binding to DNA (Song et al., 2001). RTA is also able to induce itself in a positive feedback 
loop (Deng et al., 2000).  
While RTA activates many genes containing the RRE, such as the polyadenylated nuclear 
(PAN) RNA promoter, it is also known to induce expression of genes lacking this sequence, 
such as ORF57, via an indirect mechanism. While these interactions are generally weaker, 
RTA recruits cellular transcription factors, namely Rbp-jκ (Liang et al., 2002), C/EBPα 
(Wang et al., 2003) and AP-1 (Wang et al., 2004a) to enhance the effect. Once RTA 
promoter binding has occurred, efficient recruitment of the transcription machinery 
occurs, enabling RNA polymerase II (RNAP II) to transcribe the immediate early (IE) genes 
and promoting the gene expression cascade. Hence, RTA expression is sufficient to initiate 
a cascade of events leading to the production of infectious virions. 
 In addition to its role as transcription factor, RTA has intrinsic E3 ubiquitin ligase activity 
(Yang et al., 2008). This enables RTA to target cellular and viral proteins for proteasomal 
degradation. Specifically, RTA is known to degrade the transcriptional repressor Hey1 
through a ubiquitination-mediated process (Gould et al., 2009). This leads to upregulation 
of RTA expression and lytic replication, as Hey1 occupies the ORF50 promoter to inhibit 
RTA protein production during latency.  
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Figure 1.11: RTA-mediated transactivation mechanisms. a) RTA can act directly as a transcription 
factor, binding to the RRE. b) RTA can act indirectly, by recruiting cellular transcription factors (TF) onto 
viral promoters lacking the RRE. c) Through its E3 ubiquitin ligase activity, RTA can degrade 
transcriptional repressor, upregulating the target gene expression.  
 
RTA is also involved in lytic DNA replication, through binding of the lytic origin of 
replication (ori-Lyt) via a conserved RRE (Wang et al., 2004b; AuCoin et al., 2002). Together 
with the viral protein K-bZIP, RTA facilitates formation of a replication initiation complex.  
These large, multi-protein complexes form distinct, globular replication compartments 
within the nucleus that are associated with sites of DNA synthesis during lytic replication 
(Wu et al., 2001). The viral DNA is replicated via a rolling-circle mechanism and 
subsequently cleaved into monomers within the TR region, which leads to an 
approximately 100-fold increase of viral DNA copy numbers within the cell during the lytic 
cycle.   
Alongside RTA, the second immediate-early protein essential for lytic replication is 
encoded by the ORF57 gene. ORF57 is a multifunctional protein involved in all stages of 
viral RNA processing, particularly mRNA export. To highlight the role of ORF57, the basic 
concept of mammalian mRNA export will first be explored, before describing ORF57 and 
its function in KSHV lytic replication and KSHV-mediated diseases (section 1.5).  
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1.3 Cellular mRNA export 
Eukaryotic cells are characterised by compartmentalisation, with physical boundaries 
separating organelles, which perform different biological functions. This has several 
advantages, such as the ability to maintain a specific micro-environment and to keep 
macromolecules within a region or exclude them when they are not required. However, 
this spatial separation necessities specific transport mechanisms to be present, which in 
turn allows for regulatory and quality control pathways to be incorporated. Such is the 
case with mRNAs, which are produced in the nucleus, but must be exported into the 
cytoplasm for translation to take place. The export pathway is tightly coupled to specific 
maturation processes that turn a precursor mRNA (pre-mRNA) into an export competent 
mRNA. Unsuccessful pre-mRNA processing results in nuclear retention and degradation, 
preventing faulty mRNAs from being used as templates for translation (Fasken and 
Corbett, 2009; Hilleren et al., 2001; Brodsky and Silver, 2000; Lei and Silver, 2002; Libri et 
al., 2002; Zenklusen et al., 2002). In contrast, successful maturation through splicing and 
5’- and 3’-end processing leads to a stepwise assembly of all RNA binding protein 
complexes required for efficient mRNA export.  
 
1.3.1 Cellular mRNA processing 
The first mRNA processing step occurs concurrent to transcription, after just 25–30 
nucleotides have been added to the growing pre-mRNA. The 5’-end of the nucleic acid is 
protected from 5’-3’ degradation, by a so called cap structure (Figure 1.12). The cap 
consists of a guanine nucleotide which is added to the 5’-end via an unusual 5’-5’ linkage. 
After addition, the guanine is then methylated to create a 7-methyl-guanine (m7G) cap.  
  
Figure 1.12: Structure of the mRNA 5’-cap. Taken from (Gu and Lima, 2005).  
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Next, the pre-mRNA undergoes splicing. During this process introns of the nascent 
transcript are removed and the exons are ligated together. The spliceosome, which 
facilitates this procedure, contains approximately 125 different proteins and several small 
nuclear RNAs (snRNAs) (Hocine et al., 2010). Each of the snRNAs is part of a 
ribonucleoprotein particle (RNP), which catalyses the splicing process. In addition to 
performing excision and ligation of the pre-mRNA, the spliceosome also has to negotiate 
the site of splicing, as transcripts often present multiple splicing sites in order to generate 
several proteins from one gene. Additional SR (serine/arginine-rich) proteins are often 
involved into this process (Long and Caceres, 2009).   
Finally, 5’-capped and spliced pre-mRNA is polyadenylated at the 3’-end to generate 
mature mRNA. A poly(A) tail protects the mRNA from degradation and is required for 
recognition as mature mRNA by cell surveillance mechanisms, allowing export and 
translation initiation (Doma and Parker, 2007). The polyadenylation process is again 
subject of a multiprotein complex, comprising about 85 proteins (Shi et al., 2009). This 
complex recognises polyadenylation signals transcribed in the 3’-end and cleaves the 
mRNA 10–30 nucleotides downstream of this signal, before the poly(A) tail is added. Both, 
abberant polyadenylation as well as hyperadenylation are associated with retention of the 
mRNA in the nucleus and subsequent degradation.  
 
1.3.2 The human transcription/export (hTREX) complex 
Cellular bulk mRNA export is facilitated by the human transcription/export (hTREX) 
complex, which allows recruitment of the export receptor Nxf1 (TAP) and Nxt1 (p15) onto 
mature mRNA and subsequent shuttling through the nuclear pore (Reed and Hurt, 2002; 
Aguilera, 2005; Kohler and Hurt, 2007). Several studies employing model organisms have 
shown the TREX complex to be highly conserved across plants, yeast and higher 
eukaryotes (Reed and Hurt, 2002; Reed and Cheng, 2005; Cullen, 2003; Stutz and 
Izaurralde, 2003). All known components of hTREX are listed in Table 1.3.  
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Table 1.3: Known components of hTREX. Taken from (Schumann et al., 2013). 
hTREX 
Component 
Alternative Name S. cerevisiae 
Ortholog 
Known Interactions in hTREX 
UAP56 BAT1, DDX39B Sub2 Aly, CIP29 (Dufu et al., 2010), 
Chtop (Chang et al., 2013), UIF 
(Hautbergue et al., 2009), THO 
(Masuda et al., 2005) 
DDX39 URH49, DDX39A Sub2 Aly (Golovanov et al., 2006), UIF 
(Hautbergue et al., 2009), CIP29 
(Yamazaki et al., 2010) 
Aly Ref, Alyref, Thoc4, 
Bef 
Yra1 UAP56 (Taniguchi and Ohno, 
2008), Chtop (Chang et al., 2013), 
Thoc5, Thoc2 (Chi et al., 2013) 
CIP29 HCC1, Tho1, Sarnp Tho1 UAP56 (Dufu et al., 2010) 
UIF - - UAP56 (Hautbergue et al., 2009) 
Chtop SRAG, CAO77 FOP - UAP56, Aly (Chang et al., 2013) 
SKAR pDIP3, PolDIP3 - (Folco et al., 2012) 
ZC11A ZC3H11A - (Folco et al., 2012) 
Thoc1 Hpr1, p84 Hpr1 Part of THO (Chi et al., 2013) 
Thoc2 Tho2 Tho2 Aly, Part of THO (Chi et al., 2013) 
Thoc5 fSAP79, Fmip - Aly, Part of THO (Chi et al., 2013) 
Thoc6 fSAP35, WDR58 - Part of THO (Chi et al., 2013) 
Thoc7 fSAP24 - Part of THO (Chi et al., 2013) 
Tex1 Thoc3 Tex1 Part of THO (Chi et al., 2013) 
ELG - - (Dufu et al., 2010) 
ERH DROER - (Dufu et al., 2010) 
 
1.3.2.1 Assembly and function of the hTREX complex 
As mRNAs differ greatly in length, structure and sequence, assembly of the hTREX complex 
has to be independent of these features and is instead coupled to the above mentioned 
steps of mRNA biogenesis. In 1999, research first showed that splicing events are linked to 
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mRNA export from the nucleus (Luo and Reed, 1999). Subsequently, two core proteins of 
the hTREX complex, the export adaptor Aly and the conserved RNA helicase UAP56, have 
been implicated in both processes (Zhou et al., 2000; Luo et al., 2001). UAP56, which is 
involved in spliceosome assembly, interacts with Aly directly during spliceosome formation 
and recruits the export adaptor onto the spliced mRNP. UAP56 is then believed to play a 
major role in assembly of the remaining hTREX complex, whereas Aly functions later to 
mediate binding of the export receptor Nxf1.  
In yeast, a synergy of 3’-end processing and mRNA export has also been demonstrated. 
Here, the Aly homologue Yra1 is bound by the polyadenylation factor Pcf11 at the same 
binding site used by Sub2, the UAP56 homologue, suggesting mutually exclusive 
interactions (Johnson et al., 2009b). Furthermore, a RNA- and ATP-bound Sub2 is able to 
displace Pcf11 from its interaction with Yra1, allowing Pcf11 to bind Clp1, a subunit of the 
cleavage-polyadenylation factor CF1A (Johnson et al., 2011). This interaction of Pcf11 and 
Clp1 is essential for a functioning polyadenylation complex, whereas Sub2 binding of Yra1 
is necessary for TREX formation, successfully coupling both processes. As the interaction of 
Aly and Pcf11 is conserved in metazoans (Johnson et al., 2009b), a similar combination of 
both processes can easily be imagined occurring in humans. 
Finally, hTREX is associated with the 5’-end of the mRNA (Figure 1.13). Localisation is 
determined by a direct interaction of Aly and the cap binding protein 80 (CBP80), a 
component of the cap binding complex (CBC) (Cheng et al., 2006; Chi et al., 2013; Lejeune 
et al., 2002). As such, uncapped transcripts are poorly exported (Cheng et al., 2006), 
highlighting again the cooperation between mRNA processing and export.  
 
Figure 1.13: The hTREX complex associates to the 5’-end of mRNA via an interaction with the cap 
binding complex. All components of hTREX are shown with their known interaction partner. Modified 
from (Schumann et al., 2013). 
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The THO complex, a sub-complex of hTREX formed by a number of closely-associated 
proteins, also binds CBP80 and is believed to bridge the interaction to UAP56 (Dufu et al., 
2010). However, recent contrary reports indicated THO might only associate with Aly and 
not UAP56 (Chi et al., 2013). In this study, direct interactions were detected between the 
THO components, Thoc2 and Thoc5, with Aly. These contradicting results of two 
independent studies highlight the complexity of working with a dynamically remodelled 
multi-protein complex. While a clear role has been given to THO in yeast, coupling 
transcription to mRNA export, metazoan THO subunits remain comparably poorly 
understood. In yeast, THO binding of the nascent mRNA during transcription has been 
shown, which enables the recruitment of the remaining TREX complex after mRNA binding 
(Strässer et al., 2002). No such link between transcription and export is found in 
metazoans and knockdown of THO subunits only results in a minor export block, with the 
vast majority of mRNAs still exported (Rehwinkel et al., 2004).  
In contrast, UAP56 is thought to be responsible for the recruitment and assembly of hTREX 
in metazoans. The DExD-box RNA helicase shows ATPase activity in vitro, a process now 
believed essential for complete assembly of the hTREX complex. ATP-dependency of 
hTREX was first shown for the interaction of Aly and hTREX component CIP29 (Dufu et al., 
2010). CIP29 was first identified after analysis of hepatocellular carcinoma cell proteome 
and has been implicated in several other studies in connection with cancer (Choong et al., 
2001; Fukuda et al., 2002; Hashii et al., 2004). However, bioinformatic predictions showed 
an N-terminal SAP domain and sequence homology to a variety of heterogeneous nuclear 
ribonucleoproteins (Choong et al., 2001). Following this, recent proteomic-based research 
has identified CIP29 as a new putative member of the hTREX complex, where it forms a 
trimeric complex with Aly and UAP56 (Dufu et al., 2010).  
An interaction of CIP29 and the UAP56 paralogue DDX39 has also been previously 
described (Sugiura et al., 2007). It was proposed that together, CIP29 and DDX39 form part 
of an export complex targeting a functionally distinct subset of mRNAs compared to the 
hTREX complex (Yamazaki et al., 2010). DDX39 shares 90% sequence identity and 96% 
sequence similarity with UAP56 and has also been shown to interact with Aly (Golovanov 
et al., 2006). While redundant and overlapping functions of DDX39 and UAP56 have been 
reported, the export complex formed around DDX39 was termed AREX (alternative mRNA 
export) (Yamazaki et al., 2010). Knock-down of both UAP56 and DDX39 together were 
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found to eliminate cellular bulk mRNA export, whereas loss of DDX39 or UAP56 
individually were found to cause distinct mitotic defects, consistent with each helicase 
targeting specific groups of mRNAs (Yamazaki et al., 2010). However, the function of 
DDX39 still remains poorly studied in the context of hTREX and cellular mRNA export and 
further work is required to clarify the individual roles of UAP56 and DDX39.  
UAP56 is not the only hTREX component for which redundancy has been shown. The 
serine/arginine rich proteins (SR proteins) 9G8, SRp20 and SF2/ASF can also bind the 
export receptor Nxf1, recruiting it onto spliced mRNA (Huang et al., 2003). Furthermore, 
UIF (UAP56 interacting factor) bridges the interaction of UAP56 with Nxf1, making Aly 
redundant (Hautbergue et al., 2009). Depletion of Aly or UIF individually only causes a 
minor inhibition of mRNA export, however, double knock-down causes a severe block in 
mRNA export, showing a phenotype similar to UAP56/DDX39 knock-down.  
More recently, another novel hTREX component has been identified by proteomics studies 
of the immunopurified complex: Like CIP29, Chtop was also found to bind to UAP56 in an 
ATP-dependent manner (Chang et al., 2013). However, while CIP29 binds UAP56 
concurrently with Aly, Chtop binding can be outcompeted by the presence of Aly. Both Aly 
and Chtop bind the mRNA, which is essential for mRNA export. Interestingly, this process is 
facilitated by UAP56 and can be prevented in vitro, if UAP56 is incubated with a non-
hydrolysable ATP analogue. Furthermore, Chtop, Aly and CIP29 have been shown to 
stimulate UAP56 ATPase activity in vitro. It seems therefore likely, that UAP56 loads Chtop 
and Aly sequentially onto mRNA and facilitates hTREX assembly in an ATP-cycle dependent 
manner (Figure 1.14). 
Finally, the proteins SKAR and ZC11A have also been identified as hTREX components. 
Both have been shown to interact with UAP56 in an ATP-dependent manner and function 
in mRNA export, however, their individual roles remain to be fully elucidated.  
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Figure 1.14: UAP56 assembles the hTREX complex sequentially, in an ATP-dependent manner. All 
proteins affected in the ATP-dependent assembly are shown in shades of green. Proteins not affected by 
the ATP-dependency are shown in orange. Modified from (Schumann et al., 2013). 
 
1.3.2.2 The hTREX complex and the export receptor Nxf1 
As previously mentioned, bulk mRNA exported from the nucleus into the cytoplasm of the 
cell needs to travel through selective and well controlled channels in the nuclear envelope, 
termed the nuclear pore complexes (NPCs). These NPCs are composed of around 30–50 
different nucleoporins (Nups), functioning as structural proteins, membrane anchors and 
flexible gates (phenylalanine/glycine (FG)-rich nucleoporins), which interact directly with 
nuclear export receptors. It is therefore essential that all export-competent 
ribonucleoproteins particles (RNPs) contain specific export receptors that are targeted to 
the NPC. For this, the hTREX complex recruits Nxf1 and its co-factor Nxt1, by providing a 
docking platform for the non-karyopherin heterodimer. Both Aly and Thoc5 bind Nxf1 
directly, upon assembly of the complete hTREX complex (Katahira et al., 2009). This 
induces a conformational change in Nxf1, which enables the export receptor to bind mRNA 
(Viphakone et al., 2012). Furthermore, as RNA- and Nxf1-binding domains in Aly overlap, 
binding of the export receptor induces a handover of mRNA from Aly to Nxf1 (Hautbergue 
et al., 2008). This process is controlled through post-translational methylation of the 
binding site in Aly. Moreover, binding of Nxf1 to Aly causes displacement of UAP56 from 
the hTREX complex (Figure 1.15).  
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Figure 1.15: The hTREX complex interacts with the export receptor Nxf1. The interaction with hTREX 
induces a conformational change in the export receptor. This in turn allows mRNA handover from Aly 
and leads to the dissociation of UAP56 from the complex. After Chtop binding to Nxf1 and potentially 
further remodelling (not shown here), the export competent RNP can pass through the NPC. Modified 
from (Schumann et al., 2013). 
 
Chtop, which during the earlier stages of hTREX assembly is directly associated with Aly, is 
also able to bind Nxf1 (Teng and Wilson, 2013). In addition to the above mentioned 
process, this interaction is also necessary for complete handover of mRNA from Aly to 
Nxf1 (Chang et al., 2013). The change in interacting protein partners by Chtop is regulated 
by methylation, as unmethylated Chtop was found in vivo to bind Aly, whereas methylated 
Chtop subsequently interacts with Nxf1 (Teng and Wilson, 2013). While both Chtop and 
Thoc5 are reported to bind Nxf1 directly, their interaction with the export receptor is 
mutually exclusive and yet, both proteins exist in the same complex (Chang et al., 2013). 
This suggests further remodelling of the hTREX complex upon binding of Nxf1 and prior to 
mRNA export occurring. Once transfer of mRNA to Nxf1 has taken place, the mRNP can 
traverse the NPC via a transient interaction of Nxf1 and Nxt1 with the FG-nucleoporins 
(Stewart, 2007).  
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1.3.2.3 The hTREX complex and the exon junction complex (EJC) 
The exon-junction complex (EJC) is a multiprotein complex deposited on the mRNA during 
splicing. While initially believed to be also involved in mRNA export, the EJC has more 
recently been shown to function in distinct processes, such as translational enhancement, 
mRNA localisation and nonsense-mediated decay (NMD) (Giorgi and Moore, 2007; Nott et 
al., 2004; Chang et al., 2007). Also in contrast to the hTREX complex, the EJC binds mRNA 
in more than one distinct location: proteins are deposited 20–24 nucleotides upstream of 
each exon-exon junction (Le Hir et al., 2000). This marks the spliced mRNA as mature, a 
process essential for translational enhancement of spliced transcripts (Nott et al., 2004). 
The EJC consists of four core proteins; MLN51, Magoh, Y14 and the DEAD-box protein 
eIF4AIII (DDX48) (Le Hir and Andersen, 2008). Both Y14 and Magoh are able to recruit the 
translational enhancer, PYM. PYM then functions to increase the pioneer round of 
translation, through recruitment of the 40S ribosomal subunit and assembly of the pre-
initiation complex (Diem et al., 2007). Furthermore, SKAR, a protein also found in the 
hTREX complex has been implicated in EJC functioning, where SKAR increases translation 
efficiency of spliced mRNA in response to mTOR signalling (Ma et al., 2008). This indicates 
that both complexes might be linked through individual proteins functioning in both 
processes and dynamic remodelling of both complexes.  
 
1.3.3 Alternative mRNA export pathways 
1.3.3.1 CRM1-dependent mRNA export 
In contrast to cellular bulk mRNA export, most other cargos that are moved between the 
nucleus and cytoplasm are transported via the Ran-dependent pathway. Here, proteins 
and non-coding RNAs are exported by the conserved family of karyopherin export 
receptors (exportins), namely CRM1, exportin-5 and exportin-t. While exportin-5 and 
exportin-t are utilised for miRNAs, some proteins and tRNAs, respectively, CRM1 is 
commonly used to export ribosomal RNAs (rRNAs), small nuclear RNAs (snRNAs) (Cullen, 
2003), and proteins (Kudo et al., 1997), as well as a minor subset of mRNAs. Prominent 
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examples of these mRNAs are Cd83, Fos and cyclin D1 (Prechtel et al., 2006; Brennan et al., 
2000; Alt et al., 2000). 
CRM1 is structurally different from Nxf1 and lacks an RNA binding domain (Fornerod et al., 
1997). It therefore requires the presence of an adaptor protein that bridges the CRM1-
RNA interaction. PHAX (phosphorylated adaptor for RNA export) has been named as 
CRM1-RNA adaptor protein, however, it binds exclusively to snRNAs (Ohno et al., 2000) 
and an adaptor protein for mRNA therefore remains to be identified. Recognition of 
known adaptor proteins by CRM1 occurs via a leucine-rich-type nuclear export signals 
(NES). The subsequent shuttling process is regulated by the small GTPase Ran (Moore and 
Blobel, 1993; Moore, 1998). Binding of GTP-loaded Ran (RanGTP) by CRM1 allows binding 
of the cargo, whereas the interaction with RanGDP, after GTP hydrolysis, leads to a release 
of the cargo. Directionality of transport from the nucleus into the cytoplasm is ensured via 
a gradient of RanGTP across the nuclear membrane. This gradient is generated by RanGAP 
(Ran GTPase-activating protein), which is only present in the cytoplasm (Görlich and Kutay, 
1999) and hence drives export into the cytoplasm and release of the cargo from CRM1.  
 
1.3.3.2 Nuclear budding of mRNPs 
For a long time it was believed that all mRNA was exported via the NPC, however, recently 
it was reported that, surprisingly, some mRNAs can leave the nucleus by budding through 
the nuclear membrane (Speese et al., 2012) (Figure 1.16). This process was described in 
Drosphila muscle cells during synapse development. Here, the mRNAs are packaged into 
large mRNP granules, which then bud into the perinuclear space between the inner and 
outer membrane. Interestingly, this process is mediated by Lamin C, a protein that has 
been previously implicated in muscular dystrophies when mutated (Speese et al., 2012; 
Burke and Stewart, 2002; Méjat et al., 2009). Budding from the perinuclear space into the 
cytoplasm was later found to be facilitated by the AAA-ATPase torsin (Jokhi et al., 2013). A 
similar budding mechanism has previously been described for egress of herpesvirus 
capsids after assembly in the nucleus. These multimegadalton complexes bud from the 
nucleus through inner-nuclear-membrane envelopment and outer-nuclear-membrane de-
envelopment (Lee and Chen, 2010). 
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Figure 1.16: RNP export by nuclear envelope budding. Fragments (DFz2C) of the wnt receptor 
(DFrizzled2) are internalised and transported to the nucleus. In the nucleus DFz2C forms large granules 
with RNP complexes and lamin C, which bud from the nucleus by envelopment and de-envelopment. 
Exported mRNAs function locally in synapse assembly. Taken from (Hatch and Hetzer, 2012). 
 
1.3.3.3 Export of intronless mRNA 
Export of spliced mRNA is relatively well studied, in contrast, it is fairly poorly understood 
how naturally intronless mRNAs are exported from the nucleus. Only recently, it was 
shown that some intronless transcripts can be exported via the hTREX/Nxf1 pathway (Lei 
et al., 2011). A large cytoplasmic accumulation region (CAR) is essential for export of the 
mRNA, circumventing the splicing requirement. Subsequently, a 10-nt consensus element 
(CAR-E) was found in the naturally intronless genes HSPB3, c-Jun, IFNα1 and IFNβ1 (Lei et 
al., 2013). Components of the hTREX complex, the Prp19 complex and splicing factor 
U2AF2 associate to the CAR-E and thereby facilitate mRNA export.  
An alternative mechanism has also been previously described for the transcripts of 
replication-dependent histone genes, which are intronless and lack polyadenylation. These 
mRNAs also contain consensus elements, however, they serve to recruit cellular SR 
proteins and export factors (such as 9G8 and SRp20), which in turn are able to bind the 
export receptor Nxf1 (Huang and Carmichael, 1997; Huang et al., 2003; Hargous et al., 
2006). 
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1.4 Viral mRNA export 
Viruses that replicate in the nucleus of the host cell require export of their mRNAs into the 
cytoplasm. While utilising the host machinery, viruses face the challenge of circumventing 
crucial control mechanisms to allow export of their own mRNA. The following section 
highlights how different viruses have evolved ways to exploit cellular export pathways and 
utilise them for their own need (an overview is given in Figure 1.17).  
 
1.4.1 Herpesvirus mRNA export 
Many human herpesviruses, including KSHV, EBV, HSV-1 and HCMV, recruit the complete 
or part of the hTREX complex onto their mRNA, in order to facilitate export of viral 
transcripts. However, as herpesviruses contain numerous intronless lytic genes, they face 
the conundrum of efficiently exporting these mRNAs to allow lytic replication. Therefore, 
all herpesviruses have evolved to express a highly conserved viral SR protein, which is able 
to recruit the necessary cellular proteins and facilitate export. As this forms the focus of 
this research study, herpesvirus mRNA export will be discussed in detail, as exemplified by 
KSHV and its SR protein ORF57 (section 1.5.1).  
 
1.4.2 mRNA export by other viruses 
The hTREX complex and Nxf1 export pathway is not only utilised by herpesviruses, but also 
by other viruses, such as influenza A and hepatitis B virus (HBV). While influenza A 
expresses a spectrum of different mRNAs, including intronless, intron-containing 
(unspliced) and spliced, all require the export receptor Nxf1 to be exported from the 
nucleus (Read and Digard, 2010). Viral intronless mRNAs coding for early proteins were 
shown to weakly depend on Nxf1 for export, whereas intronless transcripts coding for late 
proteins were strongly dependent on the presence of Nxf1. Unspliced, intron-containing 
mRNAs were also reliant on Nxf1, but in addition also needed to recruit UAP56. Export of 
spliced viral mRNAs, which were proposed to be exported analogous to cellular spliced 
mRNAs, showed strong dependency on UAP56, Nxf1 and weak dependency on Aly. In 
contrast, a more recent study also detected an interaction of Aly and UAP56 with the 
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intronless transcripts of the early nucleoprotein (NP), as well as for the unspliced mRNAs 
of M1 and NS1 (Yin et al., 2013). Furthermore, the same study also reported binding of 
spliced mRNA by the SR protein, 9G8. Together, this data suggests that influenza A relies 
heavily on the hTREX complex and Nxf1 export pathway. However, while spliced 
transcripts may be processed in a manner similar to cellular mRNA, it appears that 
intronless mRNA and unspliced mRNAs must employ a viral adaptor protein to bridge the 
interaction to UAP56 or Nxf1. While this protein remains yet to be identified, an 
interaction of the highly pathogenic avian influenza NP protein with Aly has recently been 
identified (Balasubramaniam et al., 2013). However, while knock-down of Aly did not 
decrease the levels of viral mRNA export; a further interaction of NP with UAP56 was 
suggested based on molecular docking evidence, and knock-down of UAP56 significantly 
reduced the viral titre. It would therefore be interesting to see if redundancy of Aly by UIF 
might be involved in this system.  
 
Figure 1.17: Strategies in viral mRNA export. Herpesviruses and hepatitis B recruit the hTREX complex 
onto their viral mRNAs to allow export via the Nxf1/Nxt1-dependent pathway. Influenza A virus is 
believed to also utilise this pathway, even though the mechanism appears to differ for subsets of 
mRNAs, whereas simple retroviruses recruit Nxf1/Nxt1 via a constitutive export element (CTE). In 
contrast, complex retroviruses utilise the CRM1-dependent export pathway.  
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Hepatitis B virus (HBV) also encodes several intronless genes. These genes contain a post-
transcriptional regulatory element (PRE), which has previously been described as essential 
for export of intronless HBV transcripts (Huang and Liang, 1993). Only very recently, the 
PRE has now been shown to specifically recruit the hTREX complex, via a cellular adaptor 
protein called ZC3H18 (Chi et al., 2014). This zinc finger protein binds to a sub-element 
within the PRE and bridges the interaction to Thoc5. Binding of Thoc5 is sufficient to 
recruit other hTREX components, as well as Nxf1 and Nxt1, for nuclear export.   
In addition to influenza viruses and HBV, simple retroviruses are also known to utilise Nxf1 
and Nxt1, to allow nuclear export of viral mRNAs. Interestingly, Nxf1 was first identified as 
a nuclear export receptor in metazoans, after it was linked with the nuclear export of 
incompletely spliced mRNAs from Mason Pfizer Monkey Virus (MPMV) (Bray et al., 1994; 
Grüter et al., 1998). These mRNAs were found to contain a constitutive transport element 
(CTE); a highly structured, cis-acting sequence sufficient for nuclear export (Bray et al., 
1994). Nxf1 was subsequently shown to bind directly to the CTE of type D retrovirus RNAs 
and thereby facilitate nuclear export (Grüter et al., 1998). Interestingly, a CTE can be found 
in both spliced and unspliced viral mRNAs, though it is only required for efficient export of 
the unspliced transcripts (Strasser et al., 2000). 
Finally, complex retroviruses, such as HIV or human T-cell leukemia virus (HTLV), are 
known to utilise the CRM1-dependent export pathway. To export viral unspliced or 
partially spliced mRNAs, HIV expresses a viral adaptor protein, termed Rev, that interacts 
with a highly structured, cis-acting motif called the Rev response element (RRE) (Malim 
and Cullen, 1991). Furthermore, Rev, which is found expressed by all members of the 
lentivirus subfamily, contains a leucine-rich sequence, serving as an NES, which recruits 
CRM1 (Fischer et al., 1995). Interestingly, Rev has been shown to suppress the Nxf1 export 
pathway via a direct interaction with CBP80, a component of the cap-binding complex 
(Taniguchi et al., 2014). Through binding of the CBC, Rev can outcompete the essential 
interaction with Aly and hence disrupt hTREX assembly and Nxf1 recruitment. Similar to 
HIV, HTLV, a member of the orthoretrovirus subfamily, encodes a Rev-like protein called 
Rex, which acts as viral interaction partner for CRM1 and functions via a similar 
mechanism (Shida, 2012).  
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1.5 KSHV ORF57 protein 
ORF57, also called MTA (mRNA transcript accumulation), is 455 aa in length, encoding a 
51 kDa protein translated from a monocistronic mRNA, containing one small intron. ORF57 
is essential for production of infectious virions during lytic replication (Han and 
Swaminathan, 2006).  Expression of ORF57 is initiated indirectly by RTA, which recruits 
other transcription factors to bind to the ORF57 promoter region. ORF57 is highly 
conserved across all Herpesviridae. Homologues in other human herpesviruses include: SM 
(also called EB2 or Mta) in EBV (Semmes et al., 1998; Ruvolo et al., 2004), ICP27 in HSV-1 
(Sandri-Goldin, 2008; Sandri-Goldin, 1998), UL69 in HCMV (Toth and Stamminger, 2008) 
and ORF4 in VZV (Ote et al., 2009). While these proteins are conserved in their function, 
they each have a distinct size and share little sequence homology, with similarities only 
described amongst the Gammaherpesvirinae. For example, the ORF57 homologues of 
KSHV, EBV and the classical gammaherpesvirus prototype herpesvirus saimiri (HVS), only 
share about 30% identity of aa residues.  
The crystal structure of ORF57 is to date not known, however, computer simulations of the 
ORF57 secondary structure suggest a largely unstructured N-terminus, while the C-
terminal domain forms primarily alpha-helices (Taylor et al., 2011). Furthermore, several 
putative functional and structural motifs have been described after analysis of the aa 
sequence (Figure 1.18) (Majerciak and Zheng, 2009). Detailed studies have revealed three 
NLS to be located within the arginine-rich region of KSHV ORF57, each of which alone is 
adequate to work as an independent NLS (Boyne and Whitehouse, 2006). However, 
mutation of any two of the three NLSs is sufficient to abolish ORF57 function (Majerciak et 
al., 2006). Concurringly, the first two of these NLSs have been shown to function together 
as a nucleolar localisation signal and it has been suggested that this nucleolar localisation 
is necessary for efficient viral mRNA export (Boyne and Whitehouse, 2006; Boyne and 
Whitehouse, 2009). 
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Figure 1.18: ORF57 aa sequence, secondary structure and putative motifs. Taken from (Majerciak and 
Zheng, 2009). 
 
ORF57 is known to bind both viral and cellular mRNAs. Accordingly, sequence analysis 
identified two RGG-motifs, putative RNA-binding sites that are commonly found in RNA-
binding proteins. While deletion of the first motif fails to cause a loss of function, mutation 
of the second motif results in a lack of mRNA binding and subsequently block in ORF57-
mediated export of target mRNAs (Nekorchuk et al., 2007). While it is presently still 
unclear, how ORF57 differentiates between cellular and viral mRNA, more recent findings 
seem to suggest an ORF57 responsive element (ORE) may be involved. The first ORE was 
identified in the KSHV polyadenylated nuclear (PAN) RNA, a non-coding RNA accounting 
for almost 80% of all KSHV lytic transcripts (Conrad et al., 2006). A 30 nucleotide ORF57-
recognition sequence has since been identified containing a specific 9 nucleotide core 
required for ORF57-binding (Sei and Conrad, 2011). Transfer of the ORE ensured ORF57 
responsiveness to a heterologous intronless reporter RNA. A very similar 9 nucleotide core 
was identified independently by a second group (Massimelli et al., 2011). Both sequences 
differ in a shift of one position. However, only 4 of these 9 nucleotides were conserved in a 
third study identifying an ORE within the KSHV vIL-6 mRNA (Kang et al., 2011). It still 
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remains to be elucidated if a similar ORE is found in other mRNAs targeted by ORF57 and if 
there is a conserved mechanism for RNA binding by this protein.  
ORF57 contains four serine/arginine or arginine/serine dipeptides, which are typical of 
cellular splicing factors, so called SR proteins. It also contains an A/T hook motif, which is 
commonly found on chromosomal DNA binding proteins, as well as transcription factors 
(Aravind and Landsman, 1998), which has led to speculation that ORF57 may also function 
as a cofactor for RTA-mediated transactivation (Kirshner et al., 2000). Furthermore, the C-
terminus contains a putative leucine zipper motif, a feature also commonly found in 
cellular transcription factors. While the leucine zipper domain is only found in KSHV ORF57 
and not its homologues, a similar leucine rich region in HSV-1 ICP27 has been shown to 
contain a nuclear export signal (Sandri-Goldin, 1998) and might therefore contribute to 
ORF57 nucleo-cytoplasmic shuttling activity (Bello et al., 1999). Two other motifs are 
found in all gammaherpesvirus homologues of ORF57: a zinc-finger motif and a GLFF motif 
that appears to be involved in ORF57-mediated transactivation and repression activities 
(Cooper et al., 1999; Hardwicke and Sandri-Goldin, 1994; Ruvolo et al., 2004).  
The high number of functional motifs encoded by ORF57 suggests that it is a 
multifunctional protein involved in all stages of viral mRNA processing. The crucial role of 
ORF57 in KSHV viral mRNA export, as well as other functions ensuring efficient expression 
of KSHV lytic genes, is discussed below.  
 
1.5.1 ORF57-mediated mRNA export 
As mentioned above, KSHV expresses numerous intronless transcripts. However, host cells 
have an arsenal of mRNA surveillance and control mechanisms coupled to the mRNA 
export pathway, meaning intronless viral mRNAs would be retained in the nucleus, as they 
cannot recruit the hTREX complex via splicing. To circumvent this serious obstacle, KSHV 
expresses the immediate early protein ORF57, which itself is intron-containing and 
therefore expressed via the cellular pathway.  
ORF57 was first shown to interact with the export adaptor Aly to form an export 
competent viral ribonucleoprotein particle (vRNP) (Malik et al., 2004b). Subsequently, the 
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complete hTREX complex was shown to be recruited onto viral mRNA through the 
interaction of Aly and ORF57 (Boyne et al., 2008). This is believed to be facilitated through 
the recruitment of UAP56 via Aly, which can then assemble the remaining members. 
Analogous to the mechanism of the endogenous hTREX complex, ORF57 recruitment of Aly 
allows the subsequent recruitment of the export receptor Nxf1, which then facilitates 
transport of the viral mRNA through the nuclear pore. Importantly, a study employing 
trans-dominant Aly mutants, which were able to interact with ORF57 and Nxf1, but unable 
to bind UAP56, failed to efficiently mediate viral mRNA export and led to a decrease in 
virus replication (Boyne et al., 2008). This confirms that recruitment of the complete 
hTREX complex is required for efficient viral mRNA export to take place, whereas the 
presence of Aly and Nxf1 alone is not sufficient.   
While little detail is known of how ORF57 recruits Aly or facilitates subsequent UAP56 
binding and assembly of the remaining hTREX components, structural data has recently 
been produced for the model gamma-herpesvirus, herpesvirus saimiri (HVS), describing a 
handover of viral mRNA from ORF57 to Aly (Tunnicliffe et al., 2014). Upon interaction of 
the viral protein with the export adaptor, the RNA binding domain in ORF57 is partially 
occupied by Aly, causing a release of part of the viral RNA, which is then bound by Aly, 
forming a ternary complex.  
As mentioned previously, ORF57 contains three nuclear localisation signals, two of which 
function together as a nucleolar localisation signal (Boyne and Whitehouse, 2006; 
Majerciak et al., 2006). Accordingly, ORF57 shuttles through the nucleolus, a process 
essential for viral mRNA export both in KSHV (Boyne and Whitehouse, 2009) and HVS 
(Boyne and Whitehouse, 2006) (Figure 1.19). ORF57 shuttling leads to all components of 
the hTREX complex to be re-localised to the nucleolus, where they co-localise with ORF57. 
It can be speculated that ORF57-mediated localisation to the nucleolus might protect viral 
mRNA from cellular mRNA surveillance and degradation. Alternatively, this could be the 
site where further viral mRNA modifications occur. This is concurrent with research 
suggesting that shuttling between the nucleus and nucleolus occurs before ORF57 
facilitates exports viral mRNA into the cytoplasm and is then recycled back into the 
nucleus (Jackson et al., 2012). However, the precise mechanisms and reasons of ORF57 
shuttling have to yet to be fully elucidated.  
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Figure 1.19: ORF57 recruits the complete hTREX complex onto the viral mRNA. ORF57-bound hTREX 
can be seen re-localising to the nucleolus of the host cell, a sub-nuclear structure through which ORF57 
is known to shuttle prior to mRNA export. Modified from (Schumann et al., 2013). 
 
ORF57 binds the mRNA export adaptor protein Aly to recruit hTREX. However, redundancy 
of Aly on a cellular level is reflected in viral mRNA export; ORF57 is also able to interact 
with UIF, enabling efficient viral mRNA export even if Aly is depleted (Jackson et al., 2011). 
Analogous to the mechanism in endogenous mRNA export, knock-down of just one of the 
two export adaptor results only in minor loss of ORF57-mediated mRNA export. However, 
siRNA knock-down of both Aly and UIF blocks viral RNA export and leads to a drastic 
decrease in viral protein expression. While UIF seems to be a compensatory export 
adaptor, with levels of mRNA export lowered upon Aly depletion and ORF57 preferentially 
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interacting with Aly, UIF is both able to bind viral mRNA, and facilitate binding of ORF57 
and the viral transcripts to UAP56 (Jackson et al., 2011). Furthermore, interactions have 
also been shown with the cellular mRNA export factors OTT3 and RBM15, both of which 
seem to play a role in the expression of some viral transcripts (Majerciak et al., 2011).  
Similar redundancy has been suspected for the HSV-1 homologue ICP27, which also 
facilitates export of viral mRNA (Koffa et al., 2001): Initial studies reported the interaction 
of the viral protein with Aly was not required for viral mRNA export, instead a direct 
interaction of ICP27 with Nxf1 was deemed essential (Johnson et al., 2009a). However, 
following studies based on structural data predicted direct binding of the two proteins and 
modelled an interface of the ICP27/Aly interaction (Tunnicliffe et al., 2011). Three key 
residues in the interaction of ICP27 and Aly were shown to be essential for HSV-1 ICP27-
mediated mRNA export and virus replication.  
As mentioned previously, ORF57 is highly conserved and several homologues have been 
shown to interact with all or some hTREX components. The EBV protein EB2 is also known 
to promote viral mRNA export via a direct interaction with Aly (Hiriart et al., 2003). VZV 
has also been reported to export viral mRNAs through the Nxf1/Nxt1 export pathway. 
Accordingly, the ORF57 homologue IE4 interacts with Aly and Nxf1, as well as other cellular 
export factors such as ASF/SF2, 9G8 and SRp20 (Boyne and Whitehouse, 2006). 
Interestingly though, not all herpesviruses require a direct interaction of their ORF57 
homologue with Aly: the HCMV UL69 protein interacts directly with UAP56, which is 
sufficient to recruit all other hTREX components (Lischka et al., 2006). Together this data 
suggests that while the precise mechanisms of mRNA export may vary, the requirement to 
recruit the TREX complex, via an interaction with ORF57 or its homologues, onto viral 
mRNA is conserved between all herpesviruses.  
 
1.5.2 Other roles of ORF57 
In addition to viral mRNA export, ORF57 is involved in all aspects of viral mRNA processing, 
as will be described in detail below. 
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1.5.2.1 Transcriptional enhancement by ORF57 
ORF57 interacts with the major transcriptional activating protein, RTA, to enhance 
efficiency of protein expression and thereby contributes to the expression cascade in KSHV 
lytic replication. As mentioned previously, ORF57 contains an A/T hook, which is able to 
bind DNA and has been shown to function as a co-transactivator for selected viral genes. 
Specifically, ORF57 enhances the effect of RTA upregulating activity of PAN/nut-1, Kaposin, 
ori-Lyt (L), K-bZIP, and TK promoters in vitro (Malik et al., 2004a; Kirshner et al., 2000; 
Palmeri et al., 2007). However, no ORF57-mediated transactivation was found on 
promoters that do not respond to RTA, such as ISRE and SV40 promoters (Malik et al., 
2004a), making this an RTA-dependent effect.  
Furthermore, ORF57 has been demonstrated to interact with a second KSHV transcription 
factor, K-bZIP. Here, ORF57 also binds the K-bZIP promoter in association with the K-bZIP 
protein, to autoregulate K-bZIP gene expression (Hunter et al., 2013).  
 
1.5.2.2 Stabilisation of mRNA by ORF57 
As the original name of ORF57, mRNA transcription accumulation (MTA), suggests, ORF57 
has long been known to enhance the accumulation and stability of viral transcripts 
(Nekorchuk et al., 2007; Stubbs et al., 2012). A prime example is the above mentioned 
polyadenylated nuclear (PAN) RNA, a transcript found in great abundance upon KSHV lytic 
replication. As stated above, studies employing PAN RNA led to advances in identifying the 
ORF57 response element (ORE) and mechanisms of ORF57-mediated transcript stability. It 
is speculated that recruitment of ORF57 and thereby recruitment of cellular mRNA 
processing proteins, allows masking of the viral mRNA against cellular aberrant RNA 
surveillance mechanisms. Specifically, ORF57 directly interacts with the cellular 
polyadenylate-binding protein cytoplasmic 1 (PABPC1), which is then recruited into the 
nucleus, where PAN is retained (Massimelli et al., 2011). The interaction with PABPC1 is 
essential for ORF57 to bind the PAN ORE and therefore it is believed to be an essential 
factor for ORF57-mediated PAN stability. A second ORF57-mediated mechanism was 
identified for the stabilisation of vIL-6. Here, binding of ORF57 to the vIL-6 mRNA was 
found to outcompete binding of a cellular miRNA and thus protect the transcript from 
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miRNA-mediated degradation (Kang et al., 2011). Moreover, ORF57 was found to protect 
the cellular IL-6 mRNA in a similar manner. This implies that ORF57 enhances transcript 
levels of both viral and cellular genes. Interestingly however, while a stabilising effect has 
been shown for many viral mRNAs (including ORF47, ORF59 and PAN), ORF57 binding does 
not necessarily convey enhanced stability, as is case for vGPCR and K5 mRNAs (Boyne et 
al., 2008; Kirshner et al., 2000). This mechanism of stability enhancement and the reasons 
for it are an ongoing area of research.   
 
1.5.2.3 Translational enhancement by ORF57 
The exon-junction complex (EJC) is a multi-protein complex deposited on the mRNA upon 
splicing, just upstream of every exon-exon junction. The EJC functions in translational 
enhancement, mRNA localisation and nonsense-mediated decay (NMD) (Giorgi and 
Moore, 2007; Nott et al., 2004; Chang et al., 2007). As marking of mRNA by the EJC is 
splicing dependent, KSHV faces a similar conundrum to the recruitment of hTREX. 
Interestingly though, ORF57 does not facilitate binding of the EJC onto unspliced viral 
mRNAs. Instead, ORF57 interacts directly with the translational enhancer PYM, which is 
endogenously recruited onto the mRNA by EJC components (Boyne et al., 2010a) (Figure 
1.20). PYM is able to directly interact with the small ribosomal subunit, and as such the 
interaction of ORF57 and PYM is sufficient to facilitate assembly of the 48S pre-initiation 
complex onto viral intronless mRNAs (Boyne et al., 2010a; Boyne et al., 2010b; Diem et al., 
2007). Furthermore, ORF57 has been shown to interact with SKAR, which has been shown 
to associate with both the EJC and the hTREX complex (Ma et al., 2008; Dufu et al., 2010). 
SKAR interacts with the 40S ribosomal protein S6 kinase 1 (S6K1), and hence regulates 
enhancement of translation in response to mTOR signalling. Together, binding of PYM and 
SKAR on mRNA leads to enhancement of the pioneer round of translation.  
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Figure 1.20: ORF57 recruits the translational enhancer PYM onto viral mRNA. This interaction is 
sufficient for recruitment of the 48S-preinitiation on viral target transcripts. It is speculated that hTREX 
components are recycled back into the nucleus at this stage. Modified from (Schumann et al., 2013). 
 
1.5.2.4 Regulation of splicing of viral transcripts by ORF57 
Though the majority of KSHV genes are intronless, a small sub-set of genes do contain 
introns. The products of these genes are essential at all stages of the KSHV life cycle. It is 
therefore not surprising that, in contrast to its viral homologues, ORF57 can also act to 
enhance splicing of viral transcripts (Majerciak et al., 2008). While cellular genes usually 
contain small exons and large introns, KSHV genes feature a large exon upstream of a 
small intron. This unusual distribution leads to poor processing of the viral transcripts by 
the cellular splicing machinery. Surprisingly, ORF57 was found to specifically interact with, 
and enhance splicing of, both viral and non-viral constructs containing a large exon 
followed by a small intron. The viral protein was found to recruit the components of the 
spliceosome complex, such as small nuclear RNAs (snRNAs) U1, U2, U4, U5 and U6, as well 
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as splicing factors ASF/SF2 and U2AF. Interestingly, the interaction of ORF57 with 
inefficiently spliced pre-mRNA only takes place in the presence of whole nuclear extracts 
and not when using purified protein in vitro. This indicates that the interaction is not 
direct, with ORF57 requiring cellular components to modulate the normal splicing process. 
The EBV-homologue SM protein has also been shown to influence splicing, though 
opposed to ORF57, it mediates the selection of the splicing site (Verma and Swaminathan, 
2008).  
In contrast, other herpesvirus ORF57 homologues, such as HSV-1 ICP27 or HVS ORF57, are 
known to inhibit cellular splicing (Bryant et al., 2001; Whitehouse et al., 1998; Hardy and 
Sandri-Goldin, 1994). This process is part of the virus host shut-off (VHS), a mechanism 
closely associated with herpesvirus lytic replication (Fenwick and Clark, 1982). Unspliced 
pre-mRNAs are retained in the nucleus and subjected to mRNA surveillance and 
degradation, which leads to an overall downregulation in host gene expression (Fasken 
and Corbett, 2009).  
 
1.6 KSHV drug discovery 
1.6.1 KSHV inhibitors 
1.6.1.1 Current treatment options 
To date, no effective vaccines have been developed to prevent KSHV infections; however, 
a small number of anti-herpesvirus drugs have been shown to be efficacious against KSHV. 
As such, both prophylactic antiviral treatment, to prevent KSHV lytic replication and thus 
KS formation, as well as treatment of KS through general chemotherapeutic agents is 
advised.   
Though in theory many aspects of the herpesviral life cycle present viable drug targets, all 
KSHV inhibitors (and in fact all general anti-herpesvirus drugs) in current clinical use are 
nucleoside analogues targeting the viral DNA polymerase. However, different efficacies are 
seen for herpesvirus subfamilies and a generally poor response is observed for KSHV for 
many of these drugs, compared to the alphaherpesvirus subfamily. Nucleoside analogues 
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are administered as pro-drugs, meaning they are provided as pharmacologically inactive 
compounds which are then converted into the active form through enzymatic processes. 
Pro-drugs are often used in drug development to enhance bioavailability, stability or target 
specificity. In case of anti-herpesvirus medication, nucleoside analogues require 
phosphorylation to be converted into triphosphates and subsequently present a target for 
the viral DNA polymerase. Many nucleoside analogues rely specifically on activation by a 
viral thymidine kinase and thus their active form is restricted to virus infected cells (Figure 
1.21a). In KSHV, two viral encoded kinases were identified to phosphorylate nucleoside 
analogues and convey drug sensitivity: ORF21, a homologue of the conserved HSV-1 
thymidine kinase, and ORF36, a homologue of the herpesvirus phosphotransferase 
(Cannon et al., 1999). However, some nucleoside analogues are activated by cellular 
kinases and function through their higher affinity for the viral DNA polymerase (Figure 
1.21b). After activation, the triphosphate form of the inhibitor functions as guanosine 
analogue and is incorporated into the DNA template, by the viral DNA polymerase, as an 
alternative substrate, where it subsequently leads to chain termination.  
 
Figure 1.21: Mechanism of action of ganciclovir and cidofovir. a) ganciclovir (GCV), b) cidofovir 
(HPMPC). Both nucleoside analogues are delivered as pro-drugs that require activation through 
phosphorylation either by the viral thymidine kinase (vTK) or cellular kinases (Kinase). They are 
subsequently used as alternative substrates by the viral DNA polymerase, where they terminate chain 
elongation. MP = monophosphate, DP = diphosphate, TP = triphosphate. Modified from (De Clercq, 
2002). 
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A number of studies have indicated gancivlovir has some efficacy against KS development, 
further implicating the lytic replication cycle in KS development (summarised in: (Gantt 
and Casper, 2011)). One study in particular included ganciclovir as an additional treatment 
of HCMV-mediated retinitis in HIV-patients, where the incidence rate of KS was found 
reduced by 75% if administered orally and by 93% if given intravenously, when compared 
to intraocular treatment alone  (Martin et al., 1999). In contrast, other studies have shown 
little efficacy for DNA synthesis inhibitors in the treatment of KS. For example, some case 
reports indicated cidofovir and foscarnet could improve KS treatment, whereas other 
observational studies failed to report any clinical benefit of these drugs (Fife et al., 1999; 
Mazzi et al., 2001; Little et al., 2003). While continuous KSHV lytic replication is essential 
for the development and persistence of KS, DNA polymerase inhibitors may not be 
effective enough to prevent complete virus replication. Alternatively, the KSHV thymidine 
kinase does not process these pro-drugs as efficiently as the alphaherpesvirus enzymes. 
Furthermore, while these drugs target termination of DNA replication, expression of 
delayed early lytic proteins with tumourigenic activity (e.g. vIL-6 and vGPCR) might still 
occur (Lu et al., 2004; Klass et al., 2005). As such, new antiviral treatments against KSHV 
are needed.  
Besides inhibition of KSHV, other approaches in the treatment of KS have focused on signal 
transduction pathways that are altered by the virus upon endothelial cell infection. While 
no therapies have been developed yet that target viral gene products directly, targeting 
cellular components within these pathways has been a promising approach. Specifically, 
inhibition of growth factor receptors c-kit and PDGF, which are activated by autocrine and 
paracrine mechanisms during KSHV endothelial cell infection, has proven successful in 
clinical trials (Koon et al., 2014). Promisingly, this c-kit/PDGF inhibitor imatinib mesylate 
(Gleevec) is already approved for the treatment of chronic myeloid leukemia. Another 
angiogenesis inhibitor, bevacizumab (trade name Avastin); a humanised anti-VEGF-A 
antibody, has also shown some efficacy in phase II clinical trials (Uldrick et al., 2012). 
Again, this inhibitor has previously been licensed to treat other cancers, such as kidney or 
ovarian cancer.  
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1.6.1.2 Novel approaches of herpesvirus therapy 
After decades of use of viral DNA polymerase inhibitors, such as acyclovir, the first HSV-1 
mutants have now evolved resistant to these drugs (Bacon et al., 2003). Therefore, novel 
approaches for herpesvirus inhibition are required. Current research has focussed on a 
series of helicase-primase inhibitors, which inhibit virus genome replication at the initial 
point of double strand unwinding (Katsumata et al., 2011). In addition, compounds 
targeting the terminase enzyme, which cleaves newly synthesised genomes prior to capsid 
packaging, were found to be promising against HCMV replication (Goldner et al., 2011). 
Other areas in herpesvirus treatment have explored drug targets in virus assembly and 
egress, protein expression, as well as attachment and entry. Promisingly, one inhibitor 
falling into the latter category was recently described for KSHV: natural ligands could 
inhibit the interaction of the viral gH/gL glycoprotein complex with the cellular ephrin 
receptor tyrosine kinase A2 (EphA2), which is utilised by the virus for cell entry (Hahn and 
Desrosiers, 2014). Though only described in vitro, the small molecule inhibitors could 
effectively prevent KSHV infection of target cells. This further highlights the little explored 
avenue of targeting cellular proteins as antiviral targets. Advantages of this are fewer 
occurrences of drug-resistance and potentially a broader activity against a range of viruses, 
although compounds targeting cellular pathways always bear the risk of cytotoxic side 
effects. 
 
1.6.2 Drug development 
Modern drug discovery and development is a very long, expensive and yet inefficient 
process. A recent estimate suggested a cost of US $1.4 billion for developing a new drug, 
with the trend of the last 50 years being a doubling in (inflation-adjusted) cost every nine 
years (Lombardino and Lowe, 2004). The average time required for research and 
development (R&D) before approval of a first-in-class drug is 22 years (Eder et al., 2014). 
However, this estimation does not take into account the numerous trials that never yield 
an approved drug. Of all potential compounds taken into the development phase of R&D, 
only 4-7 % proceed through Phase I–III clinical trials, making drug development a highly 
risk associated process. Furthermore, none of these estimates take into account time and 
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cost of the fundamental research that lead to the discovery of the biological target, on 
which the drug development is based. Typical R&D starts after key discoveries have been 
made, which allow hypotheses on potential therapeutics. Following this, high-throughput 
screening (HTS) is commonly used in both target- and system-based approaches to identify 
suitable compound “hits”. These hits are compounds that display the relevant biological 
activity, which then undergo optimisation to generate more active lead compounds, a 
process known as hit-to-lead. The next phase, called lead optimisation, aims to generate 
new analogues with more extensive changes to chemical and physical properties of the 
compound, to improve potency, reduce off-target activity and enhance theoretical 
pharmacokinetics. Finally, the lead and several backup compounds will be taken into 
preclinical and clinical development; the “D” phase of R&D. Figure 1.22 displays the major 
stages of R&D and gives indications of compound numbers taken forward.   
 
Figure 1.22: Stages of research and development during a drug discovery cascade. Numbers of HTS 
compounds and hits vary widely between screening and are for illustrative purposes only. One in 5–10 
leads are taken forward as drug candidates. One in 15–25 candidates pass phase I–III clinical trials and 
are approved as drugs. Adapted from (Hann and Oprea, 2004). 
 
Traditionally, development of a first-in-class drug focused heavily on system-based 
approaches (Figure 1.23a). These include phenotypic screening, based on a phenotype 
change in vitro or in vivo, and chemocentric approaches, which focus on known 
compounds or compound classes identified from “natural remedies” or through accidental 
findings (Eder et al., 2014). However, recent advances in research and emergence of more 
sophisticated techniques lead to more heavy investment in target-based approaches. 
Opposed to system-based drug discovery, these are hypothesis driven, focusing on a 
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known biological target. This can include development of synthetic small molecules, or 
naturally occurring, biologic compounds. Though this shift in R&D approach has taken 
place over three decades ago, results have only become visible: since 1999, target-based 
drug discovery started to yield more approved drugs than system-based approaches 
(Figure 1.23b and c). Promisingly, data suggests that drugs identified in target-based 
approaches take less time in their development, with a median of 20 instead of 25 years 
(Eder et al., 2014).  
 
Figure 1.23: Target-based vs. system-based approaches in drug discovery. First-in-class drugs approved 
between 1999 and 2013 by the US Food and Drug Administration. a) Classification of approaches. 
NDA = New drug application, BLA = biologics license application. b) Total number of first-in-class 
compounds and their discovery approach. c) 15-year trend of discovery approach yielding new drugs, 
indicating an increase in target-based approaches. Taken from (Eder et al., 2014). 
 
1.6.2.1 Rational-based drug design 
While target-based drug development is often used synonymously to rational-based drug 
design, the latter describes a more focussed approach, in which existing knowledge about 
the target allows for a smaller and better selected set of candidate compounds during the 
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screening stage (Figure 1.24). In contrast, general target-based drug design might involve a 
known purified protein (the target) and HTS of several hundred-thousand compounds for 
“trial and error” testing. As illustrated in Figure 1.24, more detailed knowledge is inversely 
correlated with the diversity needed during the screening stage of drug discovery, yielding 
rational-based drug design.  
 
Figure 1.24: Knowledge plot highlighting the approach of rational-based drug design. Available 
knowledge of the target site is inversely proportional to the diversity in screening sets needed. Adapted 
from (Leach and Hann, 2007). 
 
The aim of rational-based drug design is to identify a starting set of candidate compounds 
with “drug-like” properties. Common techniques used for rational-based drug design 
include, but are not limited to, structure-based drug design, ligand-based drug design and 
fragment-based drug design, all of which can be combined and overlapping when applied. 
Furthermore, any of these techniques can be combined with computational methods, such 
as in silico or virtual HTS (vHTS), docking studies or modelling tools, to yield an even more 
targeted set of potential drug candidates.  
Ligand-based drug design relies on previously known molecules that bind to the target 
area. Knowledge from these ligands can then be used to generate a model of the target 
site, to subsequently produce a series of new and better binding molecules. A similar 
process can be found during lead discovery and optimisation, where known ligands are 
improved in their properties through generation of a quantitative structure-activity 
relationship (SAR). Opposed to this structure-based drug design relies heavily on 
knowledge of the three dimensional structure of the biological target site. Often combined 
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with vHTS, this allows quickly narrowing down a large number of molecules to those 
complementing the targets binding properties, using bioinformatics tools. These receptor-
based screening softwares are based on docking and scoring algorithms, which allow 
prediction of the binding mode (docking) and affinity (scoring) (Ghosh et al., 2006). 
Structure-based drug design can also include de novo design of compounds, where these 
are virtually built or assembled within the constraints of the known binding pocket. This 
approach can easily be combined with fragment-based drug design, where molecules with 
low molecular mass are used for in vitro (and in silico) screening. Each fragment can be 
regarded as a binding epitope, which when combined amount to the entity of a drug 
molecule (Jencks, 1981; Farmer and Ariens, 1982). Fragment hits can be linked together 
(Figure 1.25a), or used for fragment evolution (Figure 1.25b) to generate a drug-like 
molecule.  
 
Figure 1.25: Methods in fragment-based drug design: Fragment linking and fragment evolution. 
a) Fragment linking describes the combination of several identified fragments into one drug molecule, 
whereas b) fragment evolution is based on one fragment hit, which is then expanded within the known 
constraints of the binding pocket. Modified from (Rees et al., 2004). 
 
Advantages of fragment-based drug design include the comparatively smaller and simpler 
chemical structures, which need to be targeted against the known biological features. Less 
complex structures increase the probability of matching the target binding site. 
Furthermore, even a small number of screened fragments offer the possibility to be 
combined in numerous permutations, creating large diversity with little screening efforts. 
However, because of their lower affinities, fragment screening in vitro often requires 
different assay conditions to compound screening.  
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Cut-off values are often imposed on fragments and compounds during identification and 
screening, to ensure they display lead-likeness (i.e. they are likely to be suitable for lead 
generation). During in vitro screening fragments are usually expected to function in a 
range between 100 μM to 1 mM, whereas suitable compounds identified by (v)HTS or 
structure-based drug design are expected to be potent at 100 μM or lower, in order to be 
taken forward into optimisation. Another important requirement, beside affinity for the 
target structure, is the molecular weight (Figure 1.26). During lead optimisation, which is 
used to enhance the binding affinity amongst other properties, an increase in the relative 
molecular mass is almost always unavoidable. However, functioning drug molecules tend 
to have a relative molecular mass below 500, whereas larger molecules often display 
unfavourable binding, bioavailability or pharmacokinetics. It is therefore desirable to start 
off by screening compounds of low molecular mass, to achieve development a suitable 
drug candidate.  
 
Figure 1.26: Range of potency and molecular mass of fragments, HTS hits and drugs/drug candidates. 
The schematics highlight average properties. While fragments have a lower molecular mass, their 
effective concentration range is usually one order of magnitude higher than HTS hits. Lead optimization 
will almost always increase the molecular weight of a compound, but also allow a much smaller effective 
concentration. Taken from (Rees et al., 2004). 
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1.7 Thesis aim 
The KSHV ORF57 protein is involved in all steps of viral mRNA processing, in particular viral 
nuclear mRNA export. ORF57 recruits the complete hTREX complex to form an export-
competent vRNP (Boyne et al., 2008). Disruption of the ORF57/hTREX complex interaction 
has been shown to significantly inhibit virus lytic replication, suggesting this is a viable 
antiviral target. Furthermore, KSHV lytic replication is essential for the development of KS 
tumours and as such disruption of the ORF57/hTREX interaction could have additional 
advantages for preventing KS development.  
The aim of this thesis was to determine whether the ORF57/hTREX interaction provides a 
suitable antiviral target and subsequently identify lead compounds as a novel approach in 
KSHV drug development.  
Chapter three arose from the recent finding that CIP29 is part of the hTREX complex (Dufu 
et al., 2010) and aimed to determine whether CIP29 is also part of the ORF57-induced 
vRNP. Following this, the functional significance of the CIP29/ORF57 interaction for viral 
mRNA export was explored. Finally, the ATP-dependency of the trimeric CIP29-UAP56-Aly 
complex in conjunction with the ORF57 mediated vRNP was investigated.  
Chapter four further explored the ATP-dependency of ORF57-mediated vRNP formation. 
Showing not only ATP-dependency, but an ATP-cycle dependent remodelling of the hTREX 
complex, it was established that trapping the hTREX complex in one conformation could 
disrupt vRNP formation. Based on this, rational-based drug design was utilised to identify 
possible compounds targeted to a hTREX component, UAP56. In vitro screening 
subsequently identified a suitable inhibitor, which was shown to disrupt the ORF57/hTREX 
interaction in a concentration range where no cellular toxicity was observed. Furthermore, 
this compound could prevent viral mRNA export, viral late protein expression and virus 
replication in a physiologically relevant cell line.  
Chapter five then investigated the effect of close structural analogues of the inhibitor, to 
confirm a structure-activity relationship. Furthermore, off-target effects of the inhibitor 
and its analogues were explored. Finally, the efficiency of the identified inhibitor was also 
tested against HSV-1, to examine pan-herpesviral activity.  
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2 Material and Methods 
2.1 Materials 
2.1.1 Chemicals  
All chemicals were purchased from Melford, Fisher Scientific, Sigma-Aldrich® and VWR 
International Inc., unless otherwise stated.  
 
2.1.2 Cell culture reagents 
All reagents, media and selection antibiotics used in cell culture were supplied as shown in 
the table below (Table 2.1). 
Table 2.1: List of cell culture reagents and their suppliers. 
Reagent Supplier 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
Lonza 
Phosphate buffered saline (PBS) 
RPMI1640  
Opti-MEM®  
Foetal bovine serum (FBS) Life Technologies 
Penicillin/streptomycin  
Trypsin-EDTA  
Hygromycin B 
InvitrogenTM 
Lipofectamine® 2000 
Doxycycline hyclate Sigma-Aldrich® 
Agarose (low melt temperature) Melford 
 
2.1.3 Antibodies 
All primary antibodies, their working dilutions and suppliers are shown in Table 2.2. 
Horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit secondary IgG, used 
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for Western blotting at a 1:5000 dilution, were obtained from Dako. HRP-conjugated anti-
sheep IgG, also used at a 1:5000 dilution for Western blotting, was purchased from Santa 
Cruz Biotech®. Alexa Fluor® 594- and 647-conjugated rabbit anti-mouse IgG and goat anti-
rabbit IgG, used for immunofluorescence microscopy at a dilution of 1:500, were 
purchased from Life Technologies. 
Table 2.2: Primary antibodies, their working dilution and suppliers. 
Antibody Origin Working dilution  Supplier 
     WB             IF 
Anti-GFP Mouse 1:5000 - Clontech 
Anti-ORF57 Mouse 1:1000 -  
Anti-B23.1 Mouse - 1:200 Santa Cruz Biotech® 
Anti-HSP90 Mouse 1:1000   
Anti-FLAG Rabbit 1:5000 1:200  
Sigma-Aldrich® 
Anti-Aly Mouse 1:5000 1:200 
Anti-Myc Mouse 1:5000 - 
Anti-HSP90 Mouse 1:5000 - 
Anti-UAP56 Rabbit 1:2500 - Stuart Wilson, University of 
Sheffield Anti-CIP29 Rabbit 1:2500 1:200 
Anti-Chtop Rabbit 1:5000 - Bethyl Laboratories, Inc. 
Anti-mCP Sheep 1:1000 - Exalpha Biological, Inc. 
Anti-GAPDH Mouse 1:5000 - 
Abcam® 
Anti-CDC2 Mouse 1:5000 - 
Anti-ICP27 Mouse 1:1000 - Rozanne Sandri-Goldin, 
University of California, Irvine 
 
2.1.4 Enzymes 
All enzymes used and their suppliers are listed in Table 2.3.  
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Table 2.3: List of enzymes and their suppliers.  
Enzyme Supplier 
M-MuLV Reverse Transcriptase New England Biolabs, Inc. 
DNA-free™ (DNase treatment kit) Ambion® 
Kinase Glo Promega 
DNAse I  
RNase OUTTM InvitrogenTM 
RNase A  
Lysozyme Sigma-Aldrich® 
Proteinase K Millipore 
 
2.1.5 Oligonucleotides 
Oligonucleotide primers for quantitative PCR (qPCR), as well as oligo(dT)15 were obtained 
from Sigma-Aldrich®. Utilised primers and their sequences are shown in Table 2.4. CIP29-
specific small interfering RNA (siRNA) was purchased from Thermo Scientific as siGENOME 
SMARTpool against human CIP29.  
Table 2.4: List of oligonucleotides and their sequences [Forward (F) and Reverse (R)]. 
Gene name Sequence (5’-3’) 
GAPDH  F - TGTGGTCATGAGTCCTTCCACGAT 
GAPDH  R - AGGGTCATCATCTCTGCCCCCTC 
ORF47  F - CGCGGTCGTTCGAAGATTGGG 
ORF47  R - CGAGTCTGACTTCCGCTAACA 
ORF57 F - GCCATAATCAAGCGTACTGG 
ORF57  R - GCAGACAAATATTGCGGTGT 
 
2.1.6 Plasmid expression constructs 
All plasmid expression constructs were either present in the Whitehouse laboratory or 
kindly provided by collaborators, as shown in Table 2.5.  
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Table 2.5: Plasmid expression constructs, their source and reference literature.  
Plasmid Kindly provided by Reference 
GST (pGEX-4T.1) GE Healthcare Commercially available 
GST-CIP29 Stuart Wilson, University of Sheffield (Dufu et al., 2010) 
GST-UAP56 
Robin Reed, Harvard Medical School (Masuda et al., 2005) 
GST-Aly 
GFP (pEGFP-N1) Clontech Commercially available 
ORF57-GFP James Boyne (Whitehouse laboratory) (Majerciak et al., 2006) 
GFP-UAP56 Adam Taylor (Whitehouse laboratory) - 
UIF-GFP 
Stuart Wilson, University of Sheffield 
(Hautbergue et al., 2009) 
FLAG-CIP29 (Dufu et al., 2010) 
FLAG-PYM Gideon Dreyfuss, University of 
Pennsylvania 
(Diem et al., 2007) 
FLAG-β-catenin Dave Griffith (Whitehouse laboratory) - 
mCherry-ORF57 
James Boyne (Whitehouse laboratory) 
(Boyne et al., 2010a) 
ORF47 (Boyne et al., 2008) 
 
2.1.7 Screening compounds 
All screening compounds and fragments were part of an in-house compound library of the 
University of Leeds or purchased with a Tocriscreen Compound Library from Tocris 
Bioscience. Compounds used for further characterisation and their suppliers are listed 
below.  
Table 2.6: List of small molecule inhibitors and their suppliers.   
Compound Supplier Compound ID 
C2 Tocris Bioscience CCT 018159 
An1 Sigma-Aldrich® R910589 
An3 ChembridgeTM 9284048 
SKW032 Synthesised by S. Whitehead,          
University of Leeds SKW036 
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2.2 Methods 
2.2.1 Molecular cloning 
2.2.1.1 Transformation of E. coli BL21 and DH5α 
Competent E. coli BL21 and DH5α cells were thawed on ice. GST-expressing vectors were 
transformed into BL21 and the GFP- and FLAG-expressing fusion vectors were transformed 
into DH5α. All constructs contained an ampicillin or kanamycin resistance gene. For each 
transformation 1 µg DNA was mixed with 50 µl competent cells and incubated on ice for 
30 min. Cells underwent a heat-shock at 42°C for 30 sec before immediate cooling by ice. 
Following the addition of 200 ml S.O.C medium [0.5% (w/v) yeast extract, 2% (w/v) 
Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM Glucose], the 
mixture was incubated at 37°C for 1 h while shaking. Afterwards, the cells were plated out 
onto lysogeny broth (LB) agar plates [1.5% (w/v) microagar in LB medium] containing 
50 µg/ml ampicillin or kanamycin. The plates were then incubated over night at 37°C.  
Transformed E.coli BL21 cells were kept for long term storage as glycerol stock. For this, a 
single bacteria colony was picked from the agar plates and grown in 3 ml LB medium 
containing 50 µg/ml ampicillin over night at 37°C with shaking. These starter cultures were 
then mixed in a 1:1 ratio with LB medium containing 40% glycerol and stored at -80°C. 
 
2.2.1.2 Plasmid purification 
For isolation of large amounts of plasmid DNA the QIAGEN Plasmid Maxi kit was used 
according to the manufacturer’s instructions. For each plasmid, a single bacteria colony of 
DH5α was picked from the agar plates (section 2.2.1.1) and grown in 3 ml LB medium 
containing 50 µg/ml ampicillin over night at 37°C with shaking. Of these starter cultures, 
200 μl were then used to inoculate 100 ml LB media containing 50 µg/ml ampicillin and 
grown over night (approximately 16 h) at 37°C with shaking. The bacterial cultures were 
harvested at 4,500 x g for 10 min at 4°C and then resuspended in 10 ml buffer P1. Lysis 
buffer P2 (10 ml) was then added and the solution incubated for 5 min at room 
temperature. Neutralisation buffer P3 was added (10 ml) and the mix was left on ice for 
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20 min. Insoluble cell parts were spun down at 4,500 x g for 30 min at 4°C and the clear 
supernatant was added onto a pre-equilibrated QIAGEN-tip 500. After the supernatant had 
run through the column by gravity, the resin was washed using 2 x 30 ml washing buffer 
QC. The plasmid DNA was then eluted using 15 ml elution buffer QF. The DNA was 
precipitated by addition of 10.5 ml 100% isopropanol and immediately spun down at 
16,000 x g for 20 min at 4°C. The supernatant was discarded and the DNA pellet washed 
with 5 ml 70 % (v/v) ethanol and left to air-dry. The DNA was dissolved in 500 µl dH2O. The 
DNA concentration and purity was assessed using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies). The purified DNA was stored at -20°C.  
 
2.2.2 Cell culture 
2.2.2.1  Cell lines 
Human embryonic kidney (HEK) 293T cells (referred to as 293T cells) were used for all 
experiments involving plasmid transfection (obtained from the Health Protection Agency 
Culture Collection). HFF cells, a human foreskin fibroblast cell line, were employed in all 
studies utilising HSV-1. HFF cells were a kind gift of John Sinclair, University of Cambridge. 
TREx BCBL1-Rta, a B lymphocyte cell line latently infected with KSHV and containing an 
inducible RTA-expression construct, was utilised for all experiments involving KSHV lytic 
replication, unless otherwise stated. These cells were a kind gift of Jae Jung, University of 
Southern California (Nakamura et al., 2003). Similar, 293 rKSHV.219 cells, a 293T cell line 
containing a recombinant bacterial artificial chromosome harbouring the KSHV genome, 
were utilised for protein knock-down studies during KSHV lytic replication (Vieira and 
O'Hearn, 2004).  
 
2.2.2.2 Cell maintenance 
293T, HFF and 293 rKSHV.219 cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with 10% (v/v) heat inactivated foetal bovine serum (FBS) and 
1% (v/v) penicillin/streptomycin (referred to hereafter as complete DMEM) at 37°C in the 
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presence of 5% CO2. TREx BCBL1-Rta cells were grown in RPMI1640 growth medium, also 
supplemented with 10% (v/v) FBS and 1% (v/v) penicillin/streptomycin (referred to as 
complete RPMI), under the same conditions. TREx BCBL1-Rta cells were kept under 
Hygromycin B selection (100 μg/ml) and 293 rKSHV.219 cells under puromycin selection 
(1 mg/ml).  
Cell lines were split every 3-4 days when they reached approximately 80% confluence. All 
293 derived cells were physically dislodged from the flask and split 1:20 into complete 
DMEM in a new flask. HFF cells were passaged by trypsinisation [0.05% (v/v) trypsin in 
PBS] for five minutes to dissociate adherent cells, before being resuspended in 10 ml 
complete DMEM to inactivate trypsin. A third of the resulting volume was subsequently 
transferred into a new flask containing complete media (1:3 split). HFF cells were 
subjected to a maximum of 20 passages. TREx BCBL1-Rta cells were grown in suspension 
and were diluted 1:6 into complete RPMI for passaging.   
For long term storage, cells were cryopreserved in liquid nitrogen. For this, growing cells at 
50% confluence were spun down at 500 x g for 3 min and the cell pellet was resuspended 
at 1 x 106 cells/ml in freezing medium [40% (v/v) complete medium, 50% (v/v) FBS, 
10% (v/v) DMSO]. Cells were aliquoted into CryoTubes™ (NUNC™) and placed in a 5100 
Cryo 1°C Freezing Container (NALGENE®) at -80°C for 24 hours. The tubes were then 
transferred to liquid nitrogen. 
 
2.2.2.3 Transient transfection 
For transient transfections, cells were seeded into a 6-well plate. After 20–24 h of cell 
growth, at approximately 80% confluence (or 50% confluence if used for 
immunofluorescence microscopy), transfections were performed using Lipofectamine® 
2000, following the manufacturer’s instructions. Typically, 1 µg of DNA per expression 
plasmid and 3 µl of Lipofectamine® were each diluted in 100 µl serum free DMEM and 
incubated for 5 min. Transfections for mRNA export assays were done with 2 µg of ORF57-
GFP plasmid, 1 µg ORF47 reporter construct and 9 µl of Lipofectamine®. After the 5 min 
incubation, the Lipofectamine® 2000 solution was added to the DNA solution and 
incubated for an additional 20 min at room temperature. The cell medium was exchanged 
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with fresh complete medium and the Lipofectamine®/DNA mix was then added drop by 
drop into the wells. Cells were incubated typically for 24 h to allow efficient plasmid 
expression.  
 
2.2.2.4 siRNA knock-down 
For siRNA-mediated gene knock-down, 293T and 293 rKSHV.219 cells were seeded into a 
12-well plate (with 1 ml media per well). After 20–24 h of cell growth, at approximately 
40–50% confluence, transfections were performed using Lipofectamine® 2000, following 
the manufacturer’s instructions. Typically, 5 μl of a 20 μM siRNA stock (giving 100 nM final 
concentration per knock-down) and 5 μl of Lipofectamine® were each diluted into 100 μl 
of Opti-MEM® medium and incubated for 15 min at room temperature. The siRNA and 
Lipofectamine® 2000 dilutions were then combined and incubated another 15 min. 
Growth medium was replaced with fresh complete DMEM and the Lipofectamine®/siRNA 
mix was added drop by drop into the wells. Unless otherwise stated, this procedure was 
repeated after 24 h. Protein knock-down was usually detectable after 48–72 h. 
 
2.2.2.5 Treatment with small molecule inhibitors 
Small molecule inhibitors were added to 293T cells 6 h post-transfection, to TREx 
BCBL1-Rta cells at the time of induction of virus lytic replication or to HFF cells directly 
after initial infection with HSV-1, unless otherwise indicated. All small molecule 
compounds were dissolved and diluted in DMSO. Cells were treated with 1 μl of inhibitor 
per ml of media, with the concentration being 1000 x higher than the desired final dilution, 
giving a total of 0.1% (v/v) DMSO in all experiments.  
 
2.2.2.6 Cytotoxicity assays 
Cytotoxicity of small molecule inhibitors was assessed using the MTS-based CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (Promega). For this, 293T cells were seeded 
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into a 96-well plate and left to adhere for 20–24 h. When cells reached 80% confluence, 
they were treated with the small molecule inhibitors or DMSO control (section 2.2.2.5) and 
incubated for an additional 24 or 72 h. Growth medium was then removed and replaced 
with 100 μl new complete medium per well, before addition of 20 μl CellTiter 96® AQueous 
One Solution Reagent. After approximately 1 h at 37°C, the absorbance at 490 nm was 
measured using the Infinite® F50 Robotic microplate reader (Tecan).  
Alternatively, 1 ml of TREx BCBL1-Rta cell suspension (approximately 1 x 106 cells per ml) 
was seeded in a 12-well plate and treated directly with small molecule inhibitors. After 
24 or 72 h, 100 μl of the treated cells were transferred into a 96-well plate and 20 μl 
CellTiter 96® AQueous One Solution Reagent was added. The absorbance was measured as 
described above.  
 
2.2.3 Virus based assays 
2.2.3.1 Induction of KSHV lytic replication  
Viral lytic replication in TREx BCBL1-Rta cells was induced by supplementing the media 
with 2 μg/ml doxycycline hyclate. Viral mRNA export assays, protein expression studies or 
immunofluorescence experiments cells were performed 24 h post-induction, while viral 
load or production of new infectious virions was examined at 72 h after induction.  
For induction of KSHV lytic replication in 293 rKSHV.219 cells media was supplemented 
with 3 mM sodium butyrate and 20 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA).   
 
2.2.3.2 KSHV late protein expression  
To assess viral late protein expression in the absence or presence of small molecule 
inhibitors, 1 ml of TREx BCBL1-Rta cell suspension (1 x 106 cells/ml) were seeded into 
12-well plates, induced and treated with compounds as described before (section 2.2.3.1 
and 2.2.2.5). Cells were harvested 24 h post-induction and spun at 500 x g for 5 min at 4°C. 
The supernatant was removed and cell pellets were subsequently used for analysis of 
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protein expression by SDS-PAGE and Western blotting as described below in section 
2.2.5.2 and 2.2.5.4.  
 
2.2.3.3 KSHV replication assay 
To assess the changes in KSHV viral load within cells in the absence or presence of small 
molecule inhibitors, 1 x 106 TREx BCBL1-Rta cells per ml were seeded into 12-well plates, 
induced and treated with small molecule inhibitors as described before (section 2.2.3.1 
and 2.2.2.5). Cells were harvested 72 h post-induction and spun at 500 x g for 5 min at 4°C. 
Viral and cellular DNA was purified using a QIAamp DNA mini kit (QIAGEN), following the 
manufacturer’s instructions. Briefly, the cell pellet was lysed using QIAGEN Protease and 
buffer AL, at 56°C for 10 min. Ethanol was added and the solution applied to a QIAquick 
spin column. Columns were centrifuged at 6,000 x g for 1 min at room temperature and 
the flow through discarded. This centrifugation step was repeated twice, with washes by 
buffer AW1 and AW2 in between, before a final spin at 16,000 x g for 3 min at room 
temperature. The column was then placed in a fresh microcentrifuge tube and DNA was 
eluted by addition of 50 µl dH2O and centrifugation at 13,000 x g for 1 min at room 
temperature. Eluted DNA was stored at -20°C. Viral and cellular DNA levels were 
quantified by qPCR as described below (section 2.2.8.6). 
 
2.2.3.4 HSV-1 primary infection 
HSV-1 virus stocks were stored in aliquots at -80°C. Typically, a low MOI of 0.001 was used 
for primary infection of HFF cells, unless otherwise stated. For this, the appropriate 
amount of virus stock was diluted in 100 μl complete DMEM and then further diluted by a 
1:10 dilution series, until the final concentration was reached. The medium was removed 
from HFF cells grown in a 6-well plate and 1 ml of medium containing HSV-1 at the desired 
MOI was added per well. Following 1 h incubation, virus containing media was removed 
and cells washed twice with PBS, followed by addition of 2 ml complete DMEM (for re-
infection assays) or 2 ml plaque agar (for plaque assays of primary infection) per well. 
DMSO or small molecule inhibitors in DMSO were added at 1 μl/ml to either the fresh 
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DMEM or the plaque agar and left on cells for either 72 h (re-infection assays) or 96–120 h 
(plaque assay), as described below. 
 
2.2.3.5 Viral re-infection assays 
Re-infection assays were performed with KSHV and HSV-1. For KSHV re-infection assays, 
TREx BCBL1-Rta cells were induced and treated with small molecule inhibitors as described 
above (section 2.2.3.1 and 2.2.2.5). After 72 h, cells were spun down at 500 x g for 5 min at 
room temperature and the supernatant was mixed 1:1 with complete DMEM and added to 
confluent 293T cells. Following 24 h incubation, the 293T cells were washed once with PBS 
and total RNA was extracted using TRIzol (InvitrogenTM) and subsequently used for 
quantitative reverse transcriptase PCR (qRT-PCR) (as described under 2.2.8.3–2.2.8.6). 
Viral mRNA was normalised against the housekeeping gene GAPDH and quantified using 
the comparative CT method.  
For HSV-1 re-infection, primary infected HFF cells were incubated for 72 h. Cells were then 
harvested at 500 x g for 5 min at room temperature. The supernatant was collected and 
diluted 1:10–1:1,000 for re-infection of naive HFF cells, which were analysed by flow 
cytometry and Western blot, or 1:10–1:10,000 for re-infection assay analysed by plaque 
assay, as described below (section 2.2.3.6). Diluted virus-containing supernatants were 
added to confluent HFF cells, which had been seeded the previous day. For Western blot 
and flow cytometry based analysis, supernatants were incubated for 16 or 24 h, 
respectively, before cells were harvested at 500 x g for 5 min at 4°C and washed twice with 
PBS. Cellular and viral proteins were then analysed by SDS-PAGE and Western blotting as 
described below (section 2.2.5.2 and 2.2.5.4). Alternatively, cells were fixed with 4% (v/v) 
formaldehyde for 1 h at 4°C, before being again spun at 500 x g for 5 min at room 
temperature and washed twice with PBS. As a recombinant virus expressing GFP was used, 
all virus-infected cells were fluorescently marked, therefore resuspended cells were 
analysed for fluorescence using the BD LSRFortessa flow cytometer (BD Biosciences). 
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2.2.3.6 HSV-1 plaque assay 
Plaque assays were performed after primary infection or re-infection of HFF cells with 
HSV-1. Both, virus of a known titre for primary infection (2.2.3.4), or supernatant gained 
after 72 h of primary infection and used for a re-infection assay (2.2.3.5) were incubated 
on fully confluent HFF cells in a 6-well plate for 1 h. Plaque agar was prepared by 1:1 
mixing of complete DMEM with a 2% (w/v) molten agarose solution, which was cooled to 
42°C before use. The virus containing supernatant was removed, cells were washed twice 
with PBS and then overlayed with 2 ml of plaque agar, tempered to 37°C, and left at room 
temperature until the agarose had set. Cells were incubated at 37°C for 96–120 h until 
large viral plaques were visible under the microscope. The agarose was then carefully 
removed, cells washed once with PBS and fixed with 4% (v/v) formaldehyde at 4°C for 1 h. 
The cell monolayer was subsequently stained by the addition of 0.5% (w/v) crystal violet 
stain. 
 
2.2.4 Large scale expression and purification of proteins 
2.2.4.1 Recombinant protein expression in E. coli BL21 
Glycerol stocks of transformed E. coli BL21 bacteria cells were streaked out onto LB agar 
plates containing ampicillin, before a single clone was picked to generate a starter culture 
(described in section 2.2.1.1). These starter cultures were used 1:100 to inoculate LB 
medium, containing 50 µg/ml ampicillin, and left to grow for approximately 2 h (or until 
OD600 reached 0.4–0.6) at 37 °C while shaking. Recombinant protein expression was 
induced with 1 mM isopropyl-β-D-thio-galactoside (IPTG). Bacteria samples were taken at 
0 h, 1 h, 2 h, 3 h and 4 h post-induction, spun down at 5,000 x g for 10 min and the pellets 
stored at -20 °C. The remaining bacteria solution was likewise harvested at 4 h post-
induction.  
 
71 
 
2.2.4.2 Solubilisation of bacterially expressed protein 
The pellet of 100 ml bacterial culture (section 2.2.4.1) was resuspended in 5 ml PBS 
supplemented with 1% Triton X-100 for GST-pulldowns or 5 ml lysis buffer [50 mM Tris, pH 
7.6, 0.5 M NaCl, 2 mM MgCl, 50 mM KCl, 1% Triton] for biochemical assays. Resuspended 
cells were sonicated on ice with 6 x 20 sec bursts and 20 sec breaks in between. After 
sonication lysozyme (1 mg/ml) from chicken egg white (Sigma-Aldrich®), 1 μl/ml RNase A 
and 1 μl/ml DNAse I were added and bacterial lysates incubated 20 min on ice. Cell debris 
was spun down at 16,000 x g for 30 min at 4°C. A sample of the pellet and the supernatant 
were stored separately on ice.   
 
2.2.4.3 Purification of GST-tagged proteins 
GST-tagged protein was expressed in E.coli BL-21 and solubilised as described above 
(section 2.2.4.1 and 2.2.4.2). Per 100 ml culture 500 μl Glutathione SepharoseTM 4B beads 
(GE Healthcare) were primed by washing 3 x with 5 ml lysis buffer [50 mM Tris/HCl, pH 7.6, 
0.5 M NaCl, 2mM MgCl, 50 mM KCl,  1% Triton ]. Bacteria lysates were then incubated with 
the GST-beads for 2 h at 4°C with end-over-end mixing. Lysates containing up to 1 ml of 
beads were added onto a 1 ml polypropylene column (Qiagen) and beads separated by 
gravity-flow chromatography. The columns were kept at 4°C and washed 4 x with 2ml ice 
cold wash buffer [50 mM Tris/HCl, pH 7.6, 0.5 M NaCl, 50 mM KCl, 2 mM MgCl2] without 
disturbing the top layer of the packed column. GST-tagged proteins were eluted from the 
beads with elution buffer [50 mM Tris, pH 7.6, 10 mM reduced Glutathione, 50 mM KCl, 
2 mM MgCl2]. Fractions of 0.5 ml were collected and analysed for protein by SDS-PAGE and 
Coomassie blue staining, as described before (2.2.5.2–2.2.5.3). All protein containing 
fractions were combined and buffer exchange chromatography was performed using PD 
midiTrapTM G-25 columns (GE Healthcare), following the manufacturer’s instructions. 
Briefly, G-25 columns were primed using 3 x 5 ml of ATPase assay buffer [50 mM Tris/HCl, 
pH 7.6, 50 mM KCl, 2 mM MgCl2], followed by addition of 1 ml of the combined fractions. 
Final protein was eluted using 1.5 ml ATPase assay buffer. Protein used for large scale 
compound screening was stored at -20°C; protein used for determination of binding 
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kinetics was prepared freshly and stored over night at 4°C. All work was performed on ice 
and all buffers were pre-chilled on ice prior to use. 
 
2.2.5 Analysis of proteins 
2.2.5.1 Determination of protein concentration 
The concentration of protein samples was determined using the Bio-Rad DCTM protein 
assay. In a 96-well plate, 5 μl protein sample or pre-diluted bovine serum albumin (BSA) 
standards, obtained by 1:2 dilution series of 5 mg/ml BSA stock, were mixed with 25 μl 
reagent A (an alkaline copper tartrate solution) and 200 μl reagent B (a dilute Folin 
reagent). After 15 minutes incubation, absorbance was measured at 620 nm using the 
Infinite® F50 Robotic microplate reader (Tecan).   
 
2.2.5.2 SDS-polyacrylamide gel electrophoresis  
Protein samples were separated by their molecular weight using sodium dodecyl sulphate 
(SDS)-polyacrylamide gel electrophoresis (PAGE). Protein samples were mixed 1:1 with 
2 x SDS loading dye [100 mM Tris/HCl, pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 10 mM 
DTT, 0.25% (w/v) bromophenol blue], subsequently boiled at 95°C for 5 min and loaded 
alongside the BenchMark™ Pre-Stained Protein Ladder (InvitrogenTM) onto 
10% polyacrylamide gels, composed of a resolving gel [10% (v/v) acrylamide/bis-
acrylamide 37.5:1 (Severn Biotech Ltd), 375 mM Tris/HCl; pH 8.8, 0.1%  (w/v) SDS, 
0.12% (v/v) APS, 0.012% TEMED (v/v)] and stacking gel [5% (v/v) acrylamide/bis-
acrylamide 37.5:1, 125 mM Tris/HCl; pH 6.8, 0.1% (w/v) SDS, 0.08% (v/v) APS, 0.008% (v/v) 
TEMED]. Gels were run at 180 V for 60 min or until the dye front reached the end of the 
resolving gel. The running buffer was 25 mM Tris, 192 mM Glycine and 0.1 % (w/v) SDS. 
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2.2.5.3 Coomassie blue staining 
Coomassie blue stain [50% (v/v) methanol, 10% (v/v) acetic acid, 0.05% (w/v) Brilliant Blue 
R-250] was used to permanently stain protein bands on SDS-PAGE gels (section 2.2.5.2). 
Gels were incubated for 30 min on a rocking platform at room temperature, before a 
destain solution [50% (v/v) methanol, 10% (v/v) acetic acid] was added and repeatedly  
exchanged until the desired degree of staining was reached.   
 
2.2.5.4 Western blotting 
Protein samples separated by SDS-PAGE (section 2.2.5.2) were transferred to a 
nitrocellulose HybondTM-C (GE Healthcare) membrane by Western blotting. The set up for 
the transfer was: blotting pad, two pieces of Whatman filter paper, gel, nitrocellulose 
membrane, two pieces of Whatman filter paper and blotting pad. Before use, the 
membrane was pre-soaked alongside the blotting pads and filter paper in transfer buffer 
(20% (v/v) methanol, 25 mM Tris, 192 mM glycine). The transfer took place at 100 V for 
60 min. Unspecific protein binding sites on the membrane were blocked for 1 h at room 
temperature with 5% (w/v) non-fat milk (Marvel) in Tris buffered saline and Tween-20 
(TBS-T) [150 mM NaCl, 50 mM Tris/HCl pH 7.5, 1% (v/v) Tween-20] on a rocking platform. 
The membrane was then incubated with primary antibody in 2.5% (w/v) non-fat milk in 
TBS-T for 60 min at room temperature, followed by three 5 min washes in TBS-T. 
Secondary antibody (HRP-conjugated IgG) was applied in a similar manner as the primary 
antibody, again followed by washes with TBS-T. Chemiluminescence was developed adding 
the enhanced chemiluminescence (ECL) system (Geneflow) to the membrane for 1 min. A 
photographic Hyperfilm ECLTM (GE Healthcare) was then exposed to the membrane for the 
desired amount of time. The film was processed with a Konica SRX-101A developer. 
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2.2.6 Analysis of protein-protein interactions  
2.2.6.1 GST-pulldown assay 
E. coli BL21 lysates were prepared as previously described (section 2.2.4.2), added to 25 µl 
of PBS primed Glutathione Sepharose 4B beads (GE Healthcare) per pulldown and 
incubated over night while shaking. HEK 293T cells were transfected as described in 
section 2.2.2.3. Cells were harvested 24 h after transfection at 500 x g for 5 min at 4°C, 
washed once in PBS and lysed for 20 min on ice with 1 ml modified RIPA buffer [150 mM 
NaCl, 50 mM Tris/HCl; pH 7.6, 1% NP-40] per well of a 6-well plate. Insoluble parts were 
pelleted at 12,000 x g for 10 min at 4°C and the supernatant kept on ice. Glutathione 
beads were centrifuged at 500 x g for 5 min at 4°C and the beads washed five times with 
washing buffer [250 mM NaCl, 50 mM Tris/HCl; pH 7.5]. After the final wash, a small 
amount of beads was taken aside to determine the GST protein amount bound to the 
beads by SDS-PAGE and subsequent Coomassie staining (section 2.2.5.2 and 2.2.5.3). The 
remaining GST-bound beads were added to the cell lysates and incubated for 4 h at 4°C 
while rotating. Following incubation, beads were pelleted at 500 x g for 5 min at 4°C and 
washed 5 x in modified RIPA buffer. The pelleted beads were resuspended in 75 µl of SDS 
loading buffer for protein separation by SDS-PAGE and analysis by Western blotting 
(described under 2.2.5.2 and 2.2.5.4).  
 
2.2.6.2 Co-immunoprecipitation assay  
For co-immunoprecipitation assays, 293T cells were transfected as described in section 
2.2.2.3. Transfected cells from a 6-well plate were harvested 24 h after transfection at 
500 x g for 5 min at 4°C, washed once with PBS and lysed for 20 min on ice using 1 ml of 
modified RIPA buffer. The insoluble fraction was pelleted at 16,000 x g and the 
supernatant kept on ice, to which 1 μl/ml RNase A was added to remove any protein/RNA 
interactions. Depending on whether the protein to be immunoprecipitated was GFP- or 
FLAG-tagged, 25 µl slurry of anti-DDDDK tag (equivalent to FLAG) coupled agarose beads 
(Abcam®) or 20 μl slurry of GFP-trap® beads (ChromoTek®) were used per immuno-
precipitation.  Before immunoprecipitation, beads were pelleted at 500 x g for 5 min at 4°C 
and washed 3 x with modified RIPA buffer to remove residual storage buffer. To remove 
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non-specific protein binding to the beads, the cell lysates were pre-cleared by incubation 
of 20 μl of protein A-conjugated agarose beads (Roche) for 2 h at 4 °C with rotation. The 
beads were then pelleted at 500 x g for 5 min at 4°C and the pre-cleared supernatant 
transferred onto the prepared FLAG affinity or GFP-trap® beads. Where indicated, 1 μl, 
7.5 μl, 12.5 μl or 17.5 μl ATP, ATPγS or ADP were added from a 100 mM stock (in 50 mM 
Tris/HCl, pH 7.6), to achieve 0.1 mM, 0.75 mM, 1.25 mM or 1.75 mM ATP, ATPγS or ADP 
per co-immunoprecipitation, as described for each experiment. Alternatively, 3.33 μl 
DMSO control or small molecule inhibitor C2 (150 mM in DMSO) were added to the beads 
and lysate, as described. The beads were incubated for 2.5 h at 4°C under rotation and 
subsequently centrifuged at 500 x g for 5 min at 4°C and washed 5 x in ice cold modified 
RIPA buffer. The agarose-antibody-antigen complex was then taken up in 70 µl SDS-loading 
buffer and eluted by heating to 95°C, to be analysed by SDS-gel and Western blotting.  
 
2.2.6.3 Immunofluorescence microscopy 
293T cells were grown in 12-well plates containing sterile glass coverslips, which had been 
previously coated with poly-L lysine (Sigma-Aldrich®) for 5 min and washed with PBS. At 
50% confluence, cells were transfected with expression plasmids as described in section 
2.2.2.3. TREX BCBL1-Rta cells were seeded at a concentration of 1 x 106 cells/ml on poly-L 
lysine treated glass coverslips. KSHV lytic replication was induced at the time of seeding, as 
described before (section 2.2.3.1). Before fixation, cells were washed with PBS and then 
fixed with 4% (v/v) paraformaldehyde for 10 min at room temperature, unless otherwise 
stated. Paraformaldehyde was removed and the cells washed twice in PBS, followed by 
permeabilisation with 1% (v/v) Triton X-100 in PBS for 15 min at room temperature. To 
block non-specific binding, 1% (w/v) BSA in PBS was added and the cells incubated for 
60 min at 37°C. Cells were then incubated with primary antibodies in PBS and 1% BSA 
(w/v) for 60 min in a humidity chamber at 37°C. After three washes with PBS, Alexa Fluor®-
conjugated secondary antibodies were incubated under the same conditions. Following 
three washes with PBS, coverslips were mounted onto microscope slides with DAPI 
containing mounting medium (VECTASHIELD®, Vector Laboratories) for detection of nuclei. 
The slides were stored in the dark at 4°C until visualised on an inverted LSM 700 Axio 
Observer Z1 confocal microscope (Zeiss). 
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2.2.7 Biochemical assays 
2.2.7.1 ATPase assay 
ATPase assays were performed in 96-well plates, with a total reaction volume of 50 μl. 
ATP- and yeast tRNA-stocks were added to assay buffer to give the following assay 
conditions:  
 35 μM ATP (unless otherwise indicated) 
 50 μM yeast tRNA 
 50 mM Tris/HCl, ph 7.6  
50 mM KCl 
2 mM MgCl2 
Where indicated, small molecules, fragments and ATP-analogues were diluted in DMSO or 
buffer as needed and 5 μl of the inhibitor or control was added to each reaction (10% total 
DMSO). For IC50 measurements, inhibitors were added in 0.25 μl DMSO (giving a total of 
0.5% DMSO in the assay). The ATPase reaction was started by the addition of purified 
UAP56 (section 2.2.4.3), with varying concentrations as described for each experiment, 
and incubated for 30 min at 37°C. Plates were cooled to room temperature for 2 min, 
before 50 μl Kinase-Glo® Reagent (Promega) was added to each reaction and plates were 
incubated for a further 10 min at room temperature, in the dark. Luminescence was 
measured using the FLUOstar OPTIMA plate reader (BMG LABTECH), three times over a 
period of 15 min to ensure a stable signal. The signal intensity is directly correlated to the 
concentration of ATP remaining in each assay, which could be calculated using the control 
wells containing GST protein (0% enzyme activity) or UAP56 and no inhibitor 
(100% enzyme activity) and background measurements of GST protein in buffer (no ATP).  
 
2.2.8 Analysis of mRNA  
2.2.8.1 Fluorescence in situ hybridisation (FISH) 
To detect polyadenylated (poly(A)) RNA in 293T cells, cells were transfected and fixed with 
4% (v/v) paraformaldehyde as described under 2.2.2.3 and 2.2.6.3. Cells were 
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permeabilised with 0.5% Triton X-100 for 5 min and washed twice with PBS and once with 
2 x saline-sodium citrate (SSC) buffer [300mM NaCl, 30 mM sodium citrate; pH 7.0] for 
10 min at room temperature. A fluorescently labelled oligo(dT) probe was added at a final 
concentration of 1 μg/ml in ULTRAhyb® hydridization buffer (Ambion®) and incubated for 
16–20 h at 42°C. Cells were washed twice with 2 x SSC, once with 0.5 x SSC and once with 
PBS. Coverslips were mounted using VECTASHIELD® + DAPI (Vector Laboratories) and 
visualised on an inverted LSM 700 Axio Observer Z1 confocal microscope (Zeiss). 
 
2.2.8.2 Nucleocytoplasmic fractionation for viral mRNA export assay 
TREx BCBL1-Rta and 293T cells were grown and either induced or transfected as described 
in section 2.2.2.3 and 2.2.3.1. After 24 h, cells were washed off the plate with ice cold PBS 
and pelleted at 500 x g for 5 min at 4 °C. Cell pellets were resuspended in 600 μl of PBS 
with 1 % Triton (v/v) and 1 μl/ml RNase OUT (InvitrogenTM) and lysed for 10 min on ice. Of 
this mixture, 250 μl were kept for analysis as whole cell fraction and the remaining 350 μl 
were centrifuged at 2000 x g for 5 min at 4 °C. The supernatant, containing the 
cytoplasmic fraction, was transferred to a new microcentrifuge tube for further 
processing, whereas the pelleted nuclei were washed in 1 ml of PBS and centrifuged again 
at 2000 x g for 5 min at 4 °C. The wash buffer was discarded and the nuclei resuspended in 
200 μl PBS with 1 % Triton (v/v) and 1 μl/ml RNase OUT. A small sample was taken of each 
fraction to analyse protein by SDS-PAGE and Western blotting (section 2.2.5.2 and 2.2.5.4), 
before the fractions were immediately further processed for total RNA extraction and 
subsequent qRT-PCR, the steps of which are described below (section 2.2.8.3–2.2.8.6).  
 
2.2.8.3 Total RNA isolation 
Total RNA was isolated from cells or cellular fractions with the use of TRIzol (InvitrogenTM), 
according to the manufacturer’s instruction. To each sample containing 2 x 106 TREx 
BCBL1-Rta or confluent 293T cells from one well of a 6-well plate, 1 ml TRIzol was added. 
Cells or cell fractions were homogenised in TRIzol for 5 min at room temperature, then 
200 μl of chloroform were added and samples were vigorously shaken and incubated for 
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another 2 min at room temperature. Samples were centrifuged at 10,000 x g for 15 min at 
4°C in order to separate the aqueous from the organic phenol phase. The 500 μl of the 
upper layer, the RNA-containing aqueous phase, was transferred into a new 
microcentrifuge tube containing 500 μl of isopropanol. Samples were mixed and incubated 
for 10 min at room temperature. Total RNA was precipitated by centrifugation of the 
samples at 10,000 x g for 10 min at 4°C. The supernatant was discarded, the RNA pellet 
washed in 70% ethanol and centrifuged at 10,000 x g for 5 min at 4°C. Again, the 
supernatant was discarded and the pellet air dried at room temperature for approximately 
5 min. The RNA pellet was resuspended in 20 μl of DNase and RNase free H2O (Sigma-
Aldrich®). 
 
2.2.8.4 DNAse treatment 
To remove contaminating DNA from RNA, samples were treated with the DNA-freeTM DNA 
removal kit from Ambion® following the manufacturer’s instructions. Briefly, 0.1 volumes 
of 10 x DNase I buffer and 1 μl of DNase I were added per sample and incubated for 30 min 
at 37 °C. Following DNA-digestion, each sample was treated with 0.1 volumes of DNase 
inactivating reagent and gently mixed for 2 min at room temperature. The DNase 
inactivating reagent was pelleted from the RNA solution by centrifugation at 7,500 x g for 
1.5 min at 4 °C. The supernatant was transferred to a new microcentrifuge tube. Purified 
RNA was stored at -80°C. 
 
2.2.8.5 Reverse transcription 
RNA concentration was measured using the NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies) and diluted to 500 μg/ml before reverse transcription was 
carried out to synthesise cDNA. The following master mix was added to 2 μl of RNA (1 μg 
total RNA): 
 1 μl Oligo(dT)15 (500 μg/ml)  
1 μl dNTP mix (2.5 mM/dNTP) 
8 μl DNase/RNase free H2O 
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The mixture was incubated at 60°C for 5 min and then immediately cooled on ice and 
combined with the following master mix: 
 1 μl M-MuLV Reverse Transcriptase (RT) 
4 μl 5x M-MuLV Reverse Transcriptase Reaction Buffer 
2 μl 0.1 M DTT 
1 μl RNase OUTTM (40 U/μl)  
Samples were also prepared containing the same master mix, but omitting the reverse 
transcriptase, as negative RT control (-RT). The mixture was incubated at 42°C for 50 min, 
followed by inactivation of the reverse transcriptase at 90°C for 10 min. The cDNA was 
stored at -20°C.  
 
2.2.8.6 Quantitative real-time PCR (qPCR) 
Levels of cDNA or DNA were quantified by qPCR using a Rotor-Gene 6000 Real-Time PCR 
machine (QIAGEN) and sequence-specific primers. For each sample 5 μl cDNA, as well as 
-RT samples as no-template control, were added to the following master-mix in 0.1 ml 
strip tubes (QIAGEN):   
 12.5 μl 2x SensiMix™Plus SYBR (Bioline) 
2 μl (10 μM) forward primer 
2 μl (10 μM) reverse primer 
3.5 μl DNase/RNase free H2O 
After an initial denaturation step of 95°C for 10 minutes, the cycling programme for qPCR 
was 35 cycles of a standard 3-step melt cycle, with the following parameters: denaturation 
at 95°C for 15 sec, annealing at 60°C for 30 sec and elongation at 72°C for 20 sec. Data was 
acquired during the elongation step of each cycle and analysed using the Rotor-Gene 6000 
Series Software Version 1.7. After qPCR, a melting curve analysis was performed to 
confirm amplification of a single product. Samples were normalised against the 
housekeeping gene GAPDH and quantified using the comparative CT method. 
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3 A novel interaction of ORF57 with CIP29, a hTREX component 
3.1 Introduction 
The hTREX complex is a multiprotein complex that facilitates cellular bulk mRNA export, 
from the nucleus into the cytoplasm. It consists of the following core components: UAP56, 
a RNA-helicase, which is thought to bind to RNA in the early stages of spliceosome 
formation, the export adaptor Aly, as well as the hTHO complex proteins hTho1, hTho2, 
fSAP24, fSAP35 and fSAP79 (Luo et al., 2001; Masuda et al., 2005). Redundancy was shown 
for Aly, as UIF can replace the export adaptor in hTREX (Hautbergue et al., 2009). More 
recently, the proteins CIP29, Chtop, SKAR and ZC11A were also identified as hTREX 
components (Dufu et al., 2010; Chang et al., 2013; Folco et al., 2012). Complex assembly is 
strongly coupled to cellular mRNA maturation steps, ensuring export of only correctly 
processed mRNAs. Together, the hTREX complex then provides a binding platform for the 
nuclear export factor Nxf1 and its co-factor Nxt1, allowing transport of mRNA cargo 
through the well controlled NPC.  
KSHV ORF57 is a multifunctional protein involved in all stages of viral mRNA processing. As 
many viral mRNAs are intronless, ORF57 recruits the hTREX complex, to form an export 
competent vRNP and facilitate efficient nuclear export of viral mRNAs. ORF57 is known to 
directly interact with the mRNA export adaptor proteins Aly and UIF (Boyne et al., 2008; 
Jackson et al., 2011), which facilitates subsequent recruitment of UAP56 and THO onto 
viral intronless transcripts. Furthermore, ORF57 interactions have also been shown for 
more recently identified hTREX proteins Chtop and SKAR (Baquero-Perez, unpublished 
data). We therefore speculated that CIP29 is also part of the ORF57-facilitated vRNP.  
In this results chapter, the interaction of ORF57 with CIP29 was examined through a range 
of techniques, such as GST-pulldowns, co-immunoprecipitations and immunofluorescence. 
Moreover, the role of CIP29 in ORF57-mediated export of viral mRNA was investigated 
through depletion studies of CIP29. Similarly, the requirement of CIP29 for KSHV lytic 
replication was also assessed. Finally, as ATP-dependent formation of a trimeric complex 
consisting of UAP56, Aly and CIP29 was shown in vitro (Dufu et al., 2010), it was examined 
whether a similar effect could be seen in the presence of ORF57. 
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3.2 GST pulldowns show an interaction between CIP29 and ORF57 
To examine if an interaction occurs between ORF57 and CIP29, GST-pulldowns were 
performed. Initially, bacterial expression vectors encoding GST and GST-tagged CIP29 were 
transformed into the E. coli strain BL21. Protein expression was induced by the addition of 
IPTG and samples were taken over a 4 h time period to monitor recombinant protein 
induction. The samples were then analysed by SDS-PAGE and Coomassie blue staining 
(Figure 3.1). Both proteins were seen to induce well over a 4 h period. 
 
Figure 3.1: Induction of bacterially expressed GST and GST-CIP29. Protein samples were separated 
using SDS-PAGE and stained with Coomassie blue. The lanes contain a molecular weight marker and 
samples taken at indicated hours post induction (hpi). 
 
The recombinant protein from the 4 h induction was solubilised and bound to glutathione-
conjugated agarose beads. Prior to pulldown analysis, the amounts of protein bound to 
beads was again analysed by Coomassie blue staining (Figure 3.2), to ensure that an equal 
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amount of bound protein was thereafter used for each pulldown. Both proteins were 
observed to bind well to the beads. Although, CIP29 does show a number of smaller bands, 
it is unknown whether these are GST-CIP29 breakdown products or other bacterial 
proteins.  
 
Figure 3.2: Binding of GST and GST-CIP29 to glutathione-conjugated agarose beads. Protein samples 
were separated using SDS-PAGE and stained with Coomassie blue. For each protein the following 
samples were loaded: Bacteria lysate obtained 4 h after induction, insoluble protein found in the pellet 
after centrifugation of the lysate and protein bound to agarose beads. 
 
The bead-bound GST and GST-CIP29 proteins were then used for pulldowns to investigate 
ORF57 binding. For this, GFP, UIF-GFP or ORF57-GFP were expressed in 293T cells for 24 h 
and cell lysates then incubated with the protein-associated beads. As the beads were 
sedimented, proteins and protein complexes binding to GST or CIP29 would also be 
precipitated. Analysis of the sediment by SDS-PAGE and western blotting shows bands for 
all interacting proteins (Figure 3.3). GFP, which was used as a negative control, is shown to 
be strongly expressed in 293T cells (Lysate), but no interaction with GST or GST-CIP29 can 
be observed. GFP-tagged UIF, a known member of the hTREX complex, was used as a 
positive control. UIF is specifically pulled down with GST-CIP29, while no interaction is 
observed with GST alone. In a similar manner, ORF57 is shown to interact with CIP29, but 
not with GST. The observed bands for ORF57 represent full length ORF57-GFP and a 
caspase-7 cleavage product of the fusion protein, in which 33 amino acids are removed 
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from the N-terminus (Majerciak et al., 2010).  This is the first time that CIP29 has been 
shown to interact with the viral ORF57 protein.  
 
Figure 3.3: GST-pulldown assay shows CIP29 interacting with ORF57 and UIF. Eukaryotic cells were 
transfected with plasmids expressing GFP, UIF-GFP or ORF57-GFP and the lysates incubated with GST- or 
GST-CIP29-bound beads. Beads were precipitated and the sediment, as well as utilised cell lysates, were 
analysed using SDS-PAGE and Western blotting, which was probed using GFP-specific antibodies. 
 
3.3 Co-Immunoprecipitation assays confirm an interaction between CIP29 and 
ORF57  
To confirm the results of the pulldown assay and to study if the protein-protein interaction 
takes place in a cellular system, co-immunoprecipitations were employed. Here, 293T cells 
were co-transfected with FLAG-CIP29 and GFP, UIF-GFP or ORF57-GFP. As a negative 
control FLAG-β-catenin was also co-transfected with GFP, UIF-GFP or ORF57-GFP. After 
24 h, cell lysates were incubated with FLAG-affinity beads, in order to precipitate all 
protein complexes associating to CIP29 or β-catenin. RNase and DNase were added to the 
cell lysates prior to incubation with the beads. The precipitate was then analysed by 
SDS-PAGE and Western blotting, using GFP- and FLAG-specific antibodies (Figure 3.4). The 
co-immunoprecipitation assay confirmed the results of the GST-pulldowns, showing an 
interaction of CIP29 with ORF57, as well as UIF. Both proteins precipitate specifically 
alongside CIP29, in contrast to GFP-expressing cells. As RNase was added it is likely that 
this interaction is based on a protein-protein interaction. However, it still needs to be 
confirmed that all RNA, which can bridge two mRNA binding proteins, was degraded using 
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RNase. The control experiment using FLAG-β-catenin shows no interactions with ORF57, 
confirming the above mentioned interactions are CIP29-specific.  
 
Figure 3.4: Co-Immunoprecipitations confirm an interaction of CIP29 with ORF57 and UIF. Cells were 
co-transfected with plasmids expressing FLAG-CIP29 and GFP, UIF-GFP or ORF57-GFP. Transfection of 
plasmids expressing FLAG-β-catenin and GFP, UIF-GFP or ORF57-GFP was used as a negative control. Cell 
lysates were incubated with FLAG-affinity beads. Cell lysates (Input) and precipitated proteins 
(Precipitate) were analysed by SDS-PAGE and western blotting, probing with a GFP-specific antibody 
(top) and a FLAG-specific antibody (bottom). 
 
3.4 Immunofluorescence microscopy shows ORF57 dependent relocalisation of 
CIP29 
Immunofluorescence microscopy was employed to examine the subcellular localisation of 
CIP29 in the absence and presence of ORF57. For this, cells were transfected with GFP or 
ORF57-GFP alone. After fixation and permeabilisation, cells were immunostained using 
antibodies recognising endogenous CIP29 as well as B23.1, a nucleolar marker (Figure 3.5). 
Endogenous CIP29 can be observed predominantly in the nucleus of the cell in the 
presence of GFP. Specifically, CIP29 is excluded from the nucleolus (arrows), which is 
highlighted by the nucleolar marker B23.1, and instead appears in bright, punctuate 
speckles as has been described previously (Dufu et al., 2010). In contrast, ORF57 contains a 
86 
 
nucleolar localisation signal and is known to recruit hTREX components into the nucleolus. 
Accordingly, co-localisation of CIP29 and ORF57 was observed in the nucleolus, in ORF57-
GFP transfected cells. Only minor amounts of CIP29 remain outside the nucleolus 
suggesting a redistribution of CIP29 from the nuclear speckles into the nucleolus by the 
ORF57 protein.  
 
Figure 3.5: Overexpression of ORF57 causes re-localisation of endogenous CIP29. Cells were 
transfected with plasmids expressing GFP (a) or ORF57-GFP (b) for 24 h, cells were then fixed and 
permeabilised. Cells were stained using CIP29- (red) and B23.1-specific antibodies (pink). DAPI staining 
(blue) indicates the nucleus and ORF57 was visualised by GFP-fluorescence. 
 
The same technique was employed using transfected FLAG-CIP29 and ORF57-GFP to 
examine if over-expressed and FLAG-tagged protein behaves in a similar manner. Cells 
were transfected with FLAG-CIP29 alone or co-transfected with ORF57-GFP and then 
immunostained using antibodies against the FLAG-tag (pink) and B23.1 (red) (Figure 3.6). 
Results show that FLAG-CIP29, like endogenous CIP29, localises to the nuclear speckles 
and is excluded from the nucleolus (arrows). Furthermore, when co-expressed with 
ORF57, re-localisation of FLAG-CIP29 to the nucleolus is observed. Both proteins are also 
present in the nuclear speckles, as can be seen on the merged image.  
87 
 
 
Figure 3.6: Overexpression of ORF57 leads to a redistribution of recombinant CIP29. Cells were 
transfected with a FLAG-CIP29 expression plasmid alone (a) or co-transfected with plasmids expressing 
FLAG-CIP29 and ORF57-GFP (b), fixed (1 h in ice-cold methanol) and permeabilised. Cells were stained 
using FLAG-specific antibodies to visualise CIP29 (pink), B23.1-specific antibodies (red) as a nucleolar 
marker and DAPI (blue), for staining the nucleus. ORF57 was detected by direct GFP fluorescence.  
 
3.5 Role of CIP29 in UAP56-mediated ATP hydrolysis 
UAP56, a central hTREX component is a RNA-helicase with reported ATPase activity (Shen 
et al., 2007). Recently, an ATP-dependent interaction has been shown for UAP56, binding 
to Aly and CIP29, to form a trimeric complex (Dufu et al., 2010). We therefore wanted to 
assess the role of CIP29 in UAP56-mediated ATP hydrolysis. To this end, bacterially 
expressed GST-Aly, GST-UAP56 and GST-CIP29 were bound and purified on Glutathione-
beads and, after elution from the beads, run on a buffer exchange column. Samples of all 
stages of the purification were analysed by SDS-PAGE and visualised using Coomassie 
staining (Figure 3.7).  
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Figure 3.7: Purification of GST-tagged hTREX components. a) UAP56, b) Aly and c) CIP29 were 
expressed over 4 h in E.coli BL21 and analysed by SDS-PAGE and Coomassie blue staining. Samples are as 
follows: Whole cell lysate, insoluble fraction, soluble fraction, flow through after 2 h binding to 
Glutathione-beads, flow through of washing steps 1 and 2, all protein bound to Glutathione-beads after 
washing, protein eluted with Glutathione and protein after a buffer exchange column. 
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While GST-Aly and GST-CIP29 express to high levels and can be found in large parts in the 
soluble fraction, GST-UAP56 also expresses well, but remains mostly insoluble after lysis of 
the cells. Accordingly, the amount of protein bound to beads and eluted is notably less. 
Nonetheless, relatively pure protein samples were obtained for all three GST-tagged 
components of the hTREX complex. Both for GST-Aly and GST-CIP29 breakdown products 
can be seen binding to and being eluted from beads. However, the amounts of cleaved 
protein seem negligible in comparison to the quantity of full sized protein.  
Purified proteins were then used at 1.5 μM each in an ATPase assay. The ATPase activity of 
UAP56, Aly and CIP29 were assessed on their own and in combination. For this, proteins 
were mixed with a known concentration of ATP and yeast tRNA and left for 30 mins at 
37°C. Remaining ATP was then quantified using a luciferase reaction, creating a 
luminescent signal, which directly correlated to the total ATP remaining. This amount was 
subtracted from the input, to get an overview of ATPase activity of the individual hTREX 
components (Figure 3.8). It is apparent that UAP56 hydrolyses ATP, whereas Aly and CIP29 
did not display any ATPase activity on their own, or when both are combined. However, 
both proteins appear to stimulate the ATPase activity of UAP56 to about 2-fold, when 
present in the reaction. Interestingly, the presence of Aly and CIP29 together does not 
increase ATP hydrolysis of UAP56 further than the presence of just one protein.  
 
Figure 3.8: CIP29 stimulates UAP56 ATPase activity in vitro. Purified proteins were incubated at 1.5 μM 
each with 50 μM ATP for 30 min, before remaining ATP was quantified using a luminescent signal from a 
luciferase reaction. n = 3, error bars indicate the SD. 
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3.6 An ATP-dependent interaction of hTREX components affects the ability of 
ORF57 to interact with CIP29 
After establishing that CIP29 functions as a co-factor to UAP56-mediated ATP hydrolysis, 
the effect of the ATP-dependent interaction of Aly, UAP56 and CIP29, on the ability of 
ORF57 to interact with the hTREX proteins, was explored. For this co-
immunoprecipitations were performed using FLAG-CIP29 and ORF57-GFP as described 
previously (section 3.3), but utilised FLAG-PYM as an ATP-independent positive control. 
The co-immunoprecipitations of FLAG-PYM and FLAG-CIP29 were performed in duplicate, 
once in the presence of ATP and once in the presence of Adenosine 5'-O-(3-
thio)triphosphate (ATPγS), a non-hydrolysable ATP analogue. As ATPγS has a similar 
binding affinity to UAP56 as ATP (Taniguchi and Ohno, 2008), we speculated that any 
endogenous ATP present in the cell lysate would be efficiently displaced by the presence 
of 1.25 mM ATPγS. Similarly, we utilised 1.25 mM ATP for the ATP-positive 
immunoprecipitations. Proteins were sedimented using FLAG-affinity beads and analysed 
by Western blotting using GFP- and FLAG-specific antibodies (Figure 3.9a). ORF57 is seen 
to be specifically precipitated by FLAG-PYM and FLAG-CIP29 in the presence of ATP. In the 
presence of ATPγS, ORF57 still interacts with FLAG-PYM, however, the interaction with 
FLAG-CIP29 is virtually abolished. Quantification of the Western blots was performed for 
three individual experiments. Band intensity for each protein is displayed as a fold increase 
compared to the according precipitate in the presence of ATP (Figure 3.9b). This shows a 
significant loss of ORF57 precipitated by CIP29 in the presence of ATPγS. Compared to this, 
no significant difference is seen in the amount of ORF57 precipitated by PYM, in the 
presence of the non-hydrolysable ATP analogue. Furthermore, both FLAG-PYM and FLAG-
CIP29 are found to bind to the beads equally in the presence of ATP and ATPγS, suggesting 
that the effect is specific for the interaction of ORF57 with hTREX component CIP29.  
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Figure 3.9: ATP needs to be present for ORF57 to interact with CIP29. a) Co-immunoprecipitations were 
performed as before (section 3.3) in the presence of 1.25 mM ATP or 1.25 mM ATPγS. FLAG-PYM was 
utilised as a positive control not affected by ATP-dependency. b) Quantification of band intensities by 
ImageJ software. Values are average of 3 independent immunoprecipitations, error bars present the SD. 
p < 0.001 effect of ATPγS compared to ATP. 
 
3.7 Role of CIP29 in ORF57-mediated export of viral intronless mRNAs 
To assess the role of CIP29 in ORF57-mediated viral intronless mRNA export an mRNA 
export assay was performed in CIP29-depleted cells. The hTREX component can be 
efficiently knocked down by transfection of CIP29-specific siRNA for 72 h. Protein samples 
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were taken at 0, 24, 48 and 72 h and analysed by Western blotting using CIP29- and 
GAPDH-specific antibodies (Figure 3.10). 
 
Figure 3.10: Knock-down of CIP29 using siRNA in 293T cells. Cells were transfected with CIP29-specific 
siRNA at 0 and 24 h. Cells were harvested at 0, 24, 48 and 72 h and protein expression analysed by SDS-
PAGE and Western blotting using CIP29- and GAPDH-specific antibodies.  
 
For the mRNA export assay, cells were transfected with CIP29 siRNA for 48 h, prior to 
transfection with GFP or ORF57-GFP expression plasmids, as well as an intronless ORF47 
reporter plasmid. This intronless construct generates viral intronless transcripts that were 
used as reporter mRNA in this assay. At the 72 h time point, cells were fractionated in 
order to obtain a whole cell and a cytoplasmic fraction. Knock-down, protein expression 
and fractionation were controlled by Western blotting (Figure 3.11a). Effective knock-
down of CIP29 can be seen in whole cell and cytoplasmic samples transfected with CIP29-
specific siRNA. GAPDH was used as a loading control for all protein samples. RNA from 
fractionated samples was then extracted and DNase treated, before generation of cDNA 
and analysis by quantitative PCR (qPCR). Results are presented as the fold increase of 
ORF47 mRNA relative to ORF47 amounts in scrambled siRNA (siScr-) and GFP-transfected 
controls for each fraction (Figure 3.11b). Knock-down of CIP29 in GFP-transfected cells 
appears not to affect whole cell or cytoplasmic levels of ORF47 mRNA, whereas expression 
of ORF57 in scrambled control cells leads to a 4-fold increase in whole cell reporter mRNA. 
ORF57 is known to stabilise, protect and accumulate viral intronless transcripts, hence this 
effect is not unexpected (Kirshner et al., 2000; Stubbs et al., 2012; Nekorchuk et al., 2007). 
Moreover, cytoplasmic levels of ORF47 reporter mRNA are significantly increased in the 
presence of ORF57, compared to whole cell levels, confirming ORF57-mediated intronless 
ORF47 mRNA export, in addition to accumulation of the transcript. Surprisingly, in ORF57-
transfected samples which have been depleted of CIP29 by siRNA, a further enhancement 
in whole cell ORF47 mRNA is observed. This effect of another 2-fold increase compared to 
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siScr samples is statistically significant. Similarly, cytoplasmic fractions of these samples 
again show a significant increase in mRNA export, indicating that loss of CIP29 does not 
affect the export function of ORF57. Interestingly, while total ORF47 amounts in cells with 
CIP29 knock-down are larger than in undepleted cells, mRNA export in relation to whole 
cell amounts remains similar: Both sets of samples show 1.5-fold increase in exported 
reporter mRNA compared to whole cell mRNA. This indicates that CIP29 knock-down does 
not affect specific mRNA export pathways.  
 
Figure 3.11: CIP29 knock-down does not affect ORF57-mediated mRNA export. 293T cells were 
transfected with scrambled or CIP29-specific siRNA at 0 and 24 h and then transfected with GFP or 
ORF57-GFP and an ORF47 reporter construct at 48 h. At 72 h cells were harvested and fractionated. a) 
Protein samples of fractions were analysed by SDS-PAGE and Western blotting, using ORF57-, CIP29- and 
GAPDH-specific antibodies. b) qRT-PCR results using ORF47- and GAPDH-specific primers. ORF47 CT 
values were normalised to GAPDH and the relative increase calculated using the ΔΔCT method. n = 3, 
error bars display SD, p < 0.05.  
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3.8 Loss of CIP29 does not affect KSHV late protein expression 
To examine effects of CIP29 knock-down on KSHV lytic replication, 293 rKSHV.219 cells 
were utilised, a 293T cell line containing a recombinant bacterial artificial chromosome 
containing a recombinant KSHV genome (Vieira et al., 2004). The recombinant virus 
rKSHV.219 establishes a latent infection in these cells and can be efficiently reactivated 
using TPA and sodium butyrate to undergo the lytic life cycle. Again, efficient knock-down 
of CIP29 was observed in these cells after 72 h, by transfecting CIP29-specific siRNA twice, 
at 0 and 24 h time points. Protein samples were then taken at 0, 24, 48 and 72 h after 
transfection and analysed by Western blotting using CIP29- and GAPDH-specific antibodies 
(Figure 3.12).  
 
Figure 3.12: Knock-down of CIP29 using siRNA in latent 293 rKSHV.219 cells. Cells were transfected 
with CIP29-specific siRNA at 0 and 24 h. Protein samples were taken every 24 h for 72 h and 
subsequently analysed by SDS-PAGE and Western blotting (antibodies as indicated). 
 
The effect of CIP29 knock-down on viral late protein expression was then examined. To 
this end, 293 rKSHV.219 cells were transfected with CIP29-specific or scrambled siRNA for 
72 h, before lytic replication of KSHV was induced. After another 24 h, protein samples 
were analysed by Western blotting using a series of antibodies specific to viral and cellular 
proteins (Figure 3.13). ORF57 was probed as a control for induction of lytic replication, 
CIP29 was used to assess the level of knock-down in the cells and the KSHV minor caspsid 
protein (mCP), a late viral protein translated from an intronless transcript, was used as a 
marker for lytic replication. Although good knock-down of CIP29 and successful induction 
of lytic replication is achieved, no difference was observed for mCP levels between cells 
expressing CIP29 and depleted for this protein. This result was expected, after viral mRNA 
export assays showed no decrease in viral mRNA export upon knock-down of CIP29. These 
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results suggest that CIP29 is not required for viral intronless mRNA export and efficient 
viral late protein expression. 
 
Figure 3.13: CIP29 knock-down does not affect viral late protein expression. Latent 293 rKSHV.219 cells 
were transfected at 0 and 24 h with CIP29 siRNA. KSHV lytic replication was induced at 48 h and cells 
harvested at 72 h. Protein samples were analysed by SDS-PAGE and Western blotting using specific 
antibodies as indicated (mCP = minor capsid protein).  
 
3.9 Discussion 
In this chapter an interaction between the viral mRNA export factor ORF57 and the hTREX 
component CIP29 was identified by GST-pulldowns, co-immunoprecipitation and 
subcellular co-localisation. CIP29 is one of several recently identified hTREX components 
(Dufu et al., 2010; Chang et al., 2013; Folco et al., 2012). No interaction with ORF57 has 
been shown previously; however, as ORF57 is believed to recruit the complete hTREX 
complex in order to form an export competent vRNP, this interaction was expected (Boyne 
et al., 2008). The formation of the trimeric complex of Aly-UAP56-CIP29 within the hTREX 
complex has been shown to be ATP-dependent (Dufu et al., 2010). Interestingly, UAP56 is 
a member of the RNA-helicase family with ATPase activity in vitro, which can be further 
stimulated by the presence of Aly (Shen et al., 2007; Taniguchi and Ohno, 2008). Other 
work has shown CIP29 associates with UAP56 to enhance its RNA-helicase activity (Sugiura 
et al., 2007). It has therefore been speculated that CIP29, as well as Aly, might function as 
co-factors for UAP56, potentially to unwind the 5’ end of mRNA, in order to allow binding 
of the THO complex and TAP recruitment (Dufu et al., 2010). To establish the role of CIP29 
in the ORF57-mediated export of viral mRNAs, GST-tagged CIP29, Aly and UAP56 were 
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purified and used in ATPase assays. Aly and CIP29 stimulated UAP56 ATPase activity in 
vitro, but the effect was not increased by the presence of both proteins together. Similar 
results have been recently described in the literature (Chang et al., 2013). It can therefore 
be speculated that Aly and CIP29 have overlapping and redundant functions with regard to 
UAP56 ATPase activity.  
The ATP-dependency of the complex formation was then explored, with regard to ORF57-
mediated recruitment of hTREX components. Co-immunoprecipitations in the presence of 
ATP and ATPγS confirmed that ORF57 binding is affected by the ATP-dependent formation 
of the trimeric complex and cannot override this effect: the viral protein did not co-
precipitate with CIP29 in the presence of ATPγS. ORF57 is known to directly interact with 
Aly. Hence, it appears that if the Aly-UAP56-CIP29 complex is unable to form, ORF57 is not 
able to recruit either UAP56 or CIP29. It would be intriguing to see if ORF57 remains able 
to bind Aly in the presence of ATPγS and further co-immunoprecipitations should be 
conducted in the future to clarify this point. Interestingly, as ATPγS has a similar binding 
affinity to UAP56 as ATP, but cannot be hydrolysed, this highlights further that it is not ATP 
binding, but ATP hydrolysis (or a result thereof) that is necessary for formation of the Aly-
UAP56-CIP29 interaction. 
To clarify the role of CIP29 in KSHV lytic replication, the effect of CIP29 knock-down was 
examined on viral mRNA export and on expression of viral late proteins translated from 
intronless mRNAs. Intriguingly, enhanced viral intronless transcript levels were observed in 
CIP29 depleted cells, when ORF57 was present. It cannot be ruled out that this effect is 
due to experimental errors: Western blots indicate slightly increased protein bands for 
transfected ORF57 in cells with CIP29 knock-down. As ORF57 is known to stabilise viral 
transcripts, enhanced levels of the protein could lead to an increase in ORF47 whole cell 
mRNA. However, as mRNA export is not seen to rise accordingly in these cells, it is unlikely 
that this is the case. In both, CIP29 knock-down and mock transfected cells, cytoplasmic 
levels of the reporter mRNA are 1.5-fold higher than the according whole cell amounts. 
Compared to this, cells expressing more ORF57 would be expected to display a further 
relative increase in mRNA export. It therefore appears that CIP29 knock-down leads to 
increased mRNA stability in ORF57 expressing cells. To date, this effect cannot be 
explained and further experiments have to be conducted, looking at mRNA stability in the 
presence and absence of ORF57.  
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Interestingly, employing a KSHV infected cell line no change in expression of viral late 
proteins was seen in cells depleted of CIP29. Importantly, no effect of the knock-down 
could be observed on induction of lytic replication or expression of ORF57. This confirms 
the result of the mRNA export assay, showing that CIP29 does not affect ORF57-mediated 
export of viral intronless transcripts. Even though an increase in total cytoplasmic levels of 
ORF47 mRNA could be seen, no increase in protein expression is observed. It is possible 
that cellular regulatory mechanisms, such as protein degradation or post-transcriptional 
modifications, regulate any further downstream effects after mRNA export. Again, further 
research has to be conducted to investigate this effect. Moreover, additional research 
should clarify the role of CIP29 in hTREX, as well as cellular and viral mRNA export, as 
neither has been affected by CIP29 knock-down.   
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4 ATP-cycle dependent remodelling of hTREX complex affects ORF57-
induced viral RNP formation and can be exploited as a therapeutic 
target 
4.1 Introduction 
The hTREX components UAP56, Aly and CIP29 form a trimeric complex in the presence of 
ATP, with UAP56 bridging the interaction of Aly and CIP29 (Dufu et al., 2010). This is 
perhaps not surprising, as UAP56, the core component essential for assembly of the hTREX 
complex and mRNA binding, belongs to the DExD-box family of RNA-helicases (Shen et al., 
2007). RNA-binding, unwinding and release by members of this protein family is coupled 
to ATP binding and hydrolysis. As such, they have major roles in all stages of RNA 
metabolism, where their roles vary from rearranging RNA-structures, to remodelling 
protein or RNA-protein complexes (Cordin et al., 2006). 
As shown in the previous chapter, ATPγS prevents the association of ORF57 with CIP29. 
Since ORF57 recruits the hTREX complex through a direct interaction with Aly, which in 
turn interacts with UAP56, it can be speculated that disrupting ATP hydrolysis will also 
abolish other ORF57/hTREX interactions. Recent research by Chang et al. has 
demonstrated dependency of hTREX function on UAP56-mediated ATP hydrolysis (Chang 
et al., 2013). Specifically, loading of Aly and Chtop onto RNA were prevented by a non-
hydrolysable ATP-analogue. It was therefore proposed that an ATP-cycle dependent 
remodelling of hTREX, driven by UAP56, takes place. 
After demonstrating the reliance of the ORF57/CIP29 interaction on ATP hydrolysis, we 
hypothesised that the ATP-cycle dependent remodelling of hTREX would affect the ability 
of ORF57 to form a vRNP and therefore present a novel antiviral target. The following 
chapter describes experiments performed in order to elucidate the mechanisms of ATP-
dependent hTREX remodelling and its effects on ORF57. Experiments then show that 
targeting this process using small molecule inhibitors is a valid approach to inhibit KSHV 
lytic replication. 
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4.2 ATP-dependent formation of the ORF57-mediated vRNP 
To assess the effect of ATP binding and ATP hydrolysis on vRNP formation, co-
immunoprecipitation experiments were performed. For this, GFP or GFP-UAP56 
expression vectors were transfected into 293T cells in the absence or presence of a 
mCherry-ORF57 construct. After 24 h, the cell lysates were incubated with GFP-trap® 
beads in the presence of mock, 1.25 mM ATP or ATPγS, which functions as an ATP-
inhibitor. ATPγS can only be hydrolysed very slowly by UAP56, but having a similar binding 
affinity as ATP (Taniguchi and Ohno, 2008), we speculated that the presence of 1.25 mM 
would efficiently prevent hydrolysis of any present endogenous ATP. Precipitated proteins 
were then analysed by western blotting and detected with ORF57-, Aly-, CIP29- or GFP-
specific antibodies (Figure 4.1a). Analysis of the precipitates revealed an ATP-dependent 
effect on the interaction of ORF57 with UAP56 and hence vRNP formation: ORF57, as well 
as the endogenous hTREX proteins Aly and CIP29, can be seen to specifically interact with 
UAP56. Binding of the viral and the endogenous proteins is clearly enhanced by the 
presence of ATP. In contrast, the presence of ATPγS significantly inhibits the interaction of 
ORF57 with UAP56, which highlights the necessity of ATP hydrolysis for formation of the 
vRNP. Interestingly, binding of Aly and CIP29 to UAP56 is not negatively affected by ATPγS, 
as densitometry suggest a slight increase in the formation of an Aly-UAP56-CIP29 complex 
(Figure 4.1b). A similar result is reflected in the precipitation of GFP-UAP56 in the absence 
of ORF57: The addition of ATP enhances binding of the endogenous hTREX components, 
whereas ATPγS does not have a negative effect on complex assembly. Interestingly, while 
the trend remains the same, the interaction of Aly and CIP29 with UAP56 is enhanced in 
the presence of ORF57, as less protein can be seen to co-precipitate in the absence of the 
viral protein. A GFP-specific antibody was used to confirm similar amounts of UAP56 have 
been pulled down in all samples, making the immunoprecipitations comparable. 
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Figure 4.1: ATP-dependent formation of the ORF57-mediated vRNP. a) Co-immunoprecipitations were 
performed with cell lysates from 293T cells transfected with GFP or GFP-UAP56 and mCherry-ORF57 
(Input), as indicated. Precipitations were performed with complete whole cell lysates or with the 
addition of 1.25 mM ATP or 1.25 mM ATPγS. Western blots were probed with ORF57-, Aly-, CIP29- and 
GFP-specific antibodies. b) Quantification of band intensities by ImageJ. Values are average of 
4 independent immunoprecipitations (performed with mCherry-ORF57, as shown above, or Myc-
ORF57). Error bars present the SD. p < 0.01 (**) or p < 0.05 (*), effect of ATP or ATPγS compared to 
untreated. 
 
A dose-dependency effect of ATP and ATPγS would be expected, if the interactions of the 
hTREX complex and ORF57 could be dynamically remodelled by the presence of the 
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nucleotide or the non-hydrolysable analogue. Therefore the previous immunoprecipitation 
experiment was repeated in the presence of 0–1.75 mM ATP or ATPγS. Western blots 
were then probed with GFP-specific antibodies as a precipitation control for GFP-UAP56, 
or ORF57-specific antibodies to quantify precipitation of ORF57 (Figure 4.2). The 
experiment shows a dose-dependent effect for both ATP and ATPγS on the interaction of 
ORF57 with UAP56.  
 
Figure 4.2: Dose-dependent effect of ATP and ATPγS on ORF57-mediated vRNP formation. Co-
immunoprecipitations were performed as described before (Figure 4.1), with a series of ATP and ATPγS 
concentrations, as indicated.  
 
4.3 ATP-cycle dependent remodelling of the ORF57-mediated vRNP 
Since the ORF57 interaction with hTREX is specifically interrupted by the presence of 
ATPγS, it could be speculated that the ATPase-function of UAP56 is necessary for 
remodelling of hTREX, after the initial complex formation upon ATP binding. However, the 
previous experiment left unaddressed if the actual energy generating step of ATP 
hydrolysis is essential for a reorganisation of all involved hTREX proteins and possibly 
binding of Aly and Chtop to viral mRNA. Another mechanism could be a conformational 
change of the hTREX complex upon ADP binding to UAP56. This rearrangement might be 
necessary to accommodate the viral protein and would also be prevented by the presence 
of ATPγS. Therefore, further co-immunoprecipitation assays were performed in the 
presence of ATP, ATPγS and also ADP. As before, 293T cells were transfected with GFP or 
GFP-UAP56 and mCherry-ORF57, before cell lysates were incubated with GFP-trap® beads, 
either in the absence or in the presence of 1.25 mM ATP, ATPγS or ADP. Precipitates were 
analysed by Western blotting using GFP- and ORF57-specific antibodies (Figure 4.3). 
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Figure 4.3: ATP-cycle dependent remodelling of the ORF57-mediated vRNP. Co-immunoprecipitations 
were performed as before (Figure 4.1), in the presence of 1.25 mM ATP, ATPγS or ADP, as indicated.  
 
As before, ATP can be seen to enhance the interaction of UAP56 and ORF57, whereas it is 
reduced with ATPγS. Interestingly, ADP also disrupts the interaction of UAP56 and ORF57, 
indicating that the presence of hydrolysable ATP is the essential factor for ORF57-
mediated binding of the hTREX complex. To confirm these results, co-
immunoprecipitations were performed in a dose-dependent manner. The experiment was 
conducted as before, using a concentration range from 0.1 to 1.75 mM ATP, ATPγS or ADP. 
Western blots were probed using ORF57-, Aly-, CIP29- or GFP-specific antibodies, to 
determine the effect of ATP-cycle dependent complex remodelling on both the viral 
protein and endogenous hTREX components (Figure 4.4a). Again, ADP can be seen to 
disrupt the interaction of ORF57 with UAP56 in a dose-dependent manner, in a similar 
fashion to ATPγS. Densitometry of 3 individual experiments shows for both ATPγS and ADP 
a significant decrease in precipitated ORF57 at concentrations between 1.25 and 1.75 mM 
(Figure 4.4b). Interestingly, ADP is also found to significantly disrupt the interaction of the 
endogenous hTREX components Aly and CIP29 with UAP56. This is in contrast to the effect 
observed in the presence of ATPγS, where again a stabilising effect can be seen on the 
formation of the Aly-UAP56-CIP29 complex, similar to that of ATP. 
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Figure 4.4: Dose-dependency of ATP-cycle dependent remodelling of the ORF57-mediated vRNP. 
a) Co-immunoprecipitations were performed as described before (Figure 4.1) with a series of ATP, ATPγS 
and ADP concentrations, as indicated. b) Quantification of bands at 1.25 and 1.75mM ATP, ATPγS or ADP 
by ImageJ. Values are average of 3 independent immunoprecipitations. Error bars present the SD. 
p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***) effect of ATP, ATPγS or ADP compared to untreated. 
 
Together, this data indicates an ATP-cycle dependent remodelling of the hTREX that 
affects the ability of ORF57 to interact with the complex and form a vRNP (Figure 4.5). 
Upon ATP binding (simulated by the presence of ATPγS) the endogenous trimeric complex 
Aly-UAP56-CIP29 is able to form. It can be further speculated that ATP hydrolysis (in the 
presence of ATP) allows a conformational change within hTREX, which enables ORF57 to 
interact with Aly and recruit the hTREX complex. Whereas after release of inorganic 
phosphate, bound ADP causes the protein complex to dissociate. 
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Figure 4.5: Schematics of ATP-cycle dependent remodelling of central hTREX components and the 
ORF57-mediated vRNP. Proposed model based on co-immunoprecipitations in the presence of ATP, 
ATPγS and ADP, as shown above (Figure 4.3 and Figure 4.4).  
 
4.4 High-throughput screening for UAP56 ATPase inhibitors  
We speculated that inhibitors targeted against UAP56 ATPase-activity would function to 
prevent formation of the vRNP, while allowing the interaction of hTREX components, as 
could be seen for ATPγS. In silico high-throughput screening (HTS) was therefore utilised to 
identify small molecules capable of binding in the UAP56 ATP binding site, based on the 
known crystal structure (Shi et al., 2004). Furthermore, a series of compounds were 
manually chosen from the Tocriscreen Compound Library, a screening library of known 
bioactive compounds suitable for HTS. Finally, a small number of fragments were also 
selected. Following selection of 400 compounds/fragments giving the highest score using 
the virtual docking programme eHiTS (SymBioSys), these were tested against in vitro 
ATPase activity of UAP56. Conditions for the in vitro screening were established using 
several preparations of GST-UAP56, which was purified as shown before (Figure 3.7). 
While all batches of purified protein showed RNA-dependent ATPase activity, the rates of 
hydrolysis were found to vary between preparations (Figure 4.6a). Therefore, to obtain 
comparable results with several protein preparations during the screening process, no 
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fixed protein concentration was used, but rather a specific concentration for each batch 
(between 1 and 3 μM UAP56), that resulted in hydrolysis of 30% ATP used in the assay. 
This would yield the best assay window, giving a high signal-to-background ratio and 
maintaining velocity of ATP hydrolysis in the linear range with enzyme concentration. The 
ATP concentration for the screen was set as 35 μM, which was equivalent to the average 
KM experimentally determined for three individual protein preparations (Figure 4.6b). 
Using a substrate concentration [S] = KM is recommended as “balanced assay conditions”, 
as this provides equal opportunities for all inhibitor types (Copeland, 2005).  
 
Figure 4.6: Determination of assay conditions for UAP56-ATPase assay. Purified GST-UAP56 was 
incubated with a known concentration of ATP for 30 min at 37˚ C, before remaining amounts of ATP 
were determined using a luminescent signal from a luciferase reaction. a) A fixed substrate 
concentration of 50 μM ATP was used. Error bars present the SD, n = 3. b) A fixed protein concentration 
of 1.5 μM UAP56 was used. Michaelis-Menten curve was fitted using Graphpad Prism software. Error 
bars present the SD, n = 2. 
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Under these conditions, ATPγS was used as a control inhibitor and was found to display a 
typical sigmoidal inhibition curve (Figure 4.7). 
 
Figure 4.7: Inhibition of UAP56 ATPase activity by ATPγS. Assay conditions were tested using increasing 
concentrations of a known inhibitor of UAP56, ATPγS. n = 3, error bars display SD.  
 
In vitro screening of the pre-chosen 400 small molecules/fragments identified four 
compounds, all from the Tocriscreen Compound Library, which had the ability to inhibit 
UAP56 enzyme activity to below 80% (Figure 4.8). Excitingly, none of the “hits” are 
adenosine-based structures, enhancing enzyme specificity and making them suitable for 
further characterisation.  
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Figure 4.8: Screening of small molecules and fragments against UAP56 ATPase activity identified four 
potential inhibitors. Compounds selected by vHTS are in teal, compounds manually chosen from the 
Trociscreen library are in dark orange and screened fragments are in light orange. Screening was 
performed under conditions described above with 100 μM of each compound and 1 mM of each 
fragment. UAP56 ATPase activity in the presence of inhibitor: a) 74%, b) 63%, c) 67% and d) 25%.  
 
The most potent compound (d), C2, reduced enzyme activity by 75%. AutoDoc, a software 
for calculating binding energies of small molecules to proteins, predicted C2 to bind to the 
ATP binding pocket of UAP56, suggesting an ATP competitive inhibitor (Figure 4.9). C2 is 
expected to form the indicated hydrogen-bonding interactions, π-stacking interactions 
with Phe-65 and hydrophobic interactions with Met-93. 
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Figure 4.9: Compound C2 is predicted to bind to the ATP binding pocket of UAP56. a) Crystal structure 
of UAP56 ATP binding site as solved in the presence of ADP. b) Suggested binding of C2 by AutoDock 
software is within the UAP56 ATP binding pocket (images kindly provided by Dr Ian Yule and Dr Richard 
Foster).  
 
4.5 Confirmation of UAP56 inhibition by small molecule inhibitor C2 
To confirm a dose-dependent inhibition of UAP56, the enzymes ATPase activity was 
measured over a wide concentration range of compound C2. Non-linear regression could 
then be used to determine the half maximal inhibitory concentration (IC50) of C2 for UAP56 
ATPase activity. Because of the observed variation in activity of different protein batches, 
this was done with GST-UAP56 protein from three individual purifications at set 
concentrations. Two measurements, both at a concentration of 5 μM protein, resulted in 
an averaged IC50 = 63.5 μM +/- 3.5 μM (Figure 4.10a). This indicates that while absolute 
activity between batches may vary, normalised activity of each batch yields comparable 
inhibition by C2. Since the IC50 is directly dependent on the protein concentration used in 
the assay, we also repeated the experiment with 700 nM GST-UAP56. Due to a smaller 
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signal-to-background ratio, variation between replicates is larger; however, we were still 
able to determine an IC50 of 7.6 μM at this concentration (Figure 4.10b). 
 
Figure 4.10: IC50 measurements of C2 for UAP56. Assays were performed with recombinant protein 
from three individual protein purifications. a) Two measurements using 5 μM UAP56 from individual 
protein purifications each. b) Measurement employing 700 nM UAP56 from a separate protein 
purification. UAP56 was incubated with increasing amounts of C2 in the presence of 0.5% DMSO and 
35 μM ATP for 30 min. n = 3, error bars display the SD. IC50 was determined using non-linear regression.  
 
In addition to IC50 measurements, microscale thermophoresis was performed to determine 
the dissociation constant, KD. For this, GST-UAP56 was purified as described before (Figure 
3.7) and fluorescently labelled with FITC on amine groups. Thermophoretic movement 
measured via normalised fluorescence in the presence of increasing amounts of C2 (Figure 
4.11) (assay performed by Dr Brian Jackson). A KD of 12.8 μM was calculated for the 
thermophoresis binding curve.  
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Figure 4.11: Thermophoresis binding curve for UAP56 and C2. The binding curve shows normalised 
fluorescence (Fnorm) in the presence of increasing amounts of C2. KD = 12.8 μM, calculated using the 
following formula: f(c) = unbound + (bound-unbound) / 2*(FluoConc + c + KD - Sqrt((FluoConc + c + KD) ^ 
2 - 4*FluoConc*c), with FluoConc = 2830, bound = 899.29 and unbound = 890.49, square root (Sqrt), 
concentration C2 (c). Assay performed by Dr Brian Jackson (Schumann, S., Yule, I., Jackson, B. R., Foster, 
R. and Whitehouse, A.; Manuscript in preparation). 
 
4.6 Disruption of vRNP formation in vitro by ATPase inhibitor C2 
After successful identification of an UAP56-targeted ATPase inhibitor, the effect of the 
compound on vRNP formation in vitro was tested. Because the compound has to be 
delivered in a solvent, co-immunoprecipitations were carried out in duplicate using either 
3.3% DMSO or 5% EtOH as delivering vehicles or mock control. Co-immunoprecipitations 
were performed as before, adding the compound and solvent to GFP or GFP-UAP56 and 
mCherry-ORF57 transfected cell lysates for 2 h during binding to GFP-trap® beads. 
Precipitates were analysed using ORF57-, Aly-, CIP29-, Chtop- and GFP-specific antibodies 
(Figure 4.12). Intriguingly, the presence of 0.5 mM C2 specifically disrupts binding of 
ORF57 to the hTREX complex, whereas no effect is seen on the interaction of endogenous 
hTREX components with UAP56. The same result is seen regardless of solvent used. This 
confirms the hypothesis that disruption of UAP56-mediated ATP hydrolysis prevents 
ORF57 from recruiting the hTREX complex, while allowing assembly of the endogenous 
complex. 
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Figure 4.12: Disruption of vRNP formation by UAP56 ATPase inhibitor C2. Co-immunoprecipitations 
were performed as described before (Figure 4.1), in the absence or presence of 0.5 mM C2 and 
3.3% DMSO or 5% EtOH, as indicated. Western blots were analysed using ORF57-, Aly-, CIP29-, Chtop- 
and GFP-specific antibodies.  
 
To assess the effect of C2 on vRNP formation in cell culture, MTS assays were first 
performed to identify a non-toxic working concentration of C2. Cells were treated with 
increasing amounts of the compound delivered in 0.1% total DMSO for 24 h, before cell 
viability was assessed using the calorimetric MTS assay (Figure 4.13). Up to 15 μM C2 could 
be used on 293T cells without a loss in metabolic activity, indicating 100% viable cells. 
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Figure 4.13: Cell viability of 293T cells in the presence of C2. Cells were incubated with increasing 
concentrations of C2 and a total of 0.1% DMSO for 24 h. Cell viability was assessed by MTS assay and 
normalised to untreated cells. n = 5, error bars present SD. Results are displayed as a) column graph, b) 
on a xy-graph using a log-scale and non-linear regression to determine the CC50. 
 
As previously described, ORF57 localises to the nucleolus of the cells and can be seen co-
localising with hTREX components in this subcellular compartment (Boyne and 
Whitehouse, 2009). Using immunofluorescence microscopy the localisation of ORF57 and 
hTREX components was explored in the absence and presence of compound C2. For this, 
cells were transfected with GFP-UAP56 in the absence or presence of mCherry-ORF57 and 
treated 6 h after transfection with DMSO or C2. Cells were fixed 24 h after transfection 
(Figure 4.14). GFP-UAP56 localised to the nucleus as bright, punctuate speckles, excluding 
the nucleolus (arrows) in the absence of ORF57. In cells expressing ORF57 both proteins 
are found to co-localise in the cell nucleolus, with UAP56 losing its punctuate appearance. 
However, in cells treated with 2.5 μM C2, mCherry-ORF57 is unable to sequester GFP-
UAP56 to the nucleolus and no co-localisation is detected between the two proteins. 
UAP56 is again seen localising in punctuate speckles excluding the nucleolus, whereas 
ORF57 remains in the nucleolus (arrows). 
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Figure 4.14: Disruption of UAP56 co-localisation with ORF57 in the presence of C2. 293T cells were 
transfected with plasmids expressing GFP-UAP56 in the absence or presence of mCherry-ORF57. After 
6 h transfection, cells were treated with DMSO or C2, as indicated, for another 18 h, before they were 
fixed and permeabilised. DAPI staining (blue) indicates the nucleus, UAP56 was visualised by direct 
GFP-fluorescence (green) and ORF57 by direct mCherry-fluorescence (red).  
 
Immunofluoresence microscopy was also employed to assess co-localisation of ORF57 and 
endogenous hTREX proteins. For this, GFP or ORF57-GFP transfected cells were incubated 
with DMSO or 2.5 μM C2, as indicated. After fixation and permeabilisation, cells were 
immunostained using CIP29-specific antibodies (Figure 4.15). As described in chapter 3 
(Figure 3.5), CIP29 localises to nuclear speckles and is seen excluding the nucleolus 
(arrows), but can be recruited into this compartment by ORF57, where the two proteins 
co-localise. Treatment of cells with compound C2 prevents the interaction of ORF57 and 
endogenous CIP29, stopping the viral protein from sequestering CIP29 to the nucleolus. 
These results support the hypothesis that C2 prevents the interaction of ORF57 and hTREX 
proteins.  
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Figure 4.15: Disruption of CIP29 co-localisation with ORF57 in the presence of C2. 293T cells were 
transfected with mock or a plasmid expressing ORF57-GFP. After 6 h transfection, cells were treated 
with DMSO or C2, as indicated, for another 18 h, before they were fixed and permeabilised. Cells were 
stained using a CIP29-specific antibody (red). DAPI staining (blue) indicates the nucleus, ORF57 was 
visualised by direct GFP-fluorescence (green).  
 
4.7 ATPase inhibitor C2 prevents recruitment of hTREX by ORF57 but does not 
inhibit cellular bulk mRNA export 
Compound C2 prevents ATP hydrolysis by UAP56 and subsequently ATP-cycle dependent 
remodelling of the hTREX complex, potentially rendering a dysfunctional complex. 
Therefore, to test the effect of the inhibitor on endogenous mRNA export, fluorescence in 
situ hybridisation (FISH) was employed to monitor cellular mRNA export in the absence 
and presence of both ORF57 and C2. Cells were transfected with GFP or ORF57-GFP and 
6 h later treated with DMSO or C2. After another 18 h cells were fixed, permeabilised and 
incubated with a fluorescently labelled oligo(dT) probe to detect polyadenylated (poly(A)) 
RNA (Figure 4.16). In the presence of GFP, poly(A) RNA is detected in large quantities in 
the cytoplasm of the cell (arrows) and only minor amounts remain in the nucleus within 
nuclear speckles. However, functional ORF57 recruits the complete hTREX complex and 
during this process ORF57 sequesters hTREX from endogenous mRNA, leading to a marked 
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reduction of poly(A) RNA in the cytoplasm and retention in the nucleus (arrows), when 
compared to GFP transfected cells. Excitingly, when ORF57-GFP transfected cells are 
treated with compound C2, a loss of nuclear retention can be observed (arrows) and an 
increased amount of poly(A) RNA is again found in the cytoplasm. Some co-localisation of 
ORF57 and poly(A) RNA can be observed in nuclear speckles, which is expected as both the 
viral protein and endogenous RNAs are known to localise to this subnuclear structure 
independently of each other. However, all C2 treated cells in the presence of GFP exhibit 
normal mRNA export with large amounts of poly(A) RNA being found in the cytoplasm 
(arrows). This confirms that the interaction of ORF57 and the hTREX complex is efficiently 
disrupted in the presence of C2 and, importantly, that the presence of C2 does not inhibit 
endogenous cellular bulk mRNA export. 
 
Figure 4.16: Fluorescence in situ hybridisation (FISH) demonstrates C2 prevents hTREX sequestration 
by ORF57, but does not inhibit cellular bulk mRNA export. HEK 293T cells were transfected with 
plasmids expressing GFP or ORF57-GFP and treated after 6 h with DMSO or C2, as indicated, for another 
18 h. Cells were fixed and permeabilised, before they were incubated with a fluorescently labelled 
oligo(dT) probe. DAPI staining (blue) indicates the nucleus, ORF57 was visualised by direct 
GFP-fluorescence (green) and poly(A) RNA is shown in red.  
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4.8 C2 prevents ORF57-mediated export of viral mRNAs 
After observing no change in cellular mRNA export upon C2 treatment, viral mRNA nuclear 
export was assessed. To perform a viral mRNA export assay, cells were transfected with 
GFP or ORF57-GFP, as well as an intronless construct coding for ORF47, generating viral 
intronless transcripts that function as a reporter RNA. After 6 h, cells were treated with 
DMSO or C2, 18 h later cells were fractionated in order to obtain whole cell and 
cytoplasmic fractions, before generation of cDNA and analysis by quantitative PCR (qPCR). 
Figure 4.17 presents the fold increase of ORF47 mRNA in the respective fractions 
compared to the GFP control. In the presence of ORF57, a 4-fold increase in whole cell 
reporter mRNA can be observed. This is expected, as ORF57 recruits the hTREX complex 
onto viral mRNA and thereby stabilises viral intronless transcripts, protecting them from 
cellular RNA decay mechanisms (Stubbs et al., 2012). Furthermore, ORF57 expressing cells 
show a significant increase in cytoplasmic levels of ORF47 mRNA, compared to whole cell 
levels, confirming that ORF57 enhances export of viral transcripts, in addition to protecting 
them. However, a significant decrease in whole cell ORF47 transcripts is detected in C2 
treated cells, compared to DMSO treated cells. As C2 efficiently disrupts the interaction of 
ORF57 and hTREX components, a loss in viral mRNA stability is expected. Importantly 
though, no significant export of viral mRNA can be seen in the presence of C2, as 
cytoplasmic levels do not exceed whole cell amounts. 
 
Figure 4.17: Inhibitor C2 reduces ORF57-mediated mRNA export. 293T cells were transfected with GFP 
or ORF57-GFP expressing plasmids, as well as an ORF47 reporter construct. After 6 h, cells were treated 
with DMSO or C2 as indicated and after another 16 h fractionated. qRT-PCR was performed using ORF47 
and GAPDH specific primers. ORF47 CT values were normalised to GAPDH and the relative increase 
calculated using the ΔΔCT method. n = 3, error bars display SD, p < 0.05. 
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4.9 Cytotoxicity of C2 in TREx BCBL-1 Rta cells 
To confirm the previous mRNA export results obtained in transfected 293T cells, a well 
characterised KSHV infected cell line, TREx BCBL1-Rta, was also employed. This cell line is a 
derivative of a BCBL-1 cell line (B-cell lymphoma cells latently infected with KSHV), 
containing a Myc-tagged version of RTA under the control of a tetracycline-inducible 
promoter. TREx BCBL1-Rta cells were shown to undergo the full lytic replication cycle and 
produce infectious viral progeny after induction by doxycycline (Nakamura et al., 2003). 
The viability of TREx BCBL1-Rta cells was assessed in the presence of C2 at 24 and 72 h by 
MTS assay (Figure 4.18). The half maximal cytotoxic concentration (CC50) was determined 
using non-linear regression (Figure 4.18b). No cytotoxicity was observed up to 2.5 μM C2 
at both 24 and 72 h. A small decrease in CC50 can be observed between 24 and 72 h, 
indicating that the effect of C2 within the cell is stable over the observed time. 
 
Figure 4.18: Cell viability of TREx BCBL1-Rta cells in the presence of C2. Cells were incubated with 
increasing concentrations of C2 and a total of 0.1% DMSO for 24 and 72 h. Cell viability was assessed by 
MTS assay and normalised to untreated cells. n = 5, error bars present SD. Results are displayed as a) 
column graph, b) on a xy-graph using a log-scale and non-linear regression to determine the CC50. 
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4.10 Disruption of vRNP formation by C2 in KSHV infected cells 
Immunofluorescence microscopy was employed to assess co-localisation of ORF57 and 
hTREX components in KSHV infected TREx BCBL1-Rta cells. For this, cells were treated with 
DMSO or 2.5 μM C2 at the time of induction. After 24 h, cells were fixed, permeabilised 
and immunostained with CIP29- and ORF57-specific antibodies. Cells were visualised using 
confocal microscopy (Figure 4.19). As was described earlier, CIP29 localises in nuclear 
speckles of the cell nucleus and is also found here in latently infected TREx BCBL1-Rta cells. 
The protein is visible in bright nuclear speckles and appears to be excluded from the 
nucleolus (arrows). Upon induction of KSHV lytic replication and expression of ORF57, 
CIP29 can be seen co-localising with the viral protein and appears to lose its bright, 
punctuate appearance. However, in induced cells that were treated with C2, CIP29 and 
ORF57 fail to co-localise. Furthermore, CIP29 appears again in punctuate speckles. 
Together this data confirms our previous immunofluorescence in a physiologically relevant 
KSHV-infected cell line. 
 
Figure 4.19: Disruption of CIP29 co-localisation with ORF57 in the presence of C2. TREx BCBL1-Rta cells 
were either left uninduced or induced with doxocycline, and then treated with DMSO or C2, as 
indicated, for 24 h, before they were fixed and permeabilised. Cells were stained using a CIP29- (green) 
or ORF57-specific antibody (red). DAPI staining (blue) indicates the nucleus.  
 
120 
 
4.11 Treatment of TREx BCBL1-Rta cells with C2 prevents export of viral intronless 
mRNA 
To assess the effect of C2 on viral intronless mRNA export in lytic KSHV infected cells, TREx 
BCBL1-Rta cells were used for a viral RNA export assay. Cells were induced with 
doxycycline or mock induced and treated with DMSO or 2.5 μM C2 for 24 h. Cells were 
then harvested and fractionated in order to obtain whole cell, cytoplasmic and nuclear 
fractions. Protein samples of all fractions were also obtained and analysed by SDS-PAGE 
and Western blotting (Figure 4.20a). Treatment of cells with 2.5 μM C2 does not impede 
induction of lytic replication or ORF57 expression, as similar amounts of protein were 
present in all induced samples.  
The mRNA of each fraction was analysed by reverse transcriptase quantitative PCR (qRT-
PCR). We examined ORF47 and ORF57 mRNA to contrast both viral intronless and intron-
containing mRNA. Figure 4.20b presents the fold increase of ORF47 and ORF57 mRNA in 
each fraction, normalised to induced cell samples in the presence of DMSO. Comparing 
whole cell mRNA levels between DMSO and C2 treated induced cells, a significant 
reduction can be observed for both ORF47 and ORF57. However, this effect is not a 
general effect on viral transcripts; instead there is a significant difference between the two 
types of mRNA. While ORF47 mRNA levels are reduced by more than half, only a 0.25 fold 
decrease is detected for ORF57 transcripts. It is likely that intronless viral transcripts are 
less stable in the presence of C2, as observed before for 293T cells. Furthermore, the lytic 
expression cascade of KSHV might be less efficient in the presence of C2, causing an 
additional general deficit in viral gene transcription seen for both types of mRNA. 
Interestingly, even though a decrease in whole cell ORF57 mRNA was noted, this is not 
reflected in the cytoplasmic levels of the mRNA, where no difference to untreated cells 
can be detected. This indicates efficient export of viral intron-containing transcripts, in the 
presence of the inhibitor. In contrast, ORF47 intronless mRNA is only poorly exported into 
the cytoplasm and a significant loss can be observed compared to DMSO treated cells. 
Interestingly, no significant decrease in nuclear ORF47 transcripts is detected, although 
whole cell levels were halved. This indicates retention of the intronless mRNA in the 
nucleus. Opposed to this, a further loss of nuclear ORF57 transcripts compared to whole 
cell levels suggests further depletion by efficient export into the cytoplasm. 
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Figure 4.20: Inhibitor C2 reduces ORF57-mediated mRNA export in KSHV infected cells. TREx 
BCBL1-Rta cells were induced and treated with DMSO or C2, as indicated. After 24 h, cells were 
harvested and fractionated. a) Protein samples were analysed by SDS-PAGE and Western blotting, using 
ORF57-, Lamin B- and GAPDH-specific antibodies, to detect the indicated proteins. b) qRT-PCR was 
performed using ORF47, ORF57 and GAPDH specific primers. ORF47 and ORF57 CT values were 
normalised to GAPDH and the relative increase calculated using the ΔΔCT method. n = 3, error bars 
display SD, p < 0.05. 
 
4.12 Small molecule inhibitor C2 prevents expression of viral late proteins in KSHV 
infected cells 
After showing a marked reduction in nuclear export of viral intronless transcripts in the 
presence of C2, it would be plausible if this is mirrored in decreased expression of late 
proteins translated from the mRNAs. To test this hypothesis KSHV lytic replication in TREx 
BCBL1-Rta cells was induced and cells treated with increasing amounts of C2. After 24 h, 
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protein samples were analysed by Western blotting (Figure 4.21a). Myc- and 
ORF57-specific antibodies were employed to test for the presence of RTA, the viral 
transcriptional activator, and ORF57 as markers for induction of lytic replication. 
Antibodies specific to the KSHV minor capsid protein (mCP) were used to assess the levels 
of viral late protein translated from intronless mRNA. At 2.5 μM C2, a concentration where 
cell viability was 100%, a marked reduction in expression of the mCP is visible compared to 
untreated or DMSO treated samples. No decrease in ORF57 expression is noted at this 
concentration, confirming that a decrease in mCP expression is not due to loss of ORF57 or 
reduction in lytic replication. Both ORF57 and RTA are translated from intron-containing 
transcripts and hence indicate a functional hTREX complex. All Western blots were 
quantified and levels of protein expression presented as fold increase in relation to 
induced, DMSO treated control samples (Figure 4.21b). Plotting of the mCP expression 
levels allowed for non-linear regression to obtain a half maximal effective concentration 
(EC50) for viral late protein expression (Figure 4.21c). Intriguingly, the EC50 of 0.6 μM is far 
lower than the CC50 of 21 μM at the same time point. Comparing both curves, a large 
“therapeutic window” can be observed, showing that cytotoxicity occurs at higher 
concentrations than inhibition of viral protein expression. 
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Figure 4.21: Viral late protein expression is disrupted by C2. TREx BCBL1-Rta cells were induced and 
treated with DMSO or increasing amounts of C2, as indicated, for 24 h. a) Protein samples were 
analysed by SDS-PAGE and Western blotting, using Myc-specific antibodies to detect Myc-RTA and 
ORF57-, mCP-, and GAPDH-specific antibodies to detect the indicated proteins. b) Quantification of band 
intensities by ImageJ. n = 3, error bars present SD. c) Expression levels of mCP and 24 h cell viability 
(Figure 4.18) are displayed on a log-scale. The EC50 was calculated using non-linear regression.  
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4.13 Inhibition of viral replication and production of infectious virus particles in the 
presence of C2 
Having shown a loss in viral intronless mRNA export and subsequent decrease in viral late 
protein expression, it was speculated that this would lead to a decrease in viral replication 
within C2 treated cells. To this end, TREx BCBL1-Rta cells were induced and treated with 
increasing amounts of C2. After 72 h, cells were harvested and complete genomic and viral 
DNA isolated before being analysed by quantitative PCR using primer pairs for GAPDH and 
the viral genes ORF47 and ORF57. Viral DNA levels were normalised to cellular DNA to 
account for cytotoxicity at higher concentrations of C2. Figure 4.22a shows the viral load 
within cells as a percentage of induced, DMSO treated cells. A steep decrease in viral load 
is visible at 1 and 2.5 μM C2, showing a reduction to 55 and 15%, respectively. Using non-
linear regression we plotted an inhibition curve for C2, calculating an EC50 on viral 
replication of 1.1 μM (Figure 4.22b). Again, when comparing this to the 72 h CC50 of 
16.6 μM and plotting the curves next to each other, a large “therapeutic window” can be 
observed. This range of concentrations allows for almost a complete inhibition of viral 
replication at a concentration range that does not cause cytotoxicity. 
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Figure 4.22: Reduction of viral load in KSHV-infected cells treated with C2. TREx BCBL1-Rta cells were 
induced and treated with DMSO or increasing amounts C2, as indicated, for 72 h. Viral DNA load was 
quantified using qPCR with ORF47, ORF57 and GAPDH specific primers. ORF47 and ORF57 CT values 
were normalised to GAPDH and the relative increase calculated using the ΔΔCT method. Results display 
the average of two individual experiments, with each n = 2, error bars display SD. Results are displayed 
as a) column graph, b) on a xy-graph using a log-scale and non-linear regression to determine the CC50 
and in combination with cell viability data at 72 h. 
 
The production of infectious virus particles was also examined in the presence of 2.5 μM 
C2. For this, TREx BCBL1-Rta cells were induced for 72 h, before taking the supernatant 
and adding it in a 1:1 dilution onto confluent 293T cells for 24 h, to allow infection. RNA 
was then extracted and qRT-PCR was performed. Viral transcripts were normalised to 
GAPDH and presented as fold increase of induced, DMSO treated samples (Figure 4.23). 
Results show that 293T cells incubated with supernatant from C2 treated TREx BCBL1-Rta 
cells contain 80% less viral mRNA, than cells that were re-infected with supernatant from 
DMSO treated lytic TREx BCBL1-Rta cells. This demonstrates a clear decrease in the 
production of infectious virions in KSHV infected cells upon treatment with C2. Cells that 
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were infected with the supernatant of latent TREx BCBL1-Rta cells show minor levels of 
viral mRNA. This is due to a small degree of spontaneous lytic replication occurring at all 
times in BCLB-1 cells as described before (Taylor and Blackbourn, 2011). 
 
Figure 4.23: Inhibition of infectious virion production by C2. TREx BCBL1-Rta cells were induced and 
treated with DMSO or 2.5 μM C2, as indicated, for 24 h. Cell supernatant was added 1:1 to uninfected 
293T cells for a further 24 h. qRT-PCR was performed using ORF57- and GAPDH-specific primers. ORF57 
CT values were normalised to GAPDH and the relative increase calculated using the ΔΔCT method. n = 3, 
error bars display SD, p < 0.05. 
 
4.14 Discussion 
UAP56 belongs to the family of DExD-box RNA-helicases and shows RNA-stimulated 
ATPase activity (Shen et al., 2007). Both RNA-helicase and ATPase activity of DExD-box 
proteins are known to contribute to remodelling of intramolecular RNA-, RNA-protein and 
protein-protein interactions (Cordin et al., 2006). 
In this chapter, an ATP-cycle dependent remodelling of the ORF57/hTREX complex 
interaction has been described. Results show formation of the endogenous, trimeric Aly-
UAP56-CIP29 complex upon ATP binding of UAP56 and a subsequent remodelling upon 
ATP hydrolysis. This was illustrated by ORF57, which was found to interact with hTREX 
components in the presence of ATP, but was specifically disrupted after the addition of the 
non-hydrolysable ATP analogue ATPγS. Importantly, endogenous hTREX interactions were 
retained in the presence of ATPγS, suggesting that the complex is remodelled after initial 
binding of Aly and CIP29 to UAP56, into a conformation which can then accommodate the 
ORF57 protein. This extremely exciting observation indicates that ORF57 interacts with 
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proteins that are part of an already formed complex, instead of recruiting one or more 
individual hTREX components and then facilitating recruitment of the remaining proteins. 
Whether this is the complete or a partial complex is unknown. Results further highlight a 
dissociation of UAP56 from hTREX components and ORF57 upon ADP binding, which 
completes the hTREX cycle. While no structural data has confirmed this to date, an ATP-
cycle dependent remodelling of hTREX has recently been suggested (Chang et al., 2013). 
Intriguingly, it was reported that ATP hydrolysis is necessary for loading of Aly onto the 
mRNA, as the presence of the non-hydrolysable AMP-PNP was found to prevent this 
transfer. 
Data herein indicates that inhibition of ATP hydrolysis by UAP56 would trap the hTREX 
complex in a conformation, preventing ORF57 recruitment. It was furthermore speculated 
that this disruption of ORF57/hTREX interaction would efficiently inhibit virus lytic 
replication. This is especially exciting since redundancy has been shown for the direct 
interaction of ORF57 and the mRNA adaptor Aly, through UIF, and hence this interaction 
cannot be targeted efficiently (Jackson et al., 2011). A similar approach has been described 
in the literature, where a series of small molecule inhibitors (ring expanded nucleosides) 
were shown to suppress replication of human immune deficiency virus type 1 (HIV-1) by 
inhibition of the ATP dependent activity of human helicase DDX3 (Yedavalli et al., 2008). At 
low concentrations these drugs were found to prevent virus replication without affecting 
cell viability. It was therefore speculated that a small molecule inhibitor designed for high 
affinity binding to the ATP binding site in UAP56 would prove to efficiently disrupt the 
ORF57/hTREX interaction. 
To this end, structure-based drug design was employed and 400 selected compounds and 
fragments were screened in vitro against UAP56 ATPase activity. Four novel inhibitors with 
a diverse structural background were identified. All hit compounds were sourced from a 
Tocriscreen Library, a compound library of known bioactive compounds. This is not 
surprising, as screening approaches utilising known bioactive compounds or inhibitors for 
novel targets tend to generate a higher hit rate than vHTS. Furthermore, while fragments 
were screened at a higher concentration, it is possible that assay conditions were not 
optimal for identification of fragment hits. The most potent hit, compound C2, disrupted 
vRNP formation in immunoprecipitation assays, while allowing the interaction of UAP56 
with hTREX components Aly, CIP29 and Chtop. Subsequently, disruption of co-localisation 
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of ORF57 with hTREX components in the presence of C2 was observed, both in transfected 
293T cells and in KSHV infected TREx BCBL1-Rta cells, at concentrations where no 
cytotoxicity could be observed. Importantly, using a FISH assay, it was demonstrated that 
endogenous bulk mRNA export is not disrupted in the presence of the inhibitor. 
Furthermore, ORF57 was unable to block bulk cellular mRNA export by sequestration of 
hTREX after addition of C2. Moreover, a disruption of viral intronless mRNA export was 
shown in both transfected 293T cells and in KSHV infected BCBL-1 cells. In both 
experiments, a loss in whole cell amounts of viral mRNA was observed. This effect was 
specific for viral intronless transcripts, and is likely due to the loss of ORF57-mediated 
hTREX binding to these nucleic acids. ORF57 has been shown in the past to cause 
accumulation and stabilisation of viral transcripts (Stubbs et al., 2012; Nekorchuk et al., 
2007). Unbound viral RNAs can be detected by cellular surveillance mechanisms and hence 
are more prone to RNA decay. Importantly, using a physiologically relevant cell culture 
model, results also demonstrated a loss in late viral protein production upon treatment of 
cells infected with lytic replicating KSHV. Almost a complete loss of protein was observed 
at a concentration where no loss in cytotoxicity and normal expression of RTA and ORF57, 
two protein translated from intron-containing mRNAs, was detected. Furthermore, an 85% 
reduction in viral load and an 80% reduction in the production of infectious virions was 
achieved at a non-cytotoxic concentration. For a first generation compound, this present a 
very encouraging “therapeutic window”, in which a concentration range proves effective 
against the virus induced RNP, but does not affect cellular hTREX. 
Together, work identifying and testing this first-generation compound has provided 
positive results and future work will aim to explore this novel antiviral target further by 
elucidating a structure-activity-relationship, followed by optimisation of the structure to 
reduce cytotoxic side effects and improve virus inhibition. Other interesting questions 
include the effect on other herpesviruses and viruses that utilise the hTREX complex to 
allow viral mRNA export. 
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5 Structural analogues of UAP56 ATPase inhibitor C2 and the inhibitory 
effect on HSV-1 
5.1 Introduction 
In the previous chapter, an ATP-cycle dependent remodelling of the ORF57-mediated 
vRNP was described. Intriguingly, results showed that during the ATP-cycle, hTREX enters a 
conformation in which ORF57 is unable to recruit the complex onto viral mRNA. 
Prevention of ATP-hydrolysis by UAP56 allowed the endogenous hTREX components Aly 
and CIP29 to bind to UAP56, but inhibited ORF57 binding. These findings presented a novel 
antiviral target for inhibition of lytic virus replication. Using virtual high-throughput 
screening compounds were identified, which specifically inhibited UAP56 ATPase function 
and showed subsequent disruption of vRNP formation. As a consequence the best hit was 
able to prevent viral mRNA export, lytic protein production and hence disrupted lytic virus 
replication. In this chapter, the identification of novel inhibitors was followed up by 
examining close structural analogues, to identify a structure-activity-relationship (SAR). 
Furthermore, as compound C2 has previously been described as an HSP90 inhibitor, the 
effect on HSP90 and HSP90 client proteins was assessed, in comparison with the effect on 
the hTREX complex and KSHV protein expression.   
ORF57 is conserved across all families of Herpesviridae; ICP27 in HSV-1, UL69 in HCMV, 
ORF4 in VZV and EB2 in EBV are all essential for virus replication. While these proteins are 
distinct in size and differ in large parts of their sequence, they all interact with the hTREX 
complex in order to allow viral intronless mRNA export. As this approach is targeting a 
component of the hTREX complex and not ORF57 directly, it was speculated that the 
inhibitor should also efficiently prevent replication of other herpesviruses. Therefore, the 
effect of inhibitor C2 was examined on primary infection and production of infectious 
HSV-1 virions in re-infection assays.   
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5.2 Effect of close structural analogue An1 on KSHV late protein expression and 
viral load in KSHV lytic replication 
Four structural analogues were selected, to assess a SAR and confirm the previously 
observed effects of C2 on viral protein expression and viral load.  
The first tested analogue (An1) had the dioxane ring removed (Figure 5.1a). As this 
functional group potentially forms an interaction within the UAP56 binding site, this 
compound was utilised to examine if removal could change the inhibitors properties. The 
compound was first examined for cellular toxicity (Figure 5.1b). As previously described, 
TREx BCBL1-Rta cells were treated with increasing amounts of An1, before MTS assays 
were performed after 24 and 72 h. Plotting of results and non-linear regression were 
further used to determine a CC50 for both time points (Figure 5.1c). At 24 h, the cytotoxic 
effect of An1 is reduced compared to C2. No cytotoxicity occurs at concentrations up to 
7.5 μM An1 and the CC50 is increased from 21.1 to 28.9 μM compared to C2. However, 
after 72 h the effect is reversed: concentrations above 2.5 μM An1 decrease cell viability 
noticeably and the CC50 drops to 7.6 μM, compared to 16 μM C2.  
The effect of An1 was then examined on expression of the viral late protein mCP. As 
described in chapter 4 (Figure 4.21), increasing amounts of the inhibitor were added to 
TREX BCBL1-Rta cells, before cell lysates were analysed by Western blotting (Figure 5.2a). 
Densitometry of blots was performed for all proteins (Figure 5.2b). At 5 μM An1, a 
concentration with 100% cell viability, an 82% reduction of mCP is observed, without any 
loss in expression of the viral proteins RTA and ORF57. This demonstrates a specific 
decrease in expression for viral proteins translated from intronless mRNAs, while viral 
proteins from intron-containing mRNAs remain expressed at 5 μM. This effect is 
comparable with C2 at its maximal non-cytotoxic concentration. Using non-linear 
regression, an EC50 = 3.1 μM An1 on mCP expression was determined (Figure 5.2c). This is 
larger than for C2, however as An1 also displays a larger CC50, a similar therapeutic window 
can be seen for both inhibitors.  
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Figure 5.1: Cell viability of TREx BCBL1-Rta cells in the presence of An1. The assay was performed as 
previously described (Figure 4.18). n = 5, error bars present SD. a) Chemical modifications from C2 to 
An1. Results are displayed as b) column graph, c) on a xy-graph using a log-scale and non-linear 
regression to determine the CC50. 
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Figure 5.2: Viral late protein expression is disrupted by An1. The experiment was performed and 
analysed as previously described (Figure 4.21).   
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The effect of An1 on KSHV genome load was also assessed. TREx BCBL1-Rta cells were 
treated with increasing amounts of An1 upon reactivation of virus lytic replication. Viral 
DNA was quantified 72 h after treatment and normalised to cellular DNA levels (Figure 
5.3a). Viral load is seen to decrease from 0.5 μM An1 upwards and an EC50 = 1.5 μM was 
determined (Figure 5.3b). While this is equal to the original inhibitor C2, cytotoxicity of 
An1 is increased compared to C2, leaving a smaller concentration range before cell death 
occurs. As both cell viability as well as the effective concentration on viral protein 
expression or DNA load, seem to decrease between 24 and 72 h, it can be speculated that 
An1 is less efficient in reaching the protein target within the cell. This could be due to 
slower uptake into the cell and the nucleus or potentially changed binding affinities to 
UAP56.  
 
Figure 5.3: Reduction of viral load in cells treated with An1. The assay was performed as previously 
described (Figure 4.22). n = 2, error bars display SD.  
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5.3 Effect of close structural analogue An3 on KSHV late protein expression and 
viral load in KSHV lytic replication 
An3 is another close structural analogue of C2, where the ethyl group is removed from the 
diphenol ring (Figure 5.4a). Again, the effect of An3 was assessed on cytotoxicity, viral late 
protein expression and viral load. As with both C2 and An1 before, a decrease in CC50 can 
be observed between 24 and 72 h (Figure 5.4b and Figure 5.4c). However, at both time 
points, cytotoxicity of An3 occurs at higher concentrations than with other inhibitors. 
Interestingly, below 15 μM, no difference is seen between 24 and 72 h. Only at 
concentrations of 25 and 50 μM is a reduction in cell viability visible between the two time 
points, causing the apparent drop in CC50. This means that An3 is the least cytotoxic of the 
three tested compounds.  
Nonetheless, when investigating the effect of An3 on viral late protein expression (as 
described before), a marked decrease in mCP was seen between 1 and 2.5 μM An3 (Figure 
5.5). Intriguingly, ORF57 and RTA expression was not reduced at concentrations up to 
15 μM, much higher than for any other compound, which is in accordance with the high 
cell viability.  
An3 also decreased the viral load in TREx BCBL1-Rta cells, similar to the two other tested 
compounds (Figure 5.6). The EC50 is detected at 5.1 μM, larger than for C2 and An1, but 
equally still yielding a concentration range where a reduction of 60% in viral load is 
observed, without a decrease in cell viability. It appears that while removing the ethyl 
group made the compound less cytotoxic, it has also made it slightly less effective at later 
time points. It is therefore possible that removing the ethyl group decreased the binding 
affinity of the compound to UAP56 or that it allows for faster removal from the cell, for 
example through xenobiotic metabolism of the compound.  
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Figure 5.4: Cell viability of TREx BCBL1-Rta cells in the presence of An3. The assay was performed as 
previously described (Figure 4.18). n = 5, error bars present SD. a) Chemical modifications from C2 to 
An3. Results are displayed as b) column graph, c) on a xy-graph using a log-scale and non-linear 
regression to determine the CC50. 
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Figure 5.5: Viral late protein expression is disrupted by An3. The experiment was performed and 
analysed as previously described (Figure 4.21).   
138 
 
 
Figure 5.6: Reduction of viral load in cells treated with An3. The assay was performed as previously 
described (Figure 4.22). Results display the average of 2 individual experiments, with each n = 2, error 
bars display SD.  
 
5.4 Effect of close structural analogue SKW032 on KSHV late protein expression 
and viral load in KSHV lytic replication 
SKW032 displays changes to the same functional group as An1, but with the dioxane ring 
substituted with a 4-methoxy group (Figure 5.7a). As with An1, the change in this area lead 
to an initial increase in cell viability at 24 h, but then a more marked decrease at 72 h, 
compared to the initial inhibitor hit C2 (Figure 5.7b). The 24 h CC50 = 27.9 μM of SKW032 is 
very similar to An1, however the cell viability at 72 h appears less strongly decreased, with 
CC50 = 14.7 μM (Figure 5.7c). 
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Figure 5.7: Cell viability of TREx BCBL1-Rta cells in the presence of SKW032. The assay was performed 
as previously described (Figure 4.18). n = 5, error bars present SD. a) Chemical modifications from C2 to 
SKW032. Results are displayed as b) column graph, c) on a xy-graph using a log-scale and non-linear 
regression to determine the CC50. 
 
As all tested analogues before, SKW032 decreases expression of the minor capsid protein 
in a concentration range where neither cytotoxicity, nor a decrease of ORF57 or RTA 
expression is detected (Figure 5.8a and Figure 5.8b). Even though the EC50 is more than 
doubled, compared to C2 (2.5 μM compared to 1.1 μM), due to lower cytotoxicity of 
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SKW032 the compound also achieves 80% reduction in viral protein expression, at a 
concentration where 100% cell viability occurs (Figure 5.8c).  
 
Figure 5.8: Viral late protein expression is disrupted by SKW032. The experiment was performed and 
analysed as previously described (Figure 4.21).   
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The presence of SKW032 results in almost identical inhibition of virus replication, as is seen 
for expression of mCP (Figure 5.9). With an EC50 = 2.75 μM and CC50 = 14.7 μM a 
therapeutic window can also be detected for this analogue. With either complete removal 
of the dioxane ring (An1) or substitution of this group by a methoxy group (SKW032) we 
found an initial decrease in cell viability but a stronger toxic effect at 72 h. The polar 
dioxane ring therefore seems to facilitate a faster response within the cell. This effect is 
dampened if replaced by a less polar methoxy group and further reduced by a complete 
loss of functional group in this area.  
 
Figure 5.9: Reduction of viral load in cells treated with SKW032. The assay was performed as previously 
described (Figure 4.22). n = 2, error bars display SD. 
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5.5 Effect of close structural analogue SKW036 on KSHV late protein expression 
and viral load in KSHV lytic replication 
SKW036 is based on structure SKW032, but has a carboxyl group substituting the methyl 
group (Figure 5.10a). Addition of this polar group is expected to decrease the membrane 
crossing ability of the compound, as it is less favourable to enter a lipid bilayer.  
The effect of SKW036 was first tested on cytotoxicty at 24 and 72 h (Figure 5.10b). At both 
time points almost no decrease of cell viability is seen; even at a maximum tested 
concentration of 100 μM cell viability does not drop below 80%. A CC50 = 824 μM was 
calculated at 24 h, but no curve could be fitted to the 72 h values, using non-linear 
regression.  
These results were confirmed by the expression levels of KSHV proteins in reactivated 
TREx BCBL1-Rta cells (Figure 5.11). Even with the addition of 100 μM SKW036, no 
reduction was observed. Quantification of mCP shows a slight drop of protein levels at 
higher concentrations, however, this minor change is also visible for ORF57 expression and 
could just be due to a general reduction in cell viability that has been described above 
(Figure 5.10b and c). An EC50 of 1.2 mM could be calculated, which is no feasible 
concentration for an inhibitor, and has to be seen as an unspecific effect from a loss in cell 
viability.  
As expected, the effect of SKW036 on viral load in cells infected with lytic replicating KSHV 
was similarly weak (Figure 5.12). A minimal decrease is visible above 25 μM and a 
reduction of 50% is detected at 100 μM. However, with an EC50 = 138 μM and a cell 
viability curve that falls at the same rate until 50 μM this analogue cannot be seen as an 
inhibitor of KSHV lytic replication. However, the decrease in viral load at higher 
concentrations is encouraging. Modification of this side chain to a less polar group will 
enhance uptake into the cell and bring the compound into lower effective concentration 
range, where it might demonstrate good inhibition while causing less cytotoxicity. 
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Figure 5.10: Cell viability of TREx BCBL1-Rta cells in the presence of SKW036. The assay was performed 
as previously described (Figure 4.18). n = 5, error bars present SD. a) Chemical modifications from C2 to 
SKW036. Results are displayed as b) column graph, c) on a xy-graph using a log-scale and non-linear 
regression to determine the CC50. No curve could be fitted to the 72 h values using non-linear 
regression. 
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Figure 5.11: SKW036 does not have an effect on viral late protein expression. The experiment was 
performed and analysed as previously described (Figure 4.21).   
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Figure 5.12: Reduction of viral load in cells treated with SKW036. The assay was performed as 
previously described (Figure 4.22). n = 2, error bars display SD. 
 
5.6 Effect of C2 on HSP90 and HSP90 client proteins 
Compound C2 has previously been published as a HSP90 (heat shock protein 90) inhibitor, 
identified by high-throughput screening (Sharp et al., 2007). HSP90 is a molecular 
chaperone that is responsible for maturation, stability and activity of selected client 
proteins.  
While experiments in chapter 4 were designed to provide evidence for inhibition of 
UAP56, and subsequent disruption of the ORF57/hTREX interaction, the effect of the 
inhibitor C2 and some selected analogues were also examined on HSP90 and HSP90 client 
proteins, to assess whether this might play an additional role in KSHV inhibition. To this 
end, Western blotting was performed on samples previously used in Figure 4.21, taken 
24 h after induction of KSHV lytic replication and treatment with the inhibitor, using 
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HSP90- or CDC2-specific antibodies. CDC2 is a HSP90 client protein with a half-life of 7.5–
18 h (depending on cell cycle phase) (Welch and Wang, 1992) and therefore a suitable 
control for HSP90 inhibition. 
Figure 5.13a shows Western blots from Figure 4.21, now also probed for expression of 
CDC2 and HSP90. A marked decrease in CDC2 protein expression can be seen at 5 µM C2; 
quantification shows a reduction from almost 100% expression to below 30% (Figure 
5.13b). Higher concentrations of the inhibitor do not decrease CDC2 protein levels further, 
so these can be considered background protein levels, expressed before inhibition of 
HSP90 took place. At the same concentration threshold, an increase in HSP90 expression 
can be seen. This over-expression could be a cellular counter action to inhibition of HSP90. 
It can therefore be speculated that efficient inhibition of HSP90 occurs between 2.5 and 
5 µM C2 in TREx BCBL1-Rta cells after 24 h. Intriguingly, inhibition of mCP expression 
already occurs at concentrations of 1 and 2.5 µM C2, where normal expression of CDC2 is 
observed. Comparing inhibition curves for expression of both proteins, a different trend 
can be noticed (Figure 5.13c), highlighting a specific inhibitory effect on KSHV replication, 
not mediated by HSP90 inhibition.  
The same analysis of HSP90 and CDC2 was performed in the presence of An1 (Figure 
5.14a). Interestingly, an increase in HSP90 expression can be observed from 0.5 μM An1. 
Again this could be a cellular response to the presence of an inhibitor. However, CDC2 
expression seems constant up to 15 μM An1 and at this concentration only a minor loss in 
protein expression can be observed (Figure 5.14b). Conversely, the major decrease in mCP 
expression occurs between 2.5 and 5 μM An1. This 10 μM difference in concentration, 
between the effect on the viral mCP and the effect on the HSP90 client protein CDC2 
(Figure 5.14c), is much greater than what is observed for C2.  
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Figure 5.13: Comparison of viral late protein and of HSP90 client protein expression in the presence of 
C2. The experiment was performed and analysed as previously described (Figure 4.21). a) Western blots 
were additionally probed with HSP90- and CDC2-specific antibodies. b) Quantification of Western blots 
using the ImageJ software. n = 3, error bars present SD. c) Expression levels of mCP and CDC2 are 
displayed on a log-scale.  
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Figure 5.14: Comparison of viral late protein and of HSP90 client protein expression in the presence of 
An1. The experiment was performed and analysed as previously described (Figure 5.13).  
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The activity of HSP90 and CDC2 was also examined in the presence of An3. Western blots 
of HSP90 and the client protein present contrasting observations, compared to the other 
compounds: both the viral protein mCP and the HSP90 client protein CDC2 show a marked 
decrease in expression at 2.5 μM An3 (Figure 5.15a). Comparing expression of mCP and 
CDC2 a very similar inhibition profile is seen (Figure 5.15a and b). Interestingly, 
quantification of Western blots failed to determine an increase in HSP90 expression. Based 
on CDC2 protein expression it appears that An3 is the most efficient HSP90 inhibitor of the 
three tested compounds.  
While all three compounds were found to affect expression of HSP90 client protein CDC2, 
very different responses were observed for all inhibitors. No clear trend is apparent 
between inhibition of viral late protein expression and HSP90 protein expression. While 
further tests have to be performed to rule out an involvement of HSP90-inhibition, this 
encouraging data indicates no direct connection between inhibition of HSP90 and loss of 
viral late protein expression. 
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Figure 5.15: Comparison of viral late protein and of HSP90 client protein expression in the presence of 
An3. The experiment was performed and analysed as previously described (Figure 5.13).  
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5.7 Effect of inhibitor C2 on HSV-1 replication  
All herpesviruses express an essential ORF57 protein homologue, which utilises the hTREX 
complex to export viral intronless mRNA. It was therefore speculated that the inhibitor 
identified against the KSHV ORF57/hTREX interaction would also efficiently serve to 
disrupt replication of other human herpesviruses.  
To examine this, the replication of HSV-1 in a HFF (human foreskin fibroblasts) cell line was 
examined. As before, a non-cytotoxic working concentration of C2 in HFF cells was initially 
determined using a MTS assay (Figure 5.16). Concentrations up to 25 μM could be used in 
HFF cells before a marked decrease in cell viability was observed. 
 
Figure 5.16: Cell viability of HFF cells in the presence of C2. The experiment was performed and 
analysed as previously described (Figure 4.13).  
 
HFF cells were infected with HSV-1 for 1 h, before cells were washed, to remove excess 
virus, and treated with increasing amounts of C2 or DMSO. Figure 5.17 presents images of 
HFF cells 72 h post infection with HSV-1 and treatment with C2 or DMSO. It can be seen 
that virus lytic replication causes cell death in infected, DMSO treated cells after 72 h, 
compared to uninfected cells. However, with increasing amounts of compound C2, cells 
appear viable and protected from virus-mediated lysis.  
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Figure 5.17: Compound C2 protects HFF cells from HSV-1 mediated cell lysis after primary infection. 
Confluent HFF cells were infected with HSV-1 (MOI =  0.001), treated with DMSO or increasing amounts 
of C2 and left for 72 h. Images of cells were taken at 40x magnification.  
 
The effect of C2 on HSV-1 lytic replication after primary infection was also assessed using 
plaque assays. A confluent layer of HFF cells was infected with HSV-1 for 1 h, before cells 
were washed and overlaid with a viscous layer of media containing 1% molten agarose and 
the indicated concentration of inhibitor C2. Development of primary infection was 
assessed 120 h later, after the top layer was removed (Figure 5.18). Virus lytic replication 
can be detected by plaque formation within the monolayer of stained cells. Intriguingly, 
with increasing concentrations of C2, plaque size and plaque number can be seen to 
decrease dramatically, demonstrating efficient inhibition of virus lytic replication.  
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Figure 5.18: Compound C2 decreases HSV-1 mediated plaque formation after primary infection. 
Confluent HFF cells were infected with HSV-1 (MOI = 0.001) and then treated with DMSO or increasing 
amounts of C2 for 120 h. Viral plaques were fixed using formaldehyde and visualised with crystal violet 
staining.  
 
For a quantitative assay, supernatants of HSV-1 primary infected cells were also collected 
at 72 h and used for re-infection assays. Re-infection was performed in 10-fold dilutions to 
prevent “maxing out” infectivity at high infection rates. “Maxing out” occurs when a high 
MOI is used, enabling two or more virus particles to infect the same cell, as subsequent 
results cannot differentiate between these events and will be skewed downwards. The 
most effective concentration for measuring re-infection rates is at a dilution where every 
cell is infected by one virus particle. To experimentally find this concentration, dilutions of 
1:10, 1:100 and 1:1000 were used. Also, dilutions would prevent any effect of inhibitor 
remaining within the supernatant after initial treatment. New cells were incubated for 
24 h with the diluted supernatant without any further treatment, before cells were fixed 
with formaldehyde. As the recombinant HSV-1 expressed GFP, re-infection rates were 
analysed by flow cytometry, assessing the percentage of fluorescent cells within the 
population (Figure 5.19). Samples from infected cells treated with DMSO, 1 or 2.5 μM C2 
are seen to give 100% HSV-1 positive cells at a 1:10 dilution, thus “maxing out” the 
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detection limit of this assay. However, infectious virions from cells treated with 5 μM C2 
infected less than 50% of the new cell population, indicating a strong decrease in virus 
production in the presence of the inhibitor. Furthermore, at the tested concentrations of 
7.5 and 10 μM C2, no re-infection can be seen, demonstrating that these concentrations 
sufficiently blocked HSV-1 replication and production of infectious virus particles in HFF 
cells. Re-infection at the higher dilutions (1:100 and 1:1000) was more suitable for 
assessing low concentrations of inhibitor. At a 1:100 dilution, DMSO and 1 μM C2 treated 
samples caused re-infection rates of 82% and 71%, respectively, and it is therefore likely 
that these samples were “maxing out”, too. However, treatment with 2.5 μM C2 reduced 
re-infection to 50% of cells, before a drop to 5% is seen at 5 μM C2. Both re-infection with 
a 1:100 dilution, as well as comparison to the 1:10 dilution confirm a 10-fold decrease in 
virus production between 2.5 and 5 μM C2. Again, these values are confirmed by the 
highest dilution (1:1000) which shows 5% infection rate at 2.5 μM C2. At this dilution, 12% 
infected cells were detected from DMSO treated samples and a loss of approximately half 
the virus in cells treated with 1 μM C2. Together, this data indicates a dose dependent 
reduction in HSV-1 lytic replication in the presence of inhibitor C2. An effect could be 
detected from 1 μM C2, and no infectious virus production was detected at 7.5 μM C2 and 
above.  
 
Figure 5.19: Flow cytometry analysis shows inhibition of HSV-1 infectious virion production by C2. HFF 
cells were infected with HSV-1 (MOI = 0.001) and treated with DMSO or increasing concentrations of C2 
for 72 h. Supernatants were then added to uninfected HFF cells in 1:10–1:1000 dilutions and left 
without further treatment for 24 h. Cells were fixed with formaldehyde and HSV-1 positive cells 
quantified using flow cytometry.  
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Moreover, to complement analysis of infectious virus particles by flow cytometry, plaque 
assays were used to quantify the reduction of plaque forming units upon treatment with 
C2. Again, primary infection took place for 72 h in the absence and presence of C2, before 
the supernatant was harvested and HFF cells re-infected with 1 ml supernatant diluted 
1:10–1:10,000. After 1 h re-infection, cells were washed and again overlaid with DMEM 
containing 1% agarose to prevent spread of infectious virus particles. After 96 h cells were 
fixed and stained using crystal violet stain. The number of plaque forming units (pfu) was 
determined by counting of viral plaques and multiplication by the dilution factor. The 
dose-dependent decrease in pfu over the range of effective concentrations can best be 
observed on a log scale (Figure 5.20a), whereas the linear scale (Figure 5.20b) highlights 
the large initial drop in pfu achieved by a concentration 10-times below the maximum 
non-toxic concentration of 25 μM C2.  
 
Figure 5.20: Viral plaque assays show inhibition of HSV-1 infectious virion production by C2. HFF cells 
were infected with HSV-1 (MOI = 0.001) and treated with DMSO or increasing concentrations of C2 for 
72 h. Supernatants were then added to uninfected HFF cells in 1:10–1:10,000 dilutions. Viral plaques 
were analysed after 96 h using formaldehyde fixation and crystal violet stain. Results are displayed a) on 
a log-scale and b) a linear scale. 
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Finally, these results were confirmed by Western blotting, to assess viral protein 
production after infection of a new cell population. All samples were obtained as 
described above, before dilution and re-infection of new HFF cells for 16 h. After this time, 
protein samples were obtained and analysed by Western blotting using ICP27- and 
GAPDH-specific antibodies (Figure 5.21). Again, a dose-dependent reduction in HSV-1 
ICP27 is visible in re-infected cells, indicating inhibition of lytic replication and virus 
production by C2. Interestingly, neither flow cytometry analysis nor western blotting 
detected HSV-1 re-infection in cells treated with 7.5 or 10 μM C2.  
 
Figure 5.21: Western blotting confirms inhibition of HSV-1 infectious virion production by C2. HFF cells 
were infected with HSV-1 (MOI = 0.001) and treated with DMSO or increasing concentrations of C2 for 
72 h. Supernatants were then added to uninfected HFF cells in 1:10–1:1000 dilutions. Protein samples 
were taken after 16 h and analysed by SDS-PAGE and Western blotting using ICP27 and GAPDH specific 
antibodies.  
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5.8 Effect of inhibitor C2 on HSP90 and HSP90-client proteins in HFF cells  
The HSP90 function in the presence of C2 was also examined in HFF cells, to determine if a 
HSP90-dependent effect resulted in the inhibition of HSV-1 replication. Confluent HFF cells 
were treated with increasing amounts of C2 for 72 h, before cell lysates were analysed by 
Western blotting using HSP90- and CDC2-specific antibodies (Figure 5.22a). Western blots 
were also quantified and an inhibition curve for CDC2-expression calculated using non-
linear regression (Figure 5.22b and c). Together, a marked decrease in CDC2-expression 
can be observed between 5 and 7.5 μM C2. It can therefore be concluded that effective 
inhibition of HSP90 takes place in this concentration range. Interestingly, a 90% reduction 
(by flow cytometry) or a 99% reduction (by plaque assay) was determined at a 
concentration of 5 μM C2, where no inhibition of HSP90 occurs. While an effect of HSP90 
on virus replication cannot be ruled out, this data indicates no immediate connection.  
  
Figure 5.22: Expression of HSP90 client protein CDC2 by HFF cells in the presence of C2. Confluent HFF 
cells were treated with DMSO or increasing concentrations of C2 for 72 h. a) Protein samples were 
analysed by Western blotting using CDC2 and HSP90 specific antibodies. b) Western blots were 
quantified using ImageJ. n = 3, error bars present the SD. c) CDC2 expression levels are displayed on a 
log scale. The inhibition curve was calculated using non-linear regression.  
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5.9 Discussion 
After identifying a UAP56-ATPase inhibitor by virtual high-throughput screening and 
subsequent in vitro screening, the activity of close structural analogues that had minor 
changes to functional groups of compound C2 were explored. Together the analogues 
demonstrated a structure activity relationship, with three compounds having the ability to 
inhibit KSHV lytic replication. Functional groups were identified, which could be 
manipulated to allow changes in activity and cytotoxicity. Interestingly, modifications to 
the dioxane group lead to an initial increase in cell viability and EC50 value at 24 h but a 
decrease in cell viability at later time points. Results showed one inhibitor that was unable 
to inhibit KSHV lytic replication, due to the presence of a polar carboxyl group. Again, this 
provides valuable insight into the uptake and function of the inhibitor, highlighting the fact 
that the compounds are probably taken up by passive diffusion through the cell 
membrane.  
While targeting a cellular protein carries greater risks, such as inhibition of essential 
cellular functions and subsequent cytotoxicity, it can also be advantageous: Inhibiting a 
cellular protein allows targeting several pathogens that utilise this pathway, using the 
same compound. We speculated that C2 should have the ability to act as a generic 
herpesvirus inhibitor, given the common pathway for viral mRNA export between all 
Herpesvirinae  (Schumann et al., 2013). Results showed concentrations as low as 1 μM 
significantly reduced HSV-1 lytic replication. Furthermore, 5 μM of C2 prevented 
production of 90-99% of virions. Intriguingly, this concentration was still 5-fold below the 
maximum concentration at which no cytotoxicity occurred. Together, the data herein 
showed that indeed compound C2 is able to prevent replication of both herpesviruses 
KSHV and HSV-1, and indicates potential pan-viral activity across the Herpesviridae family. 
Further testing of other herpesviruses and influenza viruses would be useful to determine 
the extent of this pan-viral activity.  
Finally, we addressed previously published reports of compound C2 as a HSP90 inhibitor 
(Cheung et al., 2005; Dymock et al., 2005; Sharp et al., 2007). An IC50 against yeast Hsp90 
ATPase activity was reported as 6.6 μM, or in a second study as 8.9 μM, whereas purified, 
recombinant HSP90β showed an IC50 of 3.2 μM (Dymock et al., 2005; Sharp et al., 2007). 
However, these values are not ideal for direct comparison to the data reported in 
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chapter 4. While the IC50 is a useful tool for comparing several inhibitors for one protein 
against each other, values are dependent on the enzyme, assay and assay conditions used: 
More sensitive assays or highly active enzymes allow for lower enzyme concentration in 
the screening, which in turn gives way to lower IC50 values.  
While data conclusively showed inhibition of UAP56 and disruption of ORF57 interaction 
with hTREX by C2, an additional effect through inhibition of HSP90 cannot be excluded. We 
used the cellular HSP90 client protein CDC2, to assess inhibition of HSP90. Specifically, we 
compared protein levels of CDC2 expression with expression of the viral late protein mCP. 
Interestingly, inhibition of KSHV and HSV-1 replication was evident at concentrations 
where no inhibition of CDC2 expression occurred. Furthermore, inhibition of HSP90 by the 
analogues An1 and An3 was compared with inhibition by C2. Intriguingly, while both 
analogues acted against HSP90, the effect did not follow an obvious trend. While An1 
showed a 6-fold difference in concentration (over 10 μM) between inhibition of the viral 
and cellular protein, An3 inhibited both proteins at a similar concentration. This indicates 
that the effect seen on viral mCP expression originates in a different upstream event than 
inhibition of CDC2. However, further testing should be done to clarify this issue. To this 
end, established HSP90 inhibitors, such as Geldanamycin, could be used to compare the 
effect on expression of viral late proteins and HSP90 client proteins. Furthermore, knock-
down of HSP90 could be attempted, followed by treatment with C2. Any effect seen by C2 
could be contributed to factors other than HSP90 inhibition.  
To summarise, results herein presented three close structural analogues, which inhibit 
KSHV late protein expression and virus replication. Furthermore, one analogue failed to 
have an inhibitory effect, due to changes in the structure. Moreover, inhibition of HSV-1 
was demonstrated, showing that C2 functions as a novel inhibitor against herpesviruses. 
Finally, the effect of HSP90 inhibition was examined for KSHV replication, where no clear 
trend could be detected. Similarly, HSV-1 replication was inhibited at concentrations 
where no effect on HSP90 could be observed.  
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6 Discussion 
The oncogenic herpesvirus KSHV replicates in the nucleus of the host cell and relies on 
cellular mRNA export factors to efficiently export viral transcripts into the cytoplasm, 
where translation occurs. Cellular mRNA export, however, is a complex and highly 
regulated process that is directly coupled to splicing. This poses a problem for KSHV and 
other herpesviruses, who express numerous intronless mRNAs. In order to circumvent the 
splicing requirement, as well as other cellular mRNA processing steps, KSHV expresses the 
conserved protein ORF57, which facilitates viral mRNA export. ORF57 is able to recruit 
components of the hTREX complex onto viral transcripts, which in turn recruits the cellular 
export receptor Nxf1, allowing export through the nuclear pore complex. Dysfunctional 
ORF57 is associated with nuclear retention of viral transcripts and inhibition of viral lytic 
replication.  
This is of significant importance, as lytic replication has been shown essential for KS 
development, the most common malignancy associated with KSHV infection. Lytic 
replication enables the virus to disseminate from its B-cell reservoir and infect endothelial 
cells, where cancer manifests. Furthermore, reoccurring lytic replication allows persistence 
of infection within these cells, and therefore enables constant expression of viral 
oncogenic proteins which drive tumourigenesis. Accordingly, disruption of lytic replication 
is associated with remission of cancer. However, clinical studies show that available 
antiherpevirus drugs are ineffective against KSHV after the onset of KS and only 
preventative use of ganciclovir showed some moderate clinical success (Gantt and Casper, 
2011). Considering the high burden of KS in sub-Saharan Africa, new, KSHV-targeted drugs 
are desperately needed.  
As detailed above, due to its essential nature, ORF57 is an attractive target for novel anti-
KSHV drug discovery. ORF57 recruits the hTREX complex via an interaction with the export 
adaptor Aly. However, this interaction cannot be targeted directly, as UIF can also be 
recruited by ORF57 to export viral mRNAs and therefore provides redundancy in the 
system.  
In 2010, a then novel hTREX component called CIP29 was identified and with it the idea of 
ATP-dependency of the hTREX complex (Dufu et al., 2010). The interaction between the 
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export adaptor Aly, the RNA-helicase UAP56 and CIP29 was shown to occur only in the 
presence of ATP. Later, UAP56 was shown to load hTREX components onto the mRNA in 
what is thought to be an ATP-cycle dependent manner (Chang et al., 2013).  
We therefore speculated that ATP-dependency would also be found to affect the 
formation of the ORF57-mediated vRNP and aimed to explore this option as a novel drug 
target.  
 
6.1 ORF57 and CIP29 
Chapter 3 first investigated the involvement of CIP29 in the KSHV-mediated vRNP. Using a 
range of methods, CIP29 was shown to be part of the hTREX complex associated with the 
ORF57-mediated vRNP. This was expected, as ORF57 has previously been shown to recruit 
all known hTREX components onto viral mRNA (Boyne et al., 2008). While no clear 
function of CIP29 in the hTREX complex is to date known, the role of this component in the 
vRNP was explored using siRNA approaches. However, even though efficient CIP29 
depletion was achieved, no effect of CIP29 knock-down could be observed on viral mRNA 
export or on viral late protein expression. Similar, Dufu and co-workers found no loss in 
cellular bulk mRNA or reporter mRNA export after knock-down of CIP29 (Dufu et al., 2010). 
However, they described a block of cellular mRNA export upon over-expression of CIP29, 
which is commonly seen for hTREX components. It is therefore possible that redundancy 
exists for CIP29 and other cellular proteins are able to take over the role upon loss of the 
protein, as is seen for Aly and UIF (Hautbergue et al., 2009). Surprisingly though, an 
increase in viral intronless transcript levels was observed after CIP29 knock-down, 
however, this effect was only visible in ORF57-expressing cells and not in control-
transfected cells. No such effect has been previously described in the literature and further 
studies are required to clarify if this is an experimental artefact, or if depletion of CIP29 
indeed leads to a greater abundance of viral intronless transcripts in the cell. If the latter is 
confirmed, this could have interesting implications, such as a role of CIP29 in transcription 
or transcriptional control, which should be explored in detail.  
We further investigated if ATP-dependency of the hTREX complex formation also affects 
the interaction of ORF57 with the hTREX complex. First, results were confirmed showing 
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that CIP29 and Aly stimulate UAP56 ATPase activity in vitro. Immunoprecipitations were 
performed using CIP29 in the presence of either ATP or the non-hydrolysable ATP-
analogue ATPγS. Interestingly, an interaction between ORF57 and CIP29 is only visible in 
the presence of ATP and not in the presence of ATPγS. CIP29 has been shown to interact 
directly with UAP56, which in turn bridges the interaction to Aly, to form a trimeric 
complex in the presence of ATP (Dufu et al., 2010). A disrupted interaction of CIP29 and 
ORF57 therefore indicates an inhibition of the trimeric complex. ORF57 might still be able 
to recruit Aly, but cannot override the ATP-dependency or interact with CIP29 directly. 
However, to explore the interaction of ORF57 with other hTREX components, namely Aly 
or UAP56 in the absence of ATP, further experiments were needed.  
 
6.2 ORF57 and hTREX: ATP-dependency and complex remodelling 
In chapter four, the ATP-dependency of the ORF57-mediated vRNP was further 
investigated. The presence of the non-hydrolysable ATP analogue ATPγS was found to 
specifically disrupt the interaction of ORF57 with UAP56 and hence the hTREX complex. 
Importantly, the formation of the endogenous trimeric Aly-UAP56-CIP29 complex was not 
prevented by the non-hydrolysable analogue. Furthermore, results show that the presence 
of ADP caused disruption of both the endogenous and the viral complex. Together these 
data lead to a proposed model of ATP-cycle dependent remodelling of hTREX which affects 
the ability of ORF57 to interact with the complex (Figure 6.1). 
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Figure 6.1: Schematics of ATP-cycle dependent remodelling of central hTREX components and the 
ORF57-mediated vRNP. a) Binding of ATP to UAP56 is believed to induce a closed conformation in the 
ATPase, which allows binding of Aly and CIP29. b) Hydrolysis of ATP mediates a further conformational 
change of UAP56 and rearrangement of hTREX components, which allows ORF57 binding. c) Exclusion of 
inorganic phosphate and subsequent ADP binding facilitates a dissociation of UAP56 from Aly and CIP29. 
d) After dissociation of ADP, UAP56 can enter the ATP-cycle again, possibly to load other ATP-dependent 
hTREX components onto the mRNA. 
 
This remodelling process is most likely mediated by UAP56, an ATP-dependent RNA 
helicase with RNA-stimulated ATPase activity (Shen et al., 2007). Like other DExD-box 
proteins, UAP56 contains an ATP binding motif, called the ‘Q-motif’, responsible for total 
ATP specificity, rather than allow binding of other nucleoside triphosphates (Cordin et al., 
2006). It is not completely understood how RNA helicases facilitate RNA unwinding, 
however two models have been proposed and seem widely accepted. Both mechanisms 
are based on a coupling of one ATPase cycle to one RNA unwinding step (Tanner and 
Linder, 2001; Rocak and Linder, 2004; Tuteja and Tuteja, 2004). In accordance, studies 
have shown RNA helicases entering several different conformational states during their 
ATPase cycle (Lorsch and Herschlag, 1998). These conformational changes are thought to 
be necessary for the progression of the protein along the RNA in vivo, but they also 
commonly confer remodelling of associated protein complexes (Pyle, 2011). The 
underlying mechanism for the conformational changes seem to be found in the ATP 
binding pocket of UAP56 and other DExD-box helicases, which is found in a cleft between 
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two loosely connected helicase domains, each assuming a RecA-like fold (Shi et al., 2004; 
Zhao et al., 2004) (Figure 6.2Figure 6.2: ). Binding of ATP is believed to induce a structural 
reorganisation in the nucleotide binding site, causing a positional change of the two 
subunits relative to each other. This brings the two domains closer together and enables a 
so called closed conformation, in a similar fashion to the HCV NS3 protein (Appleby et al., 
2011). It is not clear if the energy for the structural changes is derived from ATP hydrolysis 
or from ATP binding alone. In the latter case, hydrolysis could be used to facilitate the 
release of the protein from the RNA, as has been shown for the yeast helicase and UAP56 
ortholog, Sub2 (Kistler and Guthrie, 2001).  
 
Figure 6.2: Crystal structure of UAP56 N-terminal and C-terminal domains. a) Model of UAP56 in an 
open conformation, generated by superimposing the domains onto to corresponding domains of full-
length eIF4A. b) Model of UAP56 in a closed conformation, generated by superimposing the two α/β 
domains of hepatitis C virus (HCV) NS3 protein. Conserved helicase motifs are mapped onto the 
structure in different colours and labelled I-VI. The black dashed line represents the flexible linker 
between both domains. Taken from (Zhao et al., 2004).  
 
UAP56 was stabilised in the ATP-bound state by ATPγS, a non-hydrolysable ATP-analogue. 
Results showed that this conformation confers binding of the endogenous proteins Aly and 
CIP29 (Figure 6.1, step a). Importantly however, ORF57 could not interact with ATPγS-
bound UAP56. This extremely exciting observation suggests that the complex will be 
remodelled after initial binding of Aly and CIP29 to UAP56, into a conformation which can 
accommodate ORF57. It is possible that binding of ATP-loaded UAP56 by Aly occupies the 
ORF57 binding site and further hTREX remodelling is needed before ORF57 can interact 
with Aly.  
166 
 
While no structural data has confirmed this to date, it has been previously proposed that 
ATP hydrolysis induces further conformational changes in DExD-box proteins, which could 
function as an essential destabilisation step of base pairs in the duplex region during RNA 
unwinding (Cordin et al., 2006). It has also been reported that members of the exon 
junction complex (EJC) specifically stabilise the post-hydrolysis state of the helicase 
eIF4AIII, preventing release of inorganic phosphate, in order to inhibit ATP turnover and 
thereby trapping the protein complex onto the RNA (Nielsen et al., 2009). This also 
suggests that the helicase and protein complex enter a distinct conformation after ATP 
hydrolysis, in order for components of the EJC to differentiate the pre- and post-hydrolysis 
state. Similarly, here another reorganisation of hTREX was observed, which is driven by 
UAP56-facilitated hydrolysis of ATP. While this hydrolysis event was previously shown 
essential for the loading of Aly onto mRNA (Chang et al., 2013), our results indicate that 
Aly is able to remain in a protein-protein interaction with UAP56 post-hydrolysis and after 
the transfer of mRNA has taken place. It can therefore easily be imagined that a structural 
change and remodelling of the complex, which facilitates binding of mRNA by Aly, also 
allows ORF57 to interact with the export adaptor and hence recruit UAP56 and the 
remaining hTREX onto viral mRNA (Figure 6.1, step b). 
Finally, results suggest that binding of ADP confers another structural change in UAP56, 
disrupting endogenous hTREX. As an example, the RNA helicase DbpA has been shown to 
adopt a significantly different conformation in an ADP-bound state, when compared to 
ATP- or RNA-bound states, independently of ATP hydrolysis (Henn et al., 2002). For many 
RNA helicases this step has been found associated with release of the protein from the 
RNA (Henn et al., 2008; Cao et al., 2011; Iost et al., 1999). Here, results show that ADP 
binding disrupts the interaction of core components of the endogenous hTREX and the 
vRNP (Figure 6.1, step c). It is possible that UAP56 shuttles through this conformation to 
enable consecutive loading of Aly and the more recently identified Chtop protein onto the 
mRNA, as has been suggested before (Chang et al., 2013). As both proteins interact with 
the N-terminal region of UAP56, this might mean that one protein is recruited to hTREX 
and loaded onto the mRNA during one ATP-cycle, before the interaction to UAP56 is 
disrupted by ADP and the second protein is loaded during another ATP-cycle. Fitting with 
this hypothesis is data reported for Sub2, which shows release of the RNA from the 
helicase upon ATP-hydrolysis (Kistler and Guthrie, 2001). While subsequent binding of ADP 
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is often found to disrupt protein-RNA interactions in other helicases, here this could be 
utilised to disrupt protein-protein interactions to enable recruitment of another protein. 
To extend this idea, as ATP-dependency has also been shown for the hTREX components 
CIP29, pDIP3 and ZC11A, this loading mechanism might also be applied to them, though 
they are not associated with mRNA binding during the export process. As the THO complex 
is not associated with any ATP-dependency, but has been reported to bind the cap-binding 
complex and UAP56 or Aly (Dufu et al., 2010; Chi et al., 2013), this could be speculated to 
act as a molecular anchor throughout this process, keeping UAP56 in close proximity of the 
mRNA and the partly assembled hTREX. Finally, UAP56 has been shown to leave the hTREX 
before mRNA export occurs (Viphakone et al., 2012), which could be facilitated by 
nucleotide free UAP56.  
As previous results have shown ORF57 to bind Aly directly (Boyne et al., 2008), it is likely 
that both proteins would remain bound to the viral mRNA during the stages of hTREX and 
vRNP assembly. However, we cannot clearly determine if ORF57 recruits Aly before an 
interaction with UAP56 takes place, or if UAP56-bound Aly is recruited onto viral mRNA. 
Based on the immunoprecipitation data, it appears that ORF57 interacts with proteins that 
are part of an already formed complex, whether this is the complete or a partial complex. 
In contrast, if Aly is recruited by ORF57 before any interactions with UAP56 take place, 
then ORF57 would require the lone ability to load Aly onto viral mRNA. Such a mechanism 
has been recently suggested for the HVS ORF57 protein, where a strong affinity for Aly 
caused formation of a ternary complex and cooperative binding of viral mRNA by both 
ORF57 and Aly (Tunnicliffe et al., 2014). In this case, upon interaction of Aly with ATP-
bound UAP56, the adaptor protein might lose the direct interaction with ORF57, but 
remain within the ternary complex via binding of the RNA in vivo. However, considering 
the interlinked nature of ORF57 and viral mRNA binding by Aly shown in HVS, this seems 
questionable. Further experiments therefore need to be performed to address the 
mechanism of ORF57-mediated complex assembly in vivo.  
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6.3 Identification of a novel KSHV-inhibitor  
As it has previously been shown that ORF57-mediated recruitment of Aly and Nxf1 alone 
are not sufficient for viral mRNA export and that the remaining hTREX complex is also 
needed for functional vRNP formation, it is exciting to see that the above mentioned 
model suggests potential options for the inhibition of the ORF57/hTREX interaction. Our 
data indicates that by stabilising the ATP bound conformation of UAP56, ORF57 is 
prevented from interacting with hTREX, without disruption of the endogenously formed 
trimeric complex of Aly, UAP56 and CIP29. Furthermore, as the ORF57-mediated vRNP was 
disrupted in the absence of ATP hydrolysis by UAP56, the most promising approach was to 
identify compounds inhibiting UAP56 ATPase activity. While recent findings have indicated 
that UAP56 might have to shuttle through one or several ATP-cycles to load hTREX 
components onto mRNA, this approach might not be feasible without disrupting the 
endogenous complex and causing cytotoxicity (Chang et al., 2013). However, a similar 
approach has been described in the literature, where a series of small molecule inhibitors 
(ring expanded nucleosides) were shown to suppress replication of human immune 
deficiency virus type 1 (HIV-1) by targeting the ATPase activity of human helicase DDX3 
(Yedavalli et al., 2008). At low concentrations these drugs were found to prevent virus 
replication without affecting cell viability. We therefore speculated that a small molecule 
inhibitor designed for high affinity binding to the ATP binding site of UAP56 would prove to 
efficiently disrupt the ORF57/hTREX interaction. 
A combined approach of structure-based drug design, virtual HTS and fragment-based 
drug design was used to identify four novel inhibitors of UAP56 ATPase function, all with a 
diverse structural background. The most potent inhibitor of UAP56, C2, was taken forward 
to assess the validity of our hypothesis and its potential as anti-KSHV inhibitor. Binding of 
C2 to UAP56 was confirmed by determination of an IC50 and also through direct study of 
binding kinetics by microscale thermophoresis, which showed a KD of 12.8 μM. Chapter 4 
contains consequential evidence for a disruption of ORF57-mediated vRNP formation in a 
concentration range where neither cytotoxicity nor endogenous bulk mRNA export was 
affected. Results also show that C2 significantly reduced export of intronless viral mRNAs, 
expression of late intronless proteins and KSHV replication.  
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For all of the above mentioned experiments it was shown that a “therapeutic window” 
exists, in which a concentration range proves effective against the virus induced RNP, but 
did not affect either hTREX formation in vitro, cellular bulk mRNA export or cytotoxicity. 
There are several possibilities for this: While C2 has been shown to inhibit the ATPase 
function of UAP56, the inhibitor has not been tested against DDX39. DDX39 has recently 
been more heavily implicated in mRNA export, either with a redundant function of UAP56 
or in an alternative pathway (Sugiura et al., 2007; Yamazaki et al., 2010; Kapadia et al., 
2006; Thomas et al., 2011). While DDX39 shares a high degree of sequence similarity, it is 
likely that both proteins have different binding affinities for the small molecule inhibitor. 
Therefore, cells might compensate partially inhibited UAP56 by up-regulating DDX39 
expression, which could provide redundancy and facilitate bulk mRNA export in the 
presence of C2, as observed in the FISH experiment. Furthermore, it is feasible that KSHV is 
more sensitive to disruption of viral mRNA export, whereas the cell is able to compensate 
for these events more efficiently. As such, inhibitor concentrations that disrupt a certain 
degree of viral and cellular mRNA export might block KSHV replication but could allow 
persistence of the cell. Finally, it is possible that different affinities, association or 
dissociation rates for the compound are found in the ORF57-bound protein complex, 
compared to the endogenous complex, i.e. the inhibitor might dissociate faster from 
UAP56 in the endogenous complex, than in an ORF57-stabilised complex. None of these 
hypothetical options have been identified as mechanism of action, but remain an ongoing 
focus of our study. However, the general concept of targeting cellular enzymes to prevent 
viral or bacterial toxicity is not a novel notion; several drugs have been successfully studied 
in animal trials indicating that a therapeutic window can also be used in fully developed 
drugs (Kibler et al., 2004; Sarac et al., 2002).  
Chapter five explored further aspects of the novel inhibitor, such as the effect of close 
structural analogues, to elucidate a structure activity relationship. As such, a further three 
compounds were identified, which were able to inhibit virus late protein production and 
replication within a therapeutic window. Data generated here can be used to indicate 
future directions in the development of an anti-KSHV drug and will be discussed in more 
detail below.  
One advantage of targeting cellular proteins for the treatment of viral infections is that 
one drug could theoretically have a very broad antiviral spectrum and target multiple 
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viruses that are dependent on this host factor. As such, targeting cellular helicases is a 
novel but very attractive antiviral target (Kwong et al., 2005). ORF57 is conserved amongst 
all herpesviruses and several of these homologues are known to interact with the hTREX 
complex. It was therefore speculated that C2 would also have inhibitory effects against 
other human herpesviruses. This hypothesis was tested in chapter five using HSV-1 and 
results showed specific disruption of HSV-1 lytic replication in the presence of C2. 
Furthermore, having used a physiologically relevant cell line, we could show a broad 
therapeutic window, with cytotoxicity occurring at concentrations ten times higher than 
inhibition of the virus. This is especially encouraging, as both structures for the binding of 
HSV-1 ICP27 protein and model-gammaherpesvirus HVS ORF57 with hTREX adaptor 
protein Aly, have highlighted significant differences in their interaction with the hTREX 
complex (Tunnicliffe et al., 2011; Tunnicliffe et al., 2014). The results, showing that 
inhibition of the ATP-cycle dependent remodelling of hTREX disrupts both an alpha- and a 
gamma-herpesvirus, are therefore exciting and suggest that inhibition of other human 
herpesviruses, such as HCMV, VZV, or potentially even influenza viruses, which also utilise 
parts of hTREX (Read and Digard, 2010), might also be possible. Similar, inhibition of West 
Nile Virus and HIV-1 has been shown using the same ring-expanded nucleoside inhibitors, 
which were found to inhibit both cellular and viral helicases (Zhang et al., 2003; Yedavalli 
et al., 2008).  
 
6.4 Implication of the inhibitor as anti-KSHV drug 
Together, the data generated in chapter four suggests a very promising, novel approach to 
disrupt KSHV lytic replication and treat KS. Of special interest is also a potentially novel 
mechanism recently identified in KSHV-mediated tumourigenesis: ORF57-sequestration of 
hTREX has been shown to induce the formation of RNA:DNA hybrids, so called R-loops 
(Jackson et al., 2014). These R-loops often result in DNA double-strand breaks and genome 
instability, both of which potentially contribute to the formation of KS. As such, a 
treatment directly disrupting the interaction of ORF57 and hTREX and thereby preventing 
R-loop formation, could not only disrupt KSHV lytic replication but also prevent a direct 
pathway in KSHV tumourigenesis, strengthening the therapeutic potential of our inhibitor.  
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Two possible therapeutic scenarios can subsequently be envisaged with this type of 
inhibitor: As prophylactic treatment in high-risk transplant patients or as part of a 
combined therapy in HIV-patients. To provide preventative systemic treatment, oral 
dosing of a drug would be advantageous, though depending on the final pharmacokinetic 
properties of the drug, intravenous therapy might be necessary. As treatment of existing 
KS, a topical application could also be considered. This would allow increased local 
concentrations of the drug, while having a lower risk of systemic side effects.   
Successful preventative treatment has been suggested for the anti-HCMV drug and 
herpesvirus inhibitor ganciclovir in some clinically studies, even though ganciclovir does 
not generally provide very good activity against lytically replicating KSHV (Gantt and 
Casper, 2011). It would therefore be exciting to see the effect of a very potent anti-KSHV 
drug in preventative treatment. Patients at risk of developing KS could be identified 
through screening of KSHV-seropositivity in both the transplant recipient and donor. 
Furthermore, quantitative measurements by PCR of KSHV lytic replication have shown a 
close correlation between viral load and the risk and progression of subsequent KS (Engels 
et al., 2003; Campbell et al., 2005). This would therefore allow a personalised treatment 
approach and could prevent progression of KSHV infection from an asymptomatic 
infection to development of KS and as such increase the success of organ transplants. A 
similar approach is already used for EBV and HCMV in transplant patients (Kotton et al., 
2013; Allen et al., 2009)  
To date, the most effective treatment of AIDS-related KS is anti-retroviral therapy (ART). 
The availability of ART has previously led to a dramatic decline in occurance of KS, mostly 
through restoration of the patient’s immune functions. However, KS is still found in many 
cases of individuals treated with ART and well controlled HIV. As such, combination of 
these two treatment strategies would promise a much more enhanced efficacy.   
 
6.5 Inhibition of HSP90 and off-target effects  
Compound C2 has previously been described as an inhibitor for the molecular chaperone 
HSP90 (Dymock et al., 2005), which is responsible for correct folding and subsequent 
function of client proteins. 
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HSP90 has previously been mentioned in the context of KSHV infection in the literature: 
The latency associated nuclear antigen (LANA), responsible for maintenance of the viral 
episome during latency, has been identified as HSP90 client protein (Chen et al., 2012). 
The study showed inhibition of HSP90 lead to a loss in LANA and as such a decrease in 
latent KSHV reservoirs. Furthermore, HSP90 inhibitors had a negative effect on 
progression of KS and proliferation of latency-associated PEL tumour cells. However, it was 
speculated that anti-tumour effects on KS and PEL were also promoted through other 
cellular targets of HSP90, such as CDC2 and Akt, both of which transduce paracrine and 
autocrine growth signals during KSHV malignancies.   
Another study also identified HSP90 inhibitors for their therapeutic potential against PEL. 
Here, the viral protein K1, a transmembrane glycoprotein able to inhibit apoptosis and 
transform rodent fibroblasts, was shown to bind HSP90 and subsequently suggested as 
novel client protein (Wen and Damania, 2010). While K1 is expressed at low levels during 
latency, but also at higher levels during lytic replication, treatment with the HSP90 
inhibitors 17-AAG and 17-DMAG showed reduction of K1 expression and subsequent 
suppression of PEL cell line growth.  
Finally, the involvement of HSP90 on signal transduction in hijacked cell signalling 
pathways has been implied in KSHV pathogenesis: The viral oncoprotein vFLIP complexes 
with the IKK complex and HSP90 to activate the NF-κB pathway (Field et al., 2003). Again, 
HSP90 inhibitors have shown to reduce proliferation of KSHV infected PEL cell lines and 
induce apoptosis in KSHV-associated tumour cells. 
While all studies connected KSHV infection and pathogenesis with HSP90, the molecular 
chaperone was either implicated in viral latency, or transformation and proliferation of 
cancer cells. No association between HSP90 and ORF57 or viral lytic replication has been 
previously suggested.  
Interestingly, the effect of inhibitors on HSP90 activity and chaperone function was 
assessed using the client protein CDC2. As such, a decrease in CDC2 expression was 
associated with the loss of viral target proteins, such as LANA (Chen et al., 2012). Here, 
experiments for viral lytic protein expression were also controlled with CDC2. Interestingly 
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though, inhibition of cellular HSP90 and loss of CDC2 expression occurred at a higher 
concentrations of the inhibitors, than observed effects on virus lytic replication. 
Published data of HSP90 inhibition by C2 shows a half maximal growth-inhibitory 
concentration (GI50, 50% inhibition of cell proliferation) of 5.3 μM across a panel of tumour 
cell lines, however the effect ranged from 0.8–23 μM for individual cell lines (Cheung et 
al., 2005; Dymock et al., 2005; Sharp et al., 2007). This concentration range is comparably 
low to other pharmacological inhibitors of HSP90. As way of comparison, the 
geldanamycin-derived HSP90 inhibitors, 17-AAG and 17-DMAG, were found to suppress 
growth of KSHV-associated PEL cells at 50 nM (Wen and Damania, 2010). Furthermore, 
inhibition of HSP90 by C2 was shown on a cellular level by depletion of client proteins 
c-Raf and Cdk4 in HCT116 cells, a human colon cancer cell line, after 8–24 h at a 
concentration of 20.5 μM (Dymock et al., 2005). Similarly, SKMEL 28 cells (a human 
melanoma cell line) showed a loss in HSP90 client proteins c-Raf, CDK4, ERBB2 and 
Phospho-ERK1/2 after 24 h incubation with 14.5 μM C2 (Sharp et al., 2007). In contrast, we 
showed inhibition of ORF57-associated protein expression and viral replication around 
1 μM of the same compound, again highlighting the higher affinity of C2 for this cellular 
pathway.  
The above listed findings further strengthen our hypothesis that C2 and its analogues 
specifically inhibit the hTREX complex pathway in viral replication and not the molecular 
chaperone HSP90. However, future work will aim at reducing off target effects on HSP90 
and possibly other cellular ATPases, as discussed below. This will also serve to reduce 
cytotoxic side effects further.   
 
6.6 Hit to lead development and future work 
Present work has identified a hit compound for an UAP56 ATPase inhibitor. This compound 
has not yet been involved in hit to lead development; but nonetheless displays 
considerably good potency, which is extremely encouraging. Furthermore, the low to 
average molecular weight of C2 allows further optimisations and additions to the structure 
to increase affinity and specificity.  
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To advance the hit-to-lead development of C2 by rationale-based drug design, more 
analogues need to be tested in the future. As part of this, the known structural analogues 
already utilised in this work should be assessed for their biochemical properties, through 
determination of IC50, as well as binding kinetics to UAP56 by microscale thermophoresis. 
Optimally, a complete structure-activity-relationship (SAR) for C2 should first be 
determined by strategic changes to all functional groups of C2. Furthermore, lead-like 
properties need to be incorporated by focusing on improvement of physicochemical and 
pharmacological properties. Chemical changes for this could include substitutions which 
probe presently unoccupied sites or add solvent exposed groups, as predicted by the 
modelling of C2 binding to UAP56.  
For development of a SAR, the resorcinol group should first be maintained, as essential 
hydrogen-bonding interactions are believed to be formed here. However, this could be 
tested through a series of compounds with substitutions to the hydroxyl groups. An 
overview of possible changes is shown in Figure 6.3. For example, the pyrazole ring could 
be explored for isosteric replacement (Figure 6.3a), which is a commonly used technique in 
drug design that describes exchange of one substituent or group for another, with similar 
chemical properties. While maintaining the chemical structure, this allows change of 
physical or biological properties, such as reduced toxicity, enhanced activity or changed 
metabolism of the compound. Other chemical sub-structures of C2 could be extended to 
explore unoccupied pockets of the ATP binding site (Figure 6.3b and c), such as the 
phosphate channel. Furthermore, a substitution of the dioxane region could be used to 
exploit a free amino acid side chain of UAP56 (Figure 6.3e). All of these changes would aim 
to improve affinity for UAP56 and potentially decrease off-target activity, by enhancing the 
enzyme specificity. Another substitution could also explore the potential of adding a 
solvent exposed vector (Figure 6.3d). This could help incorporate a solubilising group and 
therefore increase bioavailability of the next generation compound. Finally, the potential 
of isosteric replacement for the resorcinol group could also be investigated (Figure 6.3f). 
Previous reports of HSP90 inhibitors with the same scaffold showed glucuronidation of 
resorcinol hydroxyl-groups, which limited the bioavailability (Biamonte et al., 2009; Eccles 
et al., 2008). As such, using resorcinol mimetics might improve lead-likeness and could 
limit this unwanted side effect.  
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Figure 6.3: Initial strategy for advancing hit compound C2. Possible chemical changes are indicated as 
teal arrows, the existing structure involved in hydrogen-bond formation is indicated in red. 
 
All changes should be assessed by biochemical in vitro evaluation, namely through 
determination of IC50 and binding kinetics by microscale thermophoresis. In a second step 
of the evaluation strategy, cellular toxicity and off-target effects could be investigated. 
Finally, the efficacy of the lead compounds should be tested regarding their inhibition of 
vRNP formation and KSHV lytic replication.  
In addition to the biochemical and cell based evaluation mentioned above, hit-to-lead 
advances could be guided and supported by computational techniques, which would 
provide quantitative SAR (QSAR) models. These regression-based models help summarise 
the relationship between chemical structures and biological activity and predict changes in 
activity through further chemical substitutions. Furthermore, generation of an X-ray crystal 
structure of UAP56 bound to C2 could confirm current docking models and advance the 
structure-based design. Once optimal crystallisation conditions were found, the aim would 
be to generate further crystal structures with advanced lead compounds.  
Finally, all compounds with lead-likeness featuring the desired potency should then be 
evaluated regarding their off-target activity. The above proposed structural changes are 
aiming to increase selectivity for UAP56, which would help increase binding affinity and 
simultaneously minimise inhibition of other ATPases and kinases. To test this, a panel of 
cellular kinases including, but not limited to, the closely related and structurally similar 
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RNA helicase DDX39 and HSP90 should be used for biochemical assessments alongside 
UAP56. If the above proposed changes were effective, the new lead compounds could 
then be tested in a recently developed humanised bone marrow, liver and thymus mouse 
model for KSHV (Wang et al., 2014).  
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